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ABSTRACT
Saturation binding studies with the K%-selective agonists pH]U-69,593 and pH]CI- 
977 have been used to quantify Ki-receptor development in the neonatal rat brain. 
Full development of Ki-receptors has been demonstrated at post-natal day 1 and 
characterised as Ki by competition studies using the selective -agonist U-69,593, 
the selective p-agonist DAGO, the selective 6 -agonist DPDPE and the opioid 
antagonist naloxone v. pH]CI-977. Functional K%-mediated antinociception against 
thermal and mechanical noxious stimuli and naloxone reversal has been demonstrated 
using the Ki-selective agonists PDl 17,302, U-69,593 and CI-977 in 5 and 10 day-old 
rat pups.
The density of the 5-opioid receptor in rat brain homogenates was quantified from 
adulthood down to as early an age as possible by means of saturation binding studies 
using the 6 -receptor-selective antagonist pH]naltrindole and the 6 -receptor-selective 
agonist pHJIle^’^ Deltorphin II and by homologous displacement studies using the 6 - 
receptor-selective agonist Deltorphin I. 6 -binding was measurable at post-natal day 3 
and steadily increased to a level not significantly different from adult levels by day 
25. Comparison of 6 -receptor densities in the brain and spinal cord of the 25-day-old 
weaned and non-weaned rat showed no difference when measured with 
pH]naltrindole or [^HJIle^»^Deltorphin II. Using pH]Deltorphin I, the 6 -receptor 
density in the weaned animals was approximately 25% higher than in the non-weaned 
animals in both tissues. Saturation binding studies in the presence of lOOmM Na+, 
50pM GMPPNP or both, conditions designed to investigate the possible influence of 
the G-protein coupled state of the receptors on the ligand binding, were carried out 
with all three ligands. The only significant difference observed was a 32% decrease 
in the binding of [^HJDeltorphin I in the weaned animals in the presence of 50|iM 
GMPPNP which did not occur in the non-weaned animals, suggesting that the 
weaned/non-weaned difference in 5-receptor density seen by [^HJDeltorphin I may be 
a consequence of different or incomplete G-protein-coupling prior to weaning.
SUMMARY
1. The historical background leading to the present day understanding of the opioid 
receptor system has been reviewed with reference to the contemporary literature. The 
existence of opioid receptor subtypes, their endogenous ligands and the development 
of highly selective agonists and antagonists has been discussed. The distribution and 
molecular pharmacology of opioid receptors has been considered with reference to the 
current literature.
2. The current understanding of the ontogeny of the opioid receptors has been 
discussed. The highly K-selective ligands pH]U-69,593 and pH]CI-977 have been 
used to study the quantitative development of the K-opioid receptor in the neonatal rat. 
Saturation binding studies were carried out in homogenates of whole brain (minus 
cerebellum) from the adult, from the 30 day-old rat pup and from successively earlier 
ages until no specific binding could be detected. High affinity saturable binding was 
observed down to postnatal day 5 (PN5) using pH]U-69,593 and down to PNl using 
pH] CI-977 . No significant difference in the affinity of either ligand was recorded 
at any age. The affinity of pH]CI-977 (Kd 0.6nM) was three times greater than that 
of pH]U-69,593 (1.82nM). Expressed relative to wet weight there was no significant 
difference in Bmax for binding of [^H]U-69,593 between PNIO and the adult and for 
pH]CI-977 between PNl and the adult. Expressed relative to total protein the Bmax 
for [^H]CI-977 was highest at PNl (33 fmol/mg protein) gradually fell to PN20 and 
rapidly fell between PN20 and PN30 by some 50% to reach adult levels of 11 
fmol/mg protein reflecting the rapid increase in protein levels over the post-natal 
period. Thus, full development of the benzacetamide sensitive Ki-opioid receptor at 
PNl was established.
3. Competition studies vs. pH]CI-977 using the K-selective agonists PDl 17,302 and 
U-69,593, the p-selective agonist DAGO, the 6 -selective agonist DPDPE and the
IV
relatively non-selective antagonist naloxone were carried out at PN3 to confirm that 
the ligands used in the quantitative study were recognising a single K-opioid receptor. 
PDl 17,302 and U-69,593 showed potent inhibition of pH]CI-977 binding (Kj 3.2nM 
and 5.7nM respectively). The Ki for DAGO was greater by a factor of 10  ^ and 
DPDPE by > 104. The Ki for naloxone was 26nM. U-69,593 vj. [3H]CI-977 at PNl 
was the same as at PN3. All displacement curves were monophasic with a slope not 
significantly different from 1 indicating interaction at a single site.
4. The literature relating to K-mediated antinociception has been briefly review^K- 
mediated antinociception was investigated in the 3, 5 and 10 day-old neonatal rat 
using the K-selective agonists PDl 17,302, U-69,593 and CI-977. The antinociceptive 
effects were tested against mechanical (paw pressure) and thermal (warm water tail 
immersion, 50°C at PNIO, 43.5°C at PN5) stimuli. Dose response relationships for 
both stimuli were established to i.p. injection of agonists over the range 0.3 - lOmg/kg 
PDl 17,302; 0.3 - 40mg/kg U-69,593 and 0.025 - l.Omg/kg CI-977 in the 5 day-old 
rat and 0.3 - 20mg/kg PDl 17,302; 0.3 - 40mg/kg U-69,593 and 0.025 - 2.0mg/kg CI- 
977 in the 10 day-old rat. CI-977 was approximately 20-fold more potent than the 
other two agonists.
5. The time course and naloxone reversal of submaximal doses of the three agonists 
was investigated. All three agonists (PDl 17,302 at Img/kg, U-69,593 at Img/kg and 
CI-977 at 0.05 mg/kg) produced rapid antinociceptive effects, the onset being at < 5 
minutes, the peak at 10 - 20 minutes and the duration 45 - 60 minutes. Full naloxone 
reversal (Img/kg i.p.) demonstrated the opioid mediated nature of the effect. Thus 
functional K-mediated antinociception, to both a mechanical and a low intensity 
thermal stimulus, at PN5 and PN 10 was correlated with the full development of the 
Ki-opioid receptor population at PNl established in the receptor binding study.
6 . After preliminary time course studies to establish suitable parameters, the highly 
0-selective hgands pKTJDELT I, pH]Ile^’^ DELT II and [^H]NTI were used to quantify 
6 -opioid receptor development in the preweanling rat from PN20 and at successively 
earlier ages until no specific binding could be detected. Saturation binding studies in 
whole brain homogenates were carried out with [^Hjlle^ ^ DELT II and [^HJNTI and 
homologous displacement studies with pHJDELTI. High affinity saturable binding 
was observed for [^HjDe^ ^DELT H down to PNIO and for [3H]NTI down to PN3. No 
significant difference in the affinity of either ligand (pH]NTI Kd = 0.21nM; 
pH]Ile3«6DELT II Kd = 1.75nM) was observed except at PN3 for [3H]NTI, Kd = 
0.38nM. [3H]DELT f  specific binding was quantified down to PN5 with no 
significant difference in the derived Kd, l.lnM. At PN3 pH]NTI specific binding 
indicated a 6 -receptor level of 0.32 fmol/mg wet weight, 14 fmol/mg protein. The 
subsequent developmental profile as seen by all the ligands was similar showing a 
steady rise in receptor density, until at PN20 there had been an approximately 10-fold 
increase to 3 fmol/mg wet weight, a 5-fold increase to 71 fmol/mg if expressed 
relative to total protein.
7. The same methods were used to measure 6 -receptor levels in homogenate of brain 
and spinal cord in the 25 day-old weaned and non-weaned rat.. No significant 
difference was found in the Kd values for any ligand betweeen the weaned and the 
non-weaned brain or the weaned and the non-weaned spinal cord. No significant 
difference was found in the Bmax for [^HJNTI or pHJIle^ADELT II binding in the 
weaned and non-weaned brain and spinal cord. The Bmax values for [^HjDELT I in 
the non-weaned brain and spinal cord were equivalent to those of [3H]NH and 
pH]Ile5.6DELT H. In the weaned brain the Bm ax for [^HJDELT I was 35% higher 
expressed per wet weight and 26% higher expressed per protein than in the non- 
weaned brain. There was a similar increase in the weaned spinal cord. These results 
indicate that weaning had induced the development of a 6 -receptor population 
recognised by [^HJDELTI but not by [^HJNTI and [^Hjlle^ ^DELT H.
VI
8 . Post-weaning 6 -receptor development was followed, using homologous 
displacement of pH]DELT I, to 40 days both in rats which had been weaned normally 
at PN21 and those in which weaning had been delayed to PN25. For comparative 
purposes 6 -receptor density was measured in the normally weaned adult (>60 days) 
using both [3H]DELT I homologous displacement and pHJNTI saturation binding. 
Between PN25 and adulthood there was an approximately 20% increase in 6 -receptor 
density as measured by [3H]DELT Land expressed relative to protein. However this 
was shown not to be statistically significant. Animalswhich were not weaned until 
PN25 had achieved the same levels of 6 -receptor as the normally weaned animals by 
PN35. [3H]NTI saturation binding also indicated no significant change in 6 -receptor 
density expressed relative to protein between PN25 and adulthood.
9. Saturation binding studies were carried out in homogenates of whole brain (minus 
cerebellum) from the weaned and non-weaned 25 day-old rat using pH]DELT I, 
[3H]De^'6DELT II and pH]NTI in the presence of 50)1 M GMPPNP and lOOmM Na+ 
or both in order to investgate the effect of the G-protein coupled state on the binding 
parameters of these ligands. Under all binding conditions and in both weaned and 
non-weaned rats, there was no significant difference in the Kd value for p  H]NTI 
binding. For any one binding condition there was no significant difference between 
the weaned and non-weaned Bmax for pHJNTI. The presence of GMPPNP or Na+ or 
both had no effect on the antagonist binding B m ax values. [^Hjlle^ ^DELT II 
saturation binding showed no significant difference between weaned and non-weaned 
animals under control binding conditions. Saturation binding studies with [^HjDELT 
I showed a 14-20% lower 6 -receptor density in the brain of the non-weaned 25 day- 
old rat compared with the weaned animals. The level in the weaned animals was not 
significantly different to the levels seen by [^HJIle^’^ DELT II and pH]NTI. In the 
presence of GMPPNP there was no significant difference between the levels of 
pH]Ile^’^ DELT II binding in the weaned and non-weaned rats. In the weaned rats 
GMPPNP produced a 32% decrease in [3H]DELT I binding while having no effect in
vu
the non-weaned animals. The presence of GMPPNP did not affect the Kd values for 
either ligand nor did the presence of Na+ alone. In the presence of Na+ and Na+ + 
GMPPNP [3H]DELT I binding was reduced by 64-70% while [^Hjlle^ ^DELT II 
binding was reduced by 30-50% in both weaned and non-weaned animals. Na+ + 
GMPPNP increased the KdoI pHJDELT I four-fold and that of [^Hjlle^.^DELT II 
two-fold. The greater shifts in both K d  and Bm ax suggest that pHJDELT I is more 
sensitive to the G-protein coupled state of the 6 -receptor than is [^HJIle^.^DELT II and 
that the binding of the antagonist [^HjNTI is not influenced by the G-protein coupled
state of the 6 -receptor. This leads to the conclusion that it is possible that the reduced
bo
level of 6 -receptors seen in non-weaned animals by [3H]DELT I may be du^^the fact
that a proportion of the population are uncoupled prior to weaning.
vm
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inset for pHJDeltorphin I in homogenates of whole brain (minus 
cerebellum) from five, ten, fifteen and twenty day-old rats.
159
Figure 30 Representative saturation curves with Scatchard analyses (inset) 
for the binding of pHJNaltrindole in homogenate of whole brain 
(minus cerebellum) from the 25 day-old weaned or non-weaned 
rat
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Figure 31 Representative saturation curves with Scatchard analyses (inset) 
for the binding of pHJNaltrindole in homogenate of spinal cord 
(minus cerebellum) from the 25 day-old weaned or non-weaned 
rat
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Figure 32 Representative saturation curves with Scatchard analyses (inset) 
for the binding of pHJIleP’^ Deltorphin II in homogenate of 
whole brain (minus cerebellum) from the 25 day-old weaned or 
non-weaned rat.
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Figure 33 Representative saturation curves with Scatchard analyses (inset) 
for the binding of p  HJDeP'^Deltorphin II in homogenate of 
spinal cord from the 25 day-old weaned or non-weaned rat.
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Figure 34 Representative homologous displacement curves for 168 
pHJDeltorphin I with Hill plots (inset) in homogenate of whole 
brain (minus cerebellum) from the 25 day-old weaned or non- 
weaned rat
Figure 35 Representative homologous displacement curves for 
pHJDeltorphin I with Hill plots (inset) in homogenate of spinal 
cord from the 25 day-old weaned or non-weaned rat
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Figure 36 The effect of weaning on ô-receptor binding in whole brain 
(minus cerebellum) homogenates from 25 day-old weaned and 
non-weaned rats
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Figure 37 The effect of weaning on ô-receptor binding in the spinal cord 
from 25 day-old weaned and non-weaned rats
Figure 38 Representative saturation curves with Scatchard analyses (inset) 
for the binding of [PHJNaltrindole to homogenate of whole brain 
(minus cerebellum) from the 25 day-old weaned and non- 
weaned 25 day-old rat measured in (a) 50mM Tris Buffer (b) 
50mM Tris Buffer + 50pM GMPPNP
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Figure 39 Representative saturation curves with Scatchard analyses (inset) 
for the binding of pHJNaltrindole to homogenate of whole brain 
(minus cerebellum) from the 25 day-old weaned and non- 
weaned 25 day-old rat measured in (a) 50mM Tris Buffer + 
lOOmM Na+ (b) 50mM Tris Buffer + lOOmM Na+ + 50|iM 
GMPPNP
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Figure 40 Representative saturation curves with Scatchard analyses (inset) 
for the binding of [PHJDeltorphin I to homogenate of whole 
brain (minus cerebellum) from the 25 day-old weaned and non- 
weaned 25 day-old rat measured in (a) 50mM Tris Buffer (b) 
50mM Tris Buffer + 50|iM GMPPNP
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Figure 41 Representative saturation curves with Scatchard analyses (inset) 
for the binding of [PHJDeltorphin I to homogenate of whole 
brain (minus cerebellum) from the 25 day-old weaned and non- 
weaned 25 day-old rat measured in (a) 50mM Tris Buffer + 
lOOmM Na+ (b) 50mM Tris Buffer + lOOmM Na+ + 50|xM 
GMPPNP
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Figure 42 Representative saturation curves with Scatchard analyses (inset) 
for the binding of [P HJIleP'^Deltorphin II to homogenate of 
whole brain (minus cerebellum) from the 25 day-old weaned 
and non-weaned 25 day-old rat measured in (a) 50mM Tris 
Buffer (b) 50mM Tris Buffer + 50 (iM GMPPNP
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Figure 43 Representative saturation curves with Scatchard analyses (inset) 
for the binding of [PRlIle^’^ Deltorphin II to homogenate of 
whole brain (minus cerebellum) from the 25 day-old weaned 
and non-weaned 25 day-old rat measured in (a) 50mM Tris 
Buffer + lOOmM Na+ (b) 50mM Tris Buffer + lOOmM Na+ +
50p,M GMPPNP
Figure 44 The efect of 50|iM GMPPNP and lOOmM Na+ or both on the 203 
Bmax for [PHJDeltorphin I, pHJIleP’^ Deltorphin II and [PHJNTI 
binding in homogenate of whole brain (minus cerbellum) from 
the weaned and the nonweaned 25 day-old rat expressed as 
percentage change relative to the control values
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CHAPTER 1
INTRODUCTION
1.1 GENERAL INTRODUCTION
1.1.1 Historical background and the endogenous opioid system in the CNS.
Opium is one of the oldest medications known to man and has been used to relieve 
pain and diarrhoea for many centuries. The name derives from the Greek opos 
meaning sap, for the juice extracted from the unripe seed capsules of Papaver 
somniferum is the source of opium which contains several alkaloids including 
morphine, thebaine, papaverine and codeine. Opium also produces drowsiness and 
sedation i.e. is narcotic, and a feeling of contentment or well-being. While these 
effects along with the analgesic effects contribute to the usefulness of opium in the 
control of pain the euphoric effects probably contribute to the development of 
dependence. Other disadvantages are respiratory depression and vomiting. Pure 
morphine was isolated from opium in 1803 by a German pharmacist Setümer and its 
chemical structure subsequently determined (Fig. la). It was shown that morphine 
was the principal alkaloid responsible for the beneficial effects of opium but also for 
the undesirable side effects. It is significant that codeine, which is methyl morphine 
(Fig. lb), is a much less potent analgesic, is not addictive and does not cause 
appreciable respiratory depression i.e. a small change in the molecule has drastic 
effects on the pharmacology. This is further exemplified by naloxone, -N allylnoroxy 
morphine (Fig. Ic), and naltrexone, -N cyclopropylmethyl morphine (Fig. Id), which 
are pure antagonists and indeed antagonism by naloxone is used as a criterion in the 
screening of compounds for opiate activity, although some reservations have been 
expressed (Sawynok et al., 1979). Many of the effects of opiates were shown to be 
stereospecific, only one enantiomer of a racemic mixture being active. The 
stereospecificity and stmctural constraints on the opiate molecules necessary for their 
activity suggested a highly specific interaction was required and that a receptor- 
mediated action was occurf^, (Portoghese, 1965).
Figure 1. Morphine: the prototypical opiate and analogues of different 
pharmacological activity
Figure la
— C ht
H
Figure lb — C H3
Figure Ic CH
OH;
NaloxoiE
H
O
H
It was not until 1973 that three independent reports of stereospecific and saturable 
opioid binding to rat brain homogenates were published (Pert and Synder, 1973; 
Simon et al., 1973; Terenius, 1973). Subsequently,the receptors were demonstrated in 
many species including invertebrates (Stefano et at.., 1980). Since they appeared 
across so many species it was difficult to postulate that there was an evolutionary 
advantage in possessing highly specific receptors for alkaloids from opium poppies 
and it was suggested that the receptors had a physiological function resulting from 
interaction with an endogenous opioid agonist.
It had been observed that a wide variety of peripheral tissues were sensitive to 
opioids, predominantly showing inhibition of smooth muscle contraction (Gyang and 
Kosterlitz, 1966; Henderson er a/., 1972; Kosterlitz and Watt, 1968; Paton, 1957). 
Thus as well as homogenate binding, isolated tissue techniques were available for 
screening brain extracts for opioid activity. The first identification of endogenous 
opioid activity was reported by Hughes in 1975 (Hughes, 1975). Subsequently, the 
same team led by Kosterlitz identified two pentapeptides in aqueous extracts of pig 
brain which they named enkephalins (Hughes et al.y 1975). The molecules differed 
only in the C-terminal amino acid and were distinguished on this basis as methionine 
enkephalin ([Met]-enkephalin) Tyr-Gly-Gly-Phe-Met-COOH, and leucine enkephalin, 
([Leu]-enkephalin) Tyr-Gly-Gly-Phe-Leu-COOH. A pituitary hormone (3-lipotropin 
(P-LPH) of 91 amino acid residues had been isolated and sequenced in 1964 (Li, 
1964). It was now recognised that residues 61-65 were identical to jfftej-enkephalin 
(Hughes et a/., 1975). There followed a number of reports of extended [Sle^r 
enkephalins with opioid activity all representing sequences present in P-LPH (Cox et 
at., 1975; Li and Chung, 1976; Teschemacher et al., 1975). Given the name 
'endorphins' (from endogenous morphine-like), the three principle molecules were a-
endorphin equivalent to p-LPH61-76, y-endorphin equivalent to p-LPH6 1 -7 7  and 13- 
endorphin equivalent to P-LPH6 1 -9 1  (Bradbury a/., 1976; Cox û/., 1976; Ling 
et al., 1976). It was also demonstrated that there existed a common precursor of P- 
LPH and of the non-opioid hormones adrenocorticotropin (ACTH) and a , P and x 
melanocyte stimulating hormone (MSH). It was given the name proopiomelanocortin 
(POMC) (Mains et al., 1977; Roberts and Herbert, 1977). However, using a 
combination of anatomical, biochemical and immunological techniques it was 
demonstrated that the distribution in the brain of P-LPH/P-endorphin reactivity did 
not correspond with thejflâeîenkephalin reactivity (Bloom et al., 1978; Rossier et al., 
1977) and although [Met]-enkephalin is expressed once in ; p-LPH this evidence 
suggested that P-LPH molecule could not be the primary source of [Met]-enkephalin. 
Two distinct opioid peptide systems were postulated, the endorphins and the 
enkephalins (Watson et al., 1978).
[Met]-enkephalin-like immunoreactivity was visualised, using immunofluorescence 
techniques, in the guinea pig adrenal medulla (Schulzberg et al., 1978) and 
subsequently in bovine adrenal medulla (Lewis et al., 1979).Using bovine adrenal 
medulla it was rapidly established that the biosynthesis of [Met]-enkephalin and 
[Leu]-enkephalin involve a large precursor molecule given the name proenkephalin 
(Lewis et al., 1980). Extended [Met]-enkephalin peptides were identified (Kilpatrick 
et al., 1981) and an adrenal protein containing four [Met]-enkephalin sequences 
(Kilpatrick et al., 1980). [Met]-enkephalin and extended [Met]-enkephalins were 
demonstrated in the brain of the rat, cattle and man (Rossier et al., 1980). [Met]- 
enkephalin and the extended heptapeptide [Met]-enkephalin-Arg-Phe and octapeptide 
[Met]-enkephalin-Arg-Gly-Leu were shown to occur in a ratio similar to their ratio in 
proenkephalin, in the brain of the guinea pig, rat and hamster (Ikeda et al., 1982). 
However, it was some time before the precursor identified in the adrenal was shown 
to occur in the brain (Beaumont et al., 1985).
A third family of opioid peptides was established when another opioid peptide was 
demonstrated in porcine pituitary, shown to be some 700 times more potent than 
[Leu]-enkephalin in the guinea pig ileum with its effects blocked by naloxone 
(Goldstein et a l, 1979). The N-terminal sequence was shown to be that of [Leu]- 
enkephalin and the whole peptide to be 17 residues in length (Goldstein et al., 1981). 
Several other extended peptides with opioid activity, also incorporating [Leu]- 
enkephalin, were subsequently extracted from bovine brain and pituitary and 
characterised. These included a-neo-endorphin (Kangawa and Matsuo, 1979; 
Kangawa et al., 1981) , dynorphin A^.g (Minamino etal., 1980), p-neo-endorphin 
(Minamino etal., 1981) and dynorphin B (rimoiphin) (Fischli etal., 1982; Kilpatrick 
et al., 1982). Immunohistochemical techniques were used to investigate the 
distribution of these [Leu]-enkephalin extended peptides and they were shown to be 
localised notably in the hypothalamus and posterior pituitary which suggested a 
common dynorphin precursor molecule might be found (Watson etal., 1981). With 
the development of DNA sequencing and the ability to produce cDNA libraries it was 
very quickly possible to confirm three families of opioid peptide genes. From the 
starting point of mRNA for mouse ACTH/LPH precursor (POMC), a cDNA for the 
precursor polypeptide containing ACTH and pLPH(4 4 .9 0) was cloned in E.coli 
(Roberts et al., 1979). It was confirmed that pLPH included [Met]-enkephalin 
(residues 61-65), almost all the residues of pMSH and all but the carboxy terminal 
amino acid of p-endorphin. Similarly the bovine corticotropin-P-lipotro'f^n 
precursor was cloned and the cDNA sequenced (Nakanishi etal., 1979). Both sources 
of mRNA confirmed the amino acid sequence previously deduced. Bovine adrenal 
medulla proenkephalin was also cloned in an E.coli plasmid and again the cDNA 
sequencing confirmed the earlier findings including the identification of four copies of 
[Met]-enkephalin, one of [Leu]-enkephalin and one of [Met]-enkephalin-Arg6 -Phe^. 
Also identified was the previously undetected opioid peptide [Met]-enkephalin-Arg^- 
Phe^Leu^; Porcine hypothalamic cDNA for P -neo-endorphin/dynorphin precursor was 
similarly obtained from the mRNA encoding it (Kakidani etal., 1982; Gubler et al..
1982). These fragments had not been identified in the POMC precursor molecule or 
in the preproenkephalin molecule and so this work completed the identification of 
three separate genes encoding for the three previouly postulated precursors 
proopiomelanocortin, proenkephalin and prodynorphin. The precursors have a 
number of features in common (see Akil et al, 1984). The initial gene products are 
inactive prepropeptides of approximately the same length and post-translational 
processing is necessary to produce biologically functional peptides. They contain 
multiple sequences of opioid peptides in the C-terminal half of the molecule and these 
are usually fi*amed by pairs of basic amino acids which are the potential sites of 
cleavage e.g. Lys-Arg, Lys-Lys, Arg-Arg. Not all potential sites are subject to 
cleavage and some cleavage occurs at single basic residues which indicates a degree 
of specificity is required in the adjacent sequences. The precursors have a cysteine 
rich N-terminal sequence preceded by similar sized signal peptides and there is a 
>50% homology in the amino acid sequences of pro-enkephalin and pro-dynorphin. 
The structural organisation of the genes encoding the precursors is similar in the 
placement of introns and exons and these similarities suggest evolution from a 
common precursor. It is hypothesised that the ancestral opioid gene was that for 
proenkephalin since it is the most widely distributed across the vertebrate phyla and 
two separate duplication events are proposed, the first giving rise to the 
proopiomelanicortin gene and the second to the prodynorphin gene (Dores et al., 
1993). The potential for the control of the production of a particular active opioid 
molecule lies not only in the control of gene expression of the precursor molecules but 
also the enzymes of cleavage and further, those which bring about subsequent 
modification of the cleavage products (Bloom, 1983; Hollt, 1983; Khachaturian et 
al., 1985; Snyder and Childers, 1979; Weber era/., 1983).
Table 1 shows the major active opioids derived from the precursors and Figure 2 the 
physical relationship between these opioids within the precursor molecules.
Table 1. Opioid precursors and major active opioid products.
PeptidePecursor 
(No.of residues)
Structure
POMC 
Human (267)
p-endorphin
i
Tyr-GIy-GIy-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro- | 
Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Val-Lys-Asn-Ala- i
7 -endorphin
1
His-Lys-Lys-Gly-Gln
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-
Leu-Val-Thr-Leu
a-endorphin Tyr-GIy-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-
Leu-Val-Thr
Proenkephalin (A) [Met]-enkephalin Tyr-Gly-Gly-Phe-Met
Human (269) [Leu]-enkephalin Tyr-Gly-Gly-Phe-Leu
[Met] -enkephalin-Arg - Tyr-Gly-Gly-Phe-Met-Arg-Phe
Rie
[Met] -enkephalin-Arg - Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu
Gly-Leu
Peptide E Tyr-GIy-GIy-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-GIu-Tip-
Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu
Prodynoiphin ot-Neo-endorphin Tyr-Gly-GIy-Phe-Leu-Arg-Lys-Tyr-Pro-Lys
(Proenkephalin B) P-Neo-endorphin Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
Porcine (256) Dynorphin A (1-17) Tyr-Gly-Gly-Phe-Leu- Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys - 
Trp-Asp-Asn-Gln
Dynorphin A (1-8) Tyr-Gly-Gly-Phe-Leu- Arg-Arg-Ile
Leumorphin Tyr-GIy-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-
(dynorphin B [1-29]) Arg-Ser-Gln-Gltt-Asp-Pro-Asn-Ala-Tyr-Tyr-Glu-Glu-Leu-
Phe-Asp-Val
Dynorphin B Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr
(rimorphin)
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1.1.2 Opioid receptor subtypes.
The demonstration of the existence of multiple opioid peptides and the knowledge
that classical neurotransmitters often interact with multiple forms of receptor strongly
suggested that there may be more than one class of opioid receptor. The first
evidence came from the investigation of opioid agonists in vivo (Martin et al., 1976).
Three agonists, defined as such since all their effects were antagonised by naltrexone,
were shown to produce a different pharmacological syndrome in chronic spinal dogs.
Chronic administration of all three induced tolerance to their agonist effects but they
could not substitute for each other in suppressing the withdrawal symptoms in
addicted dogs. Three distinct opioid receptors were hypothesised and designated
according to  the prototypic ligand  o f  h igh est sp ecific ity  i.e . |X for m orphine, K for
ketocyclazocine and a  for SKF10047 (N-allylnormetazocine). Classically the opiate
effects are naloxone reversible and should be stereospecific. However, actions
mediated by the a-receptor were demonstrated to be not naloxone reversible (Zukin
and Zukin, 1984) and D and L SKF 10047 shown to be equipotent (Akil et at., 1984).
The receptor also interacts with the non-opiate drug of abuse phencyclidine (PCP)
(Zukin and Zukin, 1979) and is now not recognised as an opioid receptor. After the
discovery of the enkephalins they were found to have potent inhibitory effects on the
electrically-induced muscle twitch in the mouse vas deferens but to be much less
potent in the isolated guinea pig ileum. The relative potency of morphine in the two
tissues was the reverse (Lord et a i, 1977) and the existence of the 6 -receptor (firom
the
vas deferens) as distinct firom^ji-receptor was postulated. In vitro binding competition 
studies in guinea pig brain homogenates supported the existence of these two receptor 
types and it was confirmed by others that an enkephalin binding site in the brain 
having characteristics different from the p-sites could be demonstrated (Chang and 
Cuatrecasa9 ,l979).
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Other opioid receptors have been postulated, notably the e-receptor in rat vas 
deferens, the electrically-induced contractions in this tissue being very sensitive to 
inhibition by P-endorphin (Garzon et al., 1985; Schulz et al., 1980). It has been 
suggested that a receptor with similar characteristics is found in rat brain (Chang et 
al., 1984; Nock et al., 1990). However its existence as a distinct receptor type is 
open to question and the evidence is reviewed in Porecca and Burkes (1993).
A variety of techniques have been employed to discriminate between the proposed p- 
6 - and K-opioid receptors. Evidence has been provided by:-
(i) Different rank order of potencies for the displacement of radio-labelled ligands 
(Chang et al., 1980; Kosterlitz et al., 1981).
(ii) Differences in localization in brain regions (Chang et al., 1979; Goodman and 
Sj^der, 1982).
(iii) Selective protection of opioid receptors against alkylation (James and Goldstein,
1984).
(iv) Development of selective receptor agonists and antagonists (Cotton et al., 1984; 
Lahti et al., 1985; Mosberg et al., 1983).
(v) Differences in behavioural effects (Schmauss and Yaksh, 1984; Wood et al., 
1981).
However, none of these techniques could be said to prove the existence of distinct 
receptor molecules rather than different interconvertible states of a single receptor. 
Separation, purification and amino acid sequencing was necessary to provide 
definitive proof and these topics are discussed in 1.4.
1.1.3 Multiple endogenous ligands and receptor subtypes..
It has been possible to provide evidence for preferential interaction of some 
endogenous ligands with a particular putative receptor type. The principle methods 
used have been the comparison of potencies in the mouse vas deferens (5) and the
11
guinea pig ileum (|i) and homogenate binding techniques, particularly competition 
studies using relatively selective labelled ligands. Table 2 summarises some of the 
selectivity demonstrated.
As a broad generalisation the opioid peptides derived from proenkephalin show 
selectivity for the 6 -receptor whereas those derived from prodynorphin show a 
selective affinity for the K-receptor. There is however, no strong link between the 
POMC derived opioids and the p,-receptor. From Table 2 it can be seen that 13- 
endorphin is equipotent at p and Ô and some prodynorphin products have some 
affinity for the p-receptor. Morphine remains the prototypical agonist for the p- 
receptor (Kosterlitz, 1985). It has been reported in mammalian tissues (Goldstein et 
al., 1985), a synthetic pathway proposed based on the identification of some of the 
precursors (Kodairah and Spector, 1988) and increases in alkaloid levels recorded in 
arthritic rats (Donnerer et al., 1986). However such observations are rare and 
morphine cannot yet be regarded as the endogenous ligand for the p-receptor.
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Table 2. Endogenous opioids and receptor selectivity
Peptide system 
Fragment
Receptor
selectivity
Reference
P-endorphin p=S (Lord et al ,  1977)
(McKnight eta l ,  1983)
Enkephalins
[Met]-enkephalin 0 >p (McKnight et a l , 1983)
ô » p (Lord etal ,  1977)
[Met]-enkephalin-Arg^-Phe^ 0 >|i (McKnight et a l , 1983)
0 >p (Wuster eta l ,  1981)
[Leuj-Enkephalin 6 >p (Lord et al ,  1977)
0 >p (McKnight et a l , 1983)
fe|i>K (Quiron, 1984)
Dynorphins
Dynoiphin A i.n K>p5 (Corbett etal,19S2)
Dynoiphin Ai.g k>p>6 (Corbett eta/., 1982)
lo p (James eta/., 1984)
Dynorphin B1 .2 9 K»p (James et al ,  1984)
Dynoiphin B1 .1 3 i o 6 >|i (Wuster et a/., 1981)
k>p>6 (Chavkin etal., 1982)
lopS (Corbett et a l , 1982)
ot-neoendoiphin K>p (James et al ,  1984)
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1.2 SELECTIVE LIGANDS FOR OPIOID RECEPTOR SUBTYPES
1.2.1 General discussion.
Clearly the prototypical agonist morphine and antagonist naloxone (Fig. 1) are very 
different in chemical structure from the endogenous opioid agonists (Table 1). The 
functional conformation of the peptide agonists must produce a molecule whose shape 
optimises potential interaction with a receptor binding site by presenting 
hydrophilic/hydrophobic, electrophilic/nucleophilic sites, charged groups etc in 
appropriate stereochemistry. The degree to which another, albeit unrelated, molecule 
mimics this stereochemistry will largely determine its agonist/antagonist potential. 
From the knowledge of the compounds that do interact with opioid receptors it has 
been possible to modify them and determine that part or parts of the molecule which 
are critical for binding and eliciting a functional response. Modified or even quite 
chemically different molecules which are predicted to have the appropriate surfaces 
have been screened for agonist or antagonist activity and above all for improved 
selectivity at the |X-, 6 - and K-opioid receptors.
The earliest methods of characterisation of these compounds for opioid 
activity/receptor selectivity were based on in vivo and in vitro pharmacological 
effects and these are still in use. The most frequently used criterion is the relative 
potency in the inhibition of electrically.evoked contractions of different isolated tissue 
preparations in which the opioid receptor population is exclusively or predominantly 
of one type or in which one type is deficient e.g. guinea pig myenteric plexus - 
longitudinal muscle, p/K (Cherubini and North, 1985; Lord et a l, 1977), rabbit vas 
deferens, k  (Oka et a i, 1980) and hamster vas deferens, Ô (McKnight et al., 1985). 
Where a receptor population is mixed e.g. guinea pig myenteric plexus, it is possible 
to irreversibly block one type by alkylation, thus leaving a 'pure' opioid-recepor-type
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preparation (Corbett et al., 1985). These approaches have been the subject of 
extensive reviews (Corbett etal., 1993; Leslie, 1987).
In terms of assessing the selectivity of compounds, the bioassays have some 
drawbacks. The measured response is never a direct measure of receptor - ligand 
interaction since a series of biochemical events will intervene. In the whole animal 
the system is even more complicated since the pharmacokinetics of the compound 
will influence it s access to the receptors e.g. failure to cross the blood - brain barrier 
may require intracerebroventricular (i.c.v.) or intrathecal (i.t.) administration. 
However, the ligand - receptor interaction will be observed in the natural functional 
state. Selectivity of agonists as defined by comparative potency i.e. the ability of the 
agonist to produce a response, in tissues with different opioid receptor populations is 
expressed as ED5 0  or IC5 0  but these are not direct measures of agonist affinity. This 
discrepancy arises because a maximal response may be elicited when only a 
proportion of the total receptor pool is occupied and this has been shown to be true of 
opioid receptors (Cox and Chavkin, 1983; Law et a i, 1983). This property of the 
agonist, which will vary between tissues (Cox and Chavkin, 1983) is termed it's 
efficacy and the relationship between potency and affinity depends on efficacy. The 
effect of a competitive antagonist is related directly to the number of receptor sites 
occupied (as opposed to the proportion of the whole) and depends on antagonist 
concentration and affinity. The selectivity of an antagonist and vice versa the use of a 
selective antagonist to classify a receptor population therefore has fewer theoretical 
limitations. However, care should be given to the interpretation of antagonist actions 
in isolated tissues since non-equilibrium steady-states can occur and measured against 
several different agonists in a heterogenous receptor population, ambiguous results 
can be obtained (Kenakin, 1985). For a full discussion of these topics see Leslie 
(1987).
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Quantification, characterisation and localisation of receptor subtypes requires 
selective ligands that can be radio-labelled. }i-, 5- and K-opioid receptors were 
defined according to their binding properties with the prototypical |i-, ô - and k- 
ligands (Goldstein and James, 1984; Lord e ta l, 1977; Paterson etal., 1983). The 
relative selectivity of new compounds can be measured by their ability to compete 
with the prototypical ligands but the selectivity demonstrated depends on the 
selectivities of the prototypical ligands and these have been found not to be as good as 
originally thought, often falling short of the minimum 1 0 0 -fold (preferably 1 0 0 0 -fold) 
higher affinity for the preferred site, the proposed criterion for opioid selectivity 
(Goldstein and Naidu, 1989; James and Goldstein, 1984). Nevertheless, as 
compounds of improved selectivity were sythesised or discovered, these could replace 
the original selective ligands as yardsticks against which others could be measured. 
The selectivity attributed to a ligand will vary depending on the assay system used, in 
particular varying between functionally based pharmacological assays and in vitro 
binding assays. In the subsequent discussion emphasis is placed on selectivity in 
ligand receptor-binding studies.
1.2.2 K-receptor ligands
1.2.2.1 K-receptor agonists
AAlthough as discussed in 1.1.3, prodynorphin products e.g. DYNi.n and DYN 
have some selectivity for the K-opioid receptor, the discrimination is not very great 
(Chavkin and Goldstein, 1981; Corbett etal., 1982; James etal., 1982). There has 
been little success in pursuing modifications of the endogenous opioids in the search 
for improved K-selectivity. An [1251] labelled K-ligand, DAKLI ([Argi hi3]dynorphin 
A-(l-13)Gly-NH2(CH2)5NH2) was produced which although it was useful since it was 
shown to have improved K-selectivity in binding to guinea pig brain membranes, was 
subject to rapid protease degradation (Goldstein etal., 1988).
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The early K-agonists were non-peptide and poorly selective. The benzomorphans 
ethylketocyclazocine and a derivative bremazocine, thought to be K-selective (Romer 
et al., 1980), proved useful in quantifying K-receptors only if used with ]X- and Ô- 
selective displacers. However they are still occasionally used in comparative studies 
(Emmerson et al., 1994). In bio-assays a 1,4 benzodiazepine derivative, tifluadom, 
was shown to be more potent than bremazocine (Romer et a i,  1980). At this time the 
first of the benzacetamide derivatives, U50,488 (Fig.3) was discovered to be K- 
selective (Von Voigtlander et al., 1983) and subsequently structural modifications 
produced molecules possessing much improved selectivity, U69593 (Lahti et al.,
1985), PD117302 (Clark et al., 1988) and CI-977 (Hunter et al., 1990). The 
benzacetamide derivatives proved useful K-selective agonists in binding studies as 
well as in bio-assays. (For a review see Corbett et al.^1993). Table 3 summarises the 
K-selectivity of agonists and antagonists as determined by homogenate binding 
methods.
1 .2 .2 .2  K-receptor antagonists.
Naloxone has historically been the best opioid antagonist in bio-assays because many 
antagonists show mixed agonist/antagonist effects either with increasing 
concentration or having different effects at the different opioid receptor subtypes. 
Naloxone and diprenorphine have a higher affinity for p- over 6- and K-receptors but 
their affinity for all opioid receptors is such that they are frequently used as displacers 
to allow non-specific binding to be determined in binding studies. The analogue of 
naloxone, naltrexone has been used as the basic structure from which further 
compounds have been developed which show competitive selective antagonism at the 
opioid receptors and also those which show selective but non-competitive irreversible 
binding. The design approach was not random but based on the concept that signal 
molecules have a recognition site more or less specific for a given receptor, that is the
17
Figure 3. The structure of K-selective agonists
(a)6anzomorphans
,N— CH2— ^  CH;—
' OH
-Cî^ CH3
:H2CI^  CH^ Hs
Ethylketocyclazocine Brem azocine
E K C
(b) Benzacetamides
CH,
o:,N — COCHj _ ^ ^ C I
y  /  U50<488
trans-3,4-dicliloio-N-methyl-N-[2-(l-pyirolidinyl>cyclohexyl]-benzeiE-acetainide
ÇHs
,j*N — COCH2 — ^  \  *
-OC
U69593 (* = ClmU62066Spiradoüne)
(5a,7a,8P)-(-)-N-meÜiyl-N-[7-( 1 -pyrrodinyl)-! -oxa^iro [4,5]dec-8yl]benzBne aceûmide 
CH,
N — COCH2
o PD117302
(±)trans-N-methyl-N-[2-(l-pyirodinyl)-cyclchexyl]benzD[b]-thiophene-4-acetamide
CH
N — COCH
CI977
(-)-N-meftiyl-N-[7-(l -pyrrodinyl)-! -oxa^iro[4,5]dec-8-yl]-4-benzDfuianacetamide
18
I!
I
I
f
1
1
I I i
8o\
I
8
o \
i
V)
00a\
ON es esoo oo
"q
O n ON
%
c Q Q
i % %
i O SE -p X)e O O
© © ©
8o\
I
8
ON
I
On
ON es
oo
wo ON
oo o sON Q
%) c«
S
Q o
% g i
1 1 1
s
ON
»o
00
ON
3
I
§
I
I
cs
o
ÎQo  *-< oo
cn o
<N
O oo o ON so § CO oj §
t 9 m
CO
O (S If)
I f )  CO O
OÎ
'A ^  
o
wo
I f)
ifi s
oi o
s
II
I
*o
I
>o
oo
CO
NO
CO
CS ON
o  o oo O < 8
czj ê  è  ê  a
f
è
II
è  è è è è
f
è I 6
I03
I I< i 1;I î Ic I ïm
19
I
m cs oo 00
0 \  ON
I 1
© © © ©
00
%
I
s
ON
S
ON
I
© ©
1 
1
m
I I I II gCOI cnI i i
ONCO
S wo r-CO 1—1 O  CO woo On 00CO & S3o  c> i
w
CO CO 
ON ON
I I
3
iZ
CO
© .
I or4
CO I
I
Tf- O  
WO ^oo A
tidû m
g  g
i i
s
NO wo
(1 oo es
9  ?  9 co es i
è  è  è  è
î
ê
i
I
1
I
• è
CDOO
8  i
i l
I I
20
!
oo
es es oooo 00 ON
ON ON 1-M
Q
Q Q %
%)
■§1 S I
g i i
oo OnON s
cs  ^ ON T-Ç oq NO ^  cs Tj; (N <N a
Jc T - I C S O O O O O
to
3 .
to
00in § ONCO cs
VO CS00 oo <N 00 o: PT-H O 1—1 1—I 00
I
1
1
I I I
è  8  è  è  è  è
1 îè % m
21
'address’ and a second site which interacts with the receptor protein, probably less 
specifically, to initiate signal transduction. This constitutes the 'message'. 
Alternatively a bivalent signal molecule with two pharmacophores separated by a 
'spacer', once bound to a receptor binding site, will effectively increase the local 
concentration of the ligand and so promote a second ligand-receptor interaction. If 
there is a mixed receptor population, the nature of the spacer may introduce a degree 
of receptor selectivity into the reaction (Portoghese, 1989; Takemori and Portoghese,
1992). Working on these principles the first selective K-receptor antagonist was 
developed, TENA (Portoghese and Takemori, 1985). The design principle was 
pursued resulting in the development of norbinaltorphimine (norBNI) which proved 
very potent in bio-assays and very K-selective. (Portoghese et al., 1987) (The 
structures are shown in Figure 4). However, later the compound was shown in vivo to 
be an antagonist at ji-, ô- and K-receptors depending on the administration regime 
(Spanagel e ta l, 1994).
1.2.2.3 Irreversible K-ligands.
A compound designed by structural modification of the K-agonist U50,488, was found 
to selectively acylate K-receptors. lS,2S-/ra«5-2-isothiocyanato-N-methyl-N-[2-(l- 
pyrrolidinyl)cyclohexyl]benzeneacetamide was structurally the same as UPHIT 
(Fig.4) but without the -Cl substitutions, UPHIT being 1S ,2S - Znzw -2-isothiocyanato - 
4,5-dichloro-N-methyl-N-[2-(l-pyrrolidinyl)cyclohexyl]benzeneacetamide.
Although both compounds will selectively acylate K-receptors, UPHIT has the 
advantage that it will do so after in vivo i.c.v. injection, reducing by 98% the 
receptors labelled by [3H]U69,593 and by 40% those labelled by pHJbremazocine 
with virtually no effect on \i- or 5-binding (de Costa et al., 1989).
22
Figure 4. The structure of K-selective antagonists
HO
2 TENA
V OH OH>
‘OH norBNIHO
H
CR,
NCS
UPHIT
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1.2.3 6-receptor ligands.
I.2.3.1 Ô-receptor antagonists.
(Table 4 illustrates the structure and acronyms of the 6-ligands mentioned in the 
following discussion). In contrast to the K-agonists, the 6-agonists of highest 
selectivity are those which have been developed i based on the structure of the 
relatively selective endogenous ligand [Leu]-enkephalin and more recently those 
developed from the naturally occuring heptapeptide found in frog skin, deltorphin. As 
well as increased selectivity, increased resistance to peptidase hydrolysis has been an 
important consideration in the development of agonists for use in bio-assays 
(McKnight et al., 1983). Substitution of D-alanine in position 2 of [Leu]-enkephalin 
was found to reduce the enzymatic cleavage of the N-terminal tyrosine (Belluzzi et 
al., 1978). This peptide, DADLE, although more potent in bio-assays was only 3-10 
fold selective for 6-receptor compared with p- in binding studies (Chang and 
Cuatrecasas, 1979). However it has frequently been used to to characterise 6-binding 
by using it in conjunction with DAGO (Tyr-D-Ala-Gly-MePhe-NH(CH2)20H), a [ i-  
selective ligand (Kosterlitz and Paterson, 1980). Other linear peptides have been 
produced such as DSLET and DTLET which are extended by a C-terminal threonine 
and have D-serine or D-threonine respectively substituted at position 2 (Gacel etal., 
1980; Zajac et a l, 1983). Although selectivity in bio-assays improved,the selectivity 
in binding assays did not show increases of the same order (James and Goldstein, 
1984).
Such peptides are flexible and if not constrained, will adopt a lowest energy 
conformation in solution, dictated by their primary structure. In close proximity to a 
receptor, a small conformational change may be induced which promotes binding. A 
single change in amino acid sequence or modification of one of the amino acid 
residues may make the ligand-receptor interaction less favourable and so change the
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affinity. It was shown that the selectivity for 6- over ji-receptors was principally due 
to reduced affinity for p-receptors. On the basis that the lower affinity was due to the 
Ser^ side chain hydroxyl, this was substituted with an 0-tertiary butyl group to make 
it even bulkier (DSTBULET), and a second such group substituted on the C-terminal 
threonine residue side chain (BUBU). Replacement of Ser^ with Cys carrying a S- 
tertiary butyl group gave the compound BUBUC which was five times more selective 
than BUBU (Gacel 1990).
The preparation of highly constrained cyclic analogues of the enkephalins, the 
bispenicillamine derivatives DPLPE and DPDPE produced molecules with better 6- 
selectivity but no dramatic improvement in affinity (Clark et al., 1986; Cotton et al., 
1985; Mosberg et al., 1983). Futher substited derivatives such as pCl-DPDPE 
showed improved selectivity (Toth et al., 1990; Toth et al., 1992; Vaughan et al., 
1989) but still selectivity in bio-assayswas considerably better than in binding studies. 
(For a review see Corbett, 1993).
In 1981, a p-selective heptapeptide given the name dermorphin was isolated from the 
skin of the South American frog Phyllomedusa sauvagii (Broccardo et al., 1981). 
While screening a cDNA library from this tissue to look for a larger precursor 
(predicted by comparison with the mammalian endogenous opioid systems) another 
heptapeptide sequence was predicted to show activity since it was flanked by the same 
signal amino acid sequences and would be generated by the same processing 
mechanism as dermorphin. This heptapeptide, given the name deltorphin, was first 
synthesised and subsequently extracted from frog skin (Kreil et al., 1989). It was also 
characterised and given the name dermenkephalin (DREK) following synthesis by 
another group (Amiche etal., 1989). Although the precursor sequence has L-Met at 
position 2, the active product arises from post-translational processing and has D-Met 
in this position. Initially characterised as 5-selective in bio-assays, these 
heptapeptides and derivatives [D-Ala^] deltorphins I and II isolated from the skin of
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p.bicolor, were demonstrated to be 0-selective in binding assays (Erspamer et al.,
1989). By studying synthetic analogues, shorter homologues and hybrids of 
dermorphin (|i-selective) and the deltorphins (6-selective) some understanding of the 
properties required to confer selectivity has been achieved (Lazarus et al., 1993; 
Melchiorri et al., 1991; Sagan etal., 1992; Sasaki etal., 1991). Figure 5 illustrates 
these findings.
Recently there have been reported nonpeptidic 6-agonists notably BW373U68. This 
compound showed 700 fold selectivity for 6-receptors over |i-receptors in bioassays 
but in binding studies the observed selectivity was only some 20 fold in rodent brain 
and spinal cord (Chang et al., 1993). In vivo given i.t , it produced naloxone 
reversible antinociception in the hot-plate and tail flick tests in the mouse but not 
when administered i.c.v., i.p. or by mouth and activity at both 6- and |i-receptors was 
indicated (Wild et al., 1993). It also showed significant toxic effects (Comer et a l,
1993). The methyl ester derivative (+)-SNC80 has been reported to show greater 
selectivity in bioassays, showing a 2000 fold preference for 6-receptors over ji- 
receptors. In parallel binding studies it proved only some 10 fold more selective than 
BW373U68 but it produced antinociception after i.c.v., i.t. and i.p. administration, 
appeared to be acting only via 6-receptors, not \L- and was free of toxic effects (Bilsky 
et aL, 1995). This compound thus appears to be the first systemically available, 6- 
selective nonpeptidic 6-agonist. An octahydroquinoline derivative, SB213689, has 
also been reported to show antinociceptive activity in the mouse abdominal 
constriction test when applied i.c.v. or i.p. but not sub-cutaneously (s.c.) and its effect 
was completely antagonised by the 6-selective antagonist naltrindole but not by 
selective p- or K-antagonists (Dondio etal., 1995).
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Figure 5. Structure/selectivity of biologically active heptapeptides from 
frog skin (C-terminal amide derivatives).
p-selective
Dermorphin Deltorphin
(DREK)
6-selective
D^ D"
TYR
d |a l a
PHE 
G
TYR 
PRO 
SER
NH.
TYR
D-MET
PHE
~ \ -------
HIS
I
LEU
MET
ASP(V(5)
I
NHo
TYR TYR
D-ALA D-ALA 
PHE PHE
— t ----------r —:
ASP(1X5) GLU(l)
VAL
VAL
G
n H.
VAL®
VAL®
GLY
I
NH.2 -J
N-terminal
common
'message'
C-terminal
'address'
(Sasaki etal 1991)
(4) (3)
(1) Negative charges produce large decrease in p-affinity and therefore increase 
6-selectivity (Melchiorri et al 1991,Sagan et al 1992)
(2) Hydrophobic VAL residues confer 6-selectivity and affinity VAL^ is particularly 
important (Sasaki et al 1991)
(3) Stepwise deletions give residues 1-6,1-5, and 1-4 which have increasing p-affinity, 
decreasing 6-affinity thus reversing selectivity (Salvador! et al 1991)
(4) Shortening reduces 6-affinity and selectivity (Melchiorri et al 1991)
(5) -ve charged ASP residues do not have a role in binding contact at 6-receptors nor
in maintaining conformational folding, but by preventing p-receptor recognition/binding, 
confer 6-selectivity (Sagan et al 1992)
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1.2.3.2 ô-receptor antagonists.
ô-opioid peptide antagonists by comparison with 6-opioid peptide agonists show 
poorer selectivity. Diallylation of the N-terminal amino group of some enkephalin 
related peptides and modification at position 3 and 4 produced some compounds with 
improved affinity and selectivity e.g ICI-174864 (Corbett et al., 1984; Cotton et al., 
1984).
The systematic approach to ligand design as indicated in 1.2.2.2, was also applied to 
the search for 6-selective ligands. The first highly selective 6-antagonist, an indole 
derivative of naltrexone, called naltrindole (NTI) was reported in 1988 (Portoghese et 
al., 1998p.,t>). " Figure 6 (a) and (b) show the possible similarity
between [Leu]-enkephalin and a non-peptide analogue of naltrexone with respect to 
the spatial arrangement of aromatic rings and other recognition elements. Figure 6(c) 
illustrates NTI, 5' naltrindole isothiocyanate (S'N'l’U) (Portoghese et al., 1990a) and 
the benzofuran derivative naltriben (NTB) (Sofuoglu et al., 1991), Figure 6(d) 
benzylidenenaltrexone (BNTX) (Portoghese etal., 1992) . In binding studies NTI 
was shown to have a 1000 fold greater 6-affinity than ICI- 174864 (Portoghese et al.,
1990) The very high affinity of NTI demonstrated in brain homogenate binding, Kd 
values are sub-nanomolar, and excellent selectivity make it the most useful 6- 
antagonist at present available (Yamamura et al., 1992).
Table 5 summarises a selection of studies carried out to determine the 6-selectivity 
shown in ligand binding studies, of the agonists and antagonists described in sections
1.2 3.1. and I.2.3.2.
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Figure 6. Comparison of non-pc.^ticleô-antagomsts and 
enkephalin structure
MESSAGE SPACER
(a) ' ' '
HO
COOH
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(b)
HO
JI________ I
SPACER ADHIESS
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NTI NH H
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1.2.3.3 Irreversible Ô-ligands.
There are also available selective irreversible inhibitors of 5-receptors including 
chemical and photoaffinity labels. FIT (Fig. 7) will bind to both |i- and 5-receptors 
but under irreversible conditions is a selective inhibitor of 5-binding. SUPERFIT 
(Fig. 7) ((+) cis-methyl fentanyl isothiocyanate) is 5-10 times more potent than FIT at 
acylating the 5-receptor. These compounds are analogues of a highly selective |i- 
agonist, fentanyl, and their 5-selectivity is a further example of the subtle differences 
in ligand moleules which can alter selectivity. The usefulness of this type of 
compound has been reviewed (Schiller, 1993; Takemori and Portoghese, 1985; 
Zimmerman and Leander, 1990).
1.2.4. p-receptor ligands.
1.2.4.1 ji-receptor agonists.
As already mentioned, it has been necessary to make use of p-selective ligands in 
order to study the 5- and K-receptors. The following is a brief resume confined to 
those p-selective ligands used in the references quoted in this thesis, p-selective 
ligands can be used to ’protect’ p-receptors prior to an investigation using a poorly p/5 
discriminating ligand which nevertheless has good p/5 selectivity over K-, e.g. 
DADLE. DAGO (Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol) is a modified enkephalin and 
shows very good p-selectivity (Kosterlitz and Paterson, 1981). PL 017 (Tyr-Pro- 
MePhe-D-Pro-NH2 ) is an agonist with a 600 fold preference for p- over 5- and a 
1500 fold preference for p -  over k- in binding studies (Chang et al., 1983; Corbett et 
al., 1993) which was developed from morphiceptin (Tyr-Pro-Phe-D-Pro-NH2 ), a p- 
selective nonenkephalin tetrapeptide (Chang et al., 1981). Dermorphin (Tyr-D-Ala- 
Phe-Gly-Tyr-Pro-Ser-NH2 ) is the p-selective heptapeptide isolated from frog skin 
(Broccardo et al., 1981). FK 33-824 (Tyr-D-Ala-Gly-(NMe)Phe-Met(0)-ol, a
36
synthetic pentapeptide (Roemer et al., 1977), has been demonstrated to be selective 
for p- over K-receptors by a factor of 380 fold in binding to rat brain homogenate 
(Lahti et al., 1982).
1.2.4.2 ji-receptor antagonists.
c r o p  (D-Phe-c[Cys-Tyr-D-Trp-0 m-Thr-Pen]-Thr-NH2 ) is an antagonist quoted as 
showing a 1000 fold preference for p- over both 5- and K-receptors (Corbett et al., 
1993).
1.2.4.3 Irreversible p-ligands
Irreversible inhibitors of p-receptors are also available, p-chlomaltrexamine (p-CNA) 
(Fig. 7) is a non-selective irreversible inhibitor at all opioid receptors but can be used 
against one subtype if the others are first protected by reversible selective ligands 
(Portoghese et al., 1979). p-fulnaltrexamine (p-FNA) is ashorfe-lived K-agonist 
exhibiting non-selective binding to all three receptors but under irreversible 
conditions is p-selective (Portoghese et al., 1980). BIT is a selective acylator of p- 
receptors (Rice et al., 1983). These ligands are illustrated in Figure 7.
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Figure 7 Irreversible opioid ligands
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1.3. SUBTYPES OF THE K- AND Ô-OPIOID RECEPTORS.
1.3.1 K -receptor su b typ es.
The earliest indication that there was a distinct k-opioid receptor population came 
from in vivo pharmacological characterisation in the dog using ketocyclazocine 
(Gilbert and Martin, 1976; Martin et a/., 1976) but early attempts to use [^HJEKC to 
demonstrate the separate existence of K-receptors in the rat brain were unsuccessful. 
Saturable high affinity binding was demonstrated but displacement studies did not 
suggest these opioid sites were different from those characterised by other opiates 
(Harris and Sethy, 1980; Hiller and Simon, 1979). The guinea pig brain proved to be 
richer in K-sites and as ligands of improved p- and 6 -selectivity (DAGO and DADLE) 
became available it was possible to identify residual [^HjEKC binding to K-sites 
(Foot and Maurer, 1982; Kosterlitz et a i, 1981). Very soon there were reports of 
differential displacement of K-binding in guinea pig lumbosacral spinal cord which 
was thought not to contain |X- or 6 -binding sites. pH]Etorphine showed high affinity 
binding to a single site completely displaced by DADLE whereas [^HJEKC bound at a 
greater density to high and low affinity components. Only part of the high affinity 
pH]EKC binding was displaced by DADLE thus dist^uishing DADLE sensitive and 
insensitive components (Attali et a i, 1982). In contrast, [^HJEKC binding in rat 
brain (with p- and 6 -sites blocked) was shown to have the binding characteristics of a 
single site and was readily displaced by DYN(_i7 and U50,488 (Weyhenmeyer and 
Mack, 1985), while there were other reports which confirmed high and lowcifinity 
binding (Castanas ef a/., 1985; Su, 1985). There was physiological evidence for 
multiple opioid K-receptors but correlation with binding studies was not definitive 
(Iyengar etal., 1986; Wood and Iyengar, 1986).
With the introduction of the benzacetamide ligands based on the original U50,488, a 
clearer distinction was made between the sites sensitive to DADLE inhibition and
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having a high affinity for DYNf.n» subsequently designated Ki, and those insensitive 
to DADLE inhibition and preferentially interacting with benzomorphans, named K2 . 
There are a number of reports which indicate that the original EKC sensitive 
population of receptors is certainly divisible into those with a high affinity for the 
benzacetamide ligands U50,488, U69,593 and PD117303, Ki and those from which 
the benzacetamides will not displace the benzomorphans, K2 . The benzomorphans 
invariably measure a higher density of receptors than the benzacetamides (Clark et 
al., 1989; Hunter et al., 1989; Tiberi and Magnan, 1990a). There has also been 
demonstrated a differential distribution of 1150,488 sensitive and insensitive sites 
(Nock et al., 1988a; Zukin et al., 1988). Proposals for further subdivisions have 
come from a number of studies. Using a variety of different species, binding 
conditions, endogenous opioids and synthetic ligands there have been reports of Ki 
subtyes, Kia and Kg (Clark etal., 1989; Kinouchi and Pasternak, 1991) and a K3 
subtype (Cheng etal., 1992; Clark et al., 1989). Also recorded are K2 high and low 
affinity states in guinea pig spinal cord (Tiberi and Magnan, 1990), two K2  sites 2A 
and 2B which differ in rat and human from those in the guinea pig (Rothman et al., 
1990; Rothman et al., 1992) and a K2b and two K2a  sites in the rat brain (Ni et al.,
1993). In vivo analgesic tests have been hypothesised to demonstate a K3 mediated 
effect. In the mouse, the mixed agonist/antagonist naloxone benzoylhydrazone 
(NalBzoH) was shown to be a p,- and Ô-antagonist and to antagonise Ki analgesia 
elicited by U50,488. However at higher doses NalBzoH produced analgesia via a 
supraspinal opioid site hypothesised to be a K3 site (Gistrak et al., 1989; Paul etal.,
1990).
The diversity of K-receptor subtypes postulated from homogenate binding and 
autoradiographic studies is poorly supported by in vivo or in vitro pharmacological 
evidence in part probably due to the fact that what appears to be an adequately 
selective ligand in a binding assay may not exert its effects through the same receptor 
in a pharmacological assay and because of pharmacokinetic considerations (Goldstein
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and James, 1984). A K2 selective ligand is needed to help to clarify the problem. Data 
suggest that the non-equilibrium antagonist UPHIT (Fig. 4) is selective, 
differentially antagonising U69593 and bremazocine analgesia in the warm water tail- 
flick test demonstrating a heterogeneous K-receptor population in the mouse (Horan et 
al., 1991) The complexity of the observations on K-multiplicity from binding studies 
is summarised in Table 6  and the evidence for K-receptor multiplicity is reviewed by 
Mansour et al. (1993) and Wolleman et al., (1993).
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1.32 ô-receptor subtypes.
Although it is nearly 20 years since the existence of 5-receptors as distinct from |X- 
and K-opioid receptors was postulated, it is only with the recent development of 
selective peptide agonists and non-peptide antagonists as described in 1.2.3 that a 
significant amount of evidence has accumulated which, as in the case of K-receptors, 
suggests but does not yet unequivocally prove the existence of 5-opioid receptor 
subtypes. There were earlier indications, based on a 30-fold difference in binding 
affinity, that the rat brain 5-receptors differed from those in the mouse vas deferens 
(Shimohigashi etal., 1987; Vaughn et al., 1990). In contrast to the indications that 
there may be subtypes of the K-receptor, which is primarily based on binding studies, 
the majority of the evidence for 5-receptor subtypes originates from in vivo and in 
vitro pharmacology.
In the early 1980s, work was published that suggested interactions between p- and 5- 
opioid receptors (Lee et al., 1980; Rothman and Westfall, 1982; Vaught et al., 
1982). Subsequent investigations led to the hypothesis that there existed a 5- 
noncomplexed (5ncx) and a second 5-complexed (5cx) site which was closely 
associated with the p-receptor. In the mouse tail immersion antinociceptive test 
intracerebroventricular (i.c.v.) morphine effects were potentiated by i.c.v. DPDPE at a 
dose which by itself would produce no antinociception and no cross tolerance 
between morphine and DPDPE could be demonstrated. This indicated that morphine 
and DPDPE were acting at different receptors, presumably p,- and 5- but the 5- 
receptor occupancy influenced the p-mediated antinociception. [Met]-enkephalin 
however, inhibited the antinociceptive effects of morphine and both positive and 
negative regulatory effects were prevented by the 5-selective antagonist ICI 174864. 
At the spinal level using intrathecal (i.t.) administration, cross tolerance between 
morphine and DPDPE was demonstrated and there was no potentiation of morphine’s 
effects by DPDPE which indicated the two agonists acted at a common site (Porreca
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et al., 1987). The short term Ô-agonist, long term irreversible Ô-antagonist DALCE 
administered i.c.v. was shown to antagonise DPDPE antinociception but not to 
influence the modulatory effects of DPDPE and [Leu]-enkephalin on morphine 
antinociception. Thus DALCE discriminated between supraspinal 6 -receptors which 
modulated p-mediated antinociception and those 5-receptors directly mediating 6 - 
agonist induced antinociception (Jiang et a i, 1990).
At the biochemical level, in rat striatal slices, inhibition of dopamine-stimulated 
increase in cAMP by DAGO was antagonised by 0.1 pM naloxone (a level insufficient 
to antagonise at 6  -receptors) and DPDPE stimulated increase in cAMP was 
antagonised by FIT (irreversible 5-antagonist). Although DAGO was not antagonised 
by FIT, in its presence naloxone could no longer antagonise DAGO indicating some 
common function of the p.- and 5-opioid receptors (Schoffelmeer et al., 1988) Also, 
cross linking of [^^Ijp-endorphin to opioid receptors in rat striatal membranes, 
visualised as a single high molecular weight band after polyacrylamide gel 
electrophoresis, was shown to be blocked by both p- and 5 -selective ligands 
suggesting interacting p-/5-receptors. In contrasty the same procedures using bovine 
frontal cortex membranes resulted in two smaller molecular weight bands, not 
indicating any cross linking and therefore not suggesting p-/5 -association in this 
species (Schoffelmeer etal., 1990) .
Observations made using newer 5-ligands have led to the concept of two subtypeSj5i 
and 5 i2^which are as yet not reconcilable with the previously envisaged 5ncx and 5cx 
receptors. The most frequently used model for the assesment of 5-mediated 
antinociception has been the warm water tail flick latency in the mouse and drug 
administration has been both supraspinal (i.c.v.) and spinal (i.t.). NTI and the 
derivative NTB were shown to shift the ED50  of i.c.v. DSLET ^-fold but that for 
DPDPE only 1.4-1.8 fold. When administered i.c.v. there was no cross tolerance 
betwen the two peptides. These results indicated mediation by different receptors
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possibly ô-opioid subtypes (Sofuoglu et al., 1991). Similarly, the antinociceptive 
actions of i.c.v. [D-Ala^] deltorphin U and DSLET were antagonised by 5'NTH but 
not DALCE whereas DPDPE antinociception was sensitive to DALCE but not 5'NTQ 
(Jiang et al., 1991). Receptors activated by DPDPE and blocked by DALCE were 
designated 6 i and those mediating the effects of DSLET and [D-Ala^]deltoAin II and 
blocked by 5'NTII, designated Ô2 . Lack of cross tolerance between DPDPE and [D- 
Ala^jdeltorhin II administered i.c.v. has been demonstrated (Mattia et al., 1991) 
however DPDPE has been shown to have some agonist activity at the Ô2 -receptor in 
mice while the 0 2 -selectivity of [D-Ala^] deltorphin II was supported (Vanderah etal.,
1994). Supraspinal dosing regimes demonstrated that the modulation of |i-mediated 
antinociception was antagonised by pretreatment with the Ô2  antagonist 5’N’l'll but not 
by the Ô1 antagonist DALCE (Porreca et al., 1992). This suggested that there was 
some similarity between the 6 2  -receptor and the hypothesised ôcx -receptor.
Spinally-mediated antinociception induced by i.t. [D-Ala^jdeltoijiin II, DPDPE and 
the acute effects of DALCE were all blocked by pretreatment with doses of 5’NTII, 
whereas DALCE pretreatment did not have this effect which indicated that whatever 
the presumed selectivity of the agonists, at the spinal level their effects were mediated 
via the 5’NTII sensitive Ô2  -receptor subtype (Mattia et al., 1991). In contrast, both 5i 
and Ô2 -mediated spinal antinociception was observed when evaluating the 5 1-selective 
antagonist BNTX (Sofuoglu etal., 1993).
Binding studies in mouse brain showed higher levels of Ô-binding when measured 
with pH]DSLET than with pH]DADLE or [^HjDPDPE and DSLET was equipotent 
in displacing pHJDADLE, [^HJDPDPE or pH]DSLET. NTB, although in vivo 
preferentially antagonising DSLET (Sofuoglu et al., 1991a), showed no difference in 
it’s ability to compete with all three ligands in the binding studies (Sofuoglu et al.,
1992). Comparison of the binding of the antagonist [^H]NTI and the agonists pH][4’- 
Cl-Phe^]DPDPE and p  H][D-Ala^]deltorphin II in mouse brain and vas deferens
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suggested that in the brain the agonists recognised two sites whereas [^H]NTI binding 
fitted a one site model. In the vas deferens all ligand binding fitted a one site model 
(Fang et al., 1994), an observation in agreement with an earlier demonstration of 
single site binding in the vas deferens (Wild e ta l, 1993).
Rather fewer observations have been made in the rat. Supraspinally, [D- 
Ala^]deltorphin ü, the Ô2 agonist, administered i.c.v has been demonstrated to elicit 
behavioural responses and exert hypothermic effects reversed by NTI but not to elicit 
antinociception in the thermal tail-flick test (Broccardo and Improta, 1992; Negri et 
al., 1991). However,suprasinal p.-/Ô-synergy was observed using DAGO and DPDPE 
by measuring antinociceptive effects using the paw pressure test (Miaskowski etal.,
1991). [D-Ala2]deltorphin II was also shown to elicit antinociception when 
administered at the spinal level but the effects of the antagonists NTI and naloxone 
suggested a possible |i-/ô- interaction (Improta and Broccardo, 1992) A similar 
conclusion, i.e. the possibility of |i-/ô- interaction in the spinal cord of the rat was 
postulated from the results of an investigation into antinociception, evaluated by the 
thermal hot-plate test, using the antagonists NTI and naloxone against DPDPE, 
DADLE and DAGO (Tiseo and Yaksh, 1993). [D-Ala^jdeltorphin II (Ô2 selective) 
and DPDPE (5i selective) administered i.t., have both been shown to elicit 
antinociception in the tail flick test in the rat and NTB (Ô2 selective antagonist) to be 
effective only against [D-Ala^jdeltorphin but in the hot-plate test, the same dose of 
NTB antagonised DPDPE suggesting DPDPE had 82 activity and higher levels of 
NTB antagonised DPDPE in both tests (Stewart and Hammond, 1993). Using the 
carragenan induced hyperalgesia model, the possibility that NTB is Ô2 -selective only 
over a limited dose range was again demonstrated and also that it may have activity at 
p.- or associated p-/5-receptors (Stewart and Hammond, 1994). In the 25 day-old rat a 
clearly different agonist profile has been demonstrated using NTB and NTI against 
DPDPE, DSLET and DELT I suggesting distinct 5 -subtypes (Crook et al., 1992; 
Crook et al., 1993). In the rat tail immersion test, i.p. NTI at 0.1 mg/kg completely
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* (Portoghese e ta l . ,  1992b).
reversed the effects of an ED7 5  dose of DPDPE and DSLET but did not alter the 
response to DELT I (Crook et a l, 1992). At a lower dose the attenuation of the 
DSLET response was greater than that of the DPDPE response. Similarly, NTB at 
5mg/kg completely abolished antinociceptive responses to DSLET with no effect on 
DPDPE or DELT I (Crook et a l, 1993). The attenuating effects of NTI against the 
three agonists were of the order DSLET > DPDPE »  DELT I and of NTB, DSLET 
»  DPDPE > DELT I suggesting that DPDPE and NTI show less discrimination 
between putative 0%- and 6 2 -sites than NTB and DSLET which show a 6 2 -selective 
profile. The DPDPE/DSLET/NTB profile of sensitivity was similar to that 
demonstrated in the mouse (Sofuoglu et a l, 1991). However the relative insensitivity 
of DELT I antinociception to antagonism by both NTI and NTB when compared with 
that of DSLET, suggests that in the young rat DELT I acts at a different site to 
DSLET. Together with the DPDPE responses, this indicates that DSLET acts at the 
putative 6 2 -site, DELT I at the putative 6 1 -site although in the mouse it has been 
suggested that the very similar DELT II has a greater affinity for the 6 2 -site (Mattia et 
al,\99\;  Mattia et a l, 1992) and that DPDPE, although having an affinity for both is 
more potent at the 6 1 -site. Overall these results emphasise that selectivity is relative 
and will vary subject to experimental conditions including test used, dose range 
investigated, species and route of administration.
The difficulty of resolving the separate existence of 6 cx, 6 ncx and 6 %, 6 2  receptors, 
clearly associating the two pairs and correlating in vivo studies with homogenate 
binding studies is exemplified within one report in which the properties of 
isothiocyanate derivatives of naltrindole including 5'NTII, were investigated in 
smooth muscle preparations in vitro, antinociceptive models in the mouse in vivo and 
in binding studies with guinea pig brain homogenate. -NCS was substituted at 
positions 4-7 (see Fig. 6 (c)). All were 6 -selective antagonists in vitro, the 7 -isomer 
being the most potent but least selective. In in vivo antinociceptive studies the 5'- 
isomer was very potent and discriminated between the 6 1  agonist DPDPE and the 6 2
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agonist DSLET . In binding assays all the isomers significantly reduced [^HJDPDPE 
binding with negli^le effect on Kd whereas for pH]DSLET the Kd showed marked 
increase and B^ax showed very large increase, by a factor of 9 for the 4-isomer, xl5 
for the 5’ and >x30 for the 6 '-isomer which is an unusual observation but clearly 
differentiates between recognition sites (Portoghese et al., 1992b). No adequate 
explanation for the conflicting observations is available although interspecies 
variation may be a contributary factor since the antinociception was observed in the 
mouse and the binding studies were carried out in guinea pig brain homogenate. Thus 
in spite of discriminating ligands having become available, the nature of the apparent 
sub-types of the 6 -receptor remains unclear and whether they represent 6 -receptors 
unassociated or associated with ji-receptors, coupled or uncoupled to signal 
transduction molecules, truly separate gene products, the result of post-translational 
modifications or simply the same protein showing different characteristics as a 
consequence of the membrane environment remains to be resolved.
51
1.4 MOLECULAR PHARMACOLOGY OF THE Ô- AND k-O P IO ID  
RECEPTORS.
1.4.1 Receptor isolation and cloning.
Once opiate receptors had been demonstrated to exist, intensive efforts began to 
separate and purify the membrane-bound protein or proteins. Following solubilization 
of the membrane components with a variety of detergents, separation of the 
components was attempted by means of density gradient centrifugation, sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis or column gel filtration. 
Success was limited, frequently only a partial purification being observed and 
reconstitution of active opioid binding proved difficult to achieve. The first purification 
to homogeneity of an inactive 5-opioid receptor from NG108-15 cell membranes was 
reported by Simonds et al. (1985) and a partial purification and reconstitution of active 
receptor protein from bovine frontal cortex (Gomathi and Sharma, 1993). An active Ô- 
receptor has also been purified from rat brain (Loukas et al., 1994). The first physical 
separation of active K-opioid receptor from guinea pig brain was reported in 1984 (Itzak 
et al., 1984) and later from Rana esculenta brain homogenate (Simon et al., 1987). 
Human placental tissue has been used as a source of K-opioid receptors and a 
preparation has been made which has a high affinity for K-ligands (U50,488H and 
DYN^g) and shows specific binding at 50% of theoretical levels (Ahmed et al.., 1989). 
Purification of an active |i-ligand binding receptor protein derived from bovine striatum 
and firom rat brain has been documented (Cho et al., 1986; Gioannini et al, 1994).
The isolation of opioid receptor protein opened up the possibility of synthesising 
radiolabelled RNA sequences cor^sponding to some part of the amino acid sequence. 
These could then be used to screen the fragmented genomic library of appropriate 
eukaryotic tissues expressed in bacteria by means of plasmid or phage vectors. 
However, an alternative method of screening was used which resulted in the virtually
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simultaneous isolation and cloning, by two different groups, of the DNA coding for a 
protein having the characteristics of the 6 -opioid receptor (Evans et al., 1992; Kieffer 
et al., 1992). Both used NG108-15 cells which express high levels of 6 -receptor. 
When proteins are being expressed in a cell there wiU be quantities of the corresponding 
mRNA present and although at any one time there will be many functional RNAs it is 
possible to search out the required message. The mRNA from an actively growing 
culture of NG108-15 cells was extracted and a cDNA library constructed from these by 
means of a reverse transcriptase, a viral enzyme capable of synthesising DNA from an 
RNA template. From the single stranded complementary DNA a double stranded 
cDNA was obtained using DNA polymerase. The double stranded cDNA thus obtained 
was incorporated into a plasmid which also contained a mammalian expression vector 
and the plasmids amplified in bacterial cells. Plasmid double stranded cDNA was 
extracted from pools of bacterial colonies and transfected into COS-1 cells. COS -1 
cells are monkey kidney fibroblast cells modified to replicate plasmids which contain 
the appropriate origin of replication and if a eukaryotic promotor is present, will 
transcribe mRNA and proceed to manufacture the protein. If the complete receptor 
protein coding domain is present, the receptor will be expressed and inserted in the cell 
membrane where it may be characterised by ligand binding and/or appropriate 
physiological response. [i^I]DADLE (Evans) or [^HQDTLET (Kieffer) were used to 
identify cells exhibiting functional 6 -receptor expression, plasmid DNA isolated, 
transfected to bacteria and thence again to COS-1 cells. Repeated cycling eventually 
produced a pure cDNA clone designated DOR-1 (6 -opioid receptor - 1). PCR 
(polymerase chain reaction) was used to generate sufficient quantities of the DOR-1 
DNA for sequencing. The DNA comprised 2.2 kbases encoding a 372 amino acid 
residue protein. The NG108-15 cell line is a hybrid cell line between mouse N18TG 
neuroblastoma and rat C6 Bu-l glioma cell lines and the origin of the DOR-1 receptor 
DNA had to be established. By sequence comparison of a 3' noncoding region of the 
DNA (not thought to be conserved among different species) with mouse and rat 
genomic DNA, a 100% match was made between the mouse genomic DNA and the
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cloned DNA (Kieffer et al., 1992). Cloning of the same nucleotide sequence for the 6 - 
receptor from mouse brain cDNA library supported this finding (Yasuda et al., 1993). 
The murine DOR has been expressed in the CHO-DG44 cell line and characterised by 
ligand binding displacement studies. It was demonstrated that DSLET and [D-Ala^]- 
deltorphin II ( 6 2  selective) were more potent than DPDPE (Ô1 selective) in displacing 
[^Hjnaltrindole and naltrindole and NTB (6 2 ) more effective than BNTX (6 1 ) thus 
showing a resemblance to the 6 2  -receptor (Raynor et al., 1993). Further studies have 
been carried out in which 2 0  base oligonucleotides from the 5 -end of the coding 
sequence of the cloned receptor, both sense and antisense, were applied i.c.v. in mice 
prior to antinociceptive testing with ô-selective compounds. It has been shown that 
treatment with an antisense oligonucleotide sequence produces changes in receptor 
number by a mechanism which is as yet unclear (Wahlestedt, 1994). In the 
experiments with the 5-receptor antisense oligonucleotides, mice treated for three days 
showed a selective inhibition of the antinociception produced by [D-Ala^]-deltorphin II 
as measured by the hot-plate test and the tail-flick test but no change in the 
antinociception produced by the administration of DPDPE. Sense oligonucleotide- 
treated animals showed no change in responses. Assuming the antisense 
oligonucleotide suppressed the expression of the receptor protein for which the 
co&sponding sense sequence part-coded, these findings further confirm the similarity 
of the pharmacological profile of the cloned 5-receptor with that of the hypothesised 5 2 - 
receptor (Lai et al., 1994).
PCR amplified probes corresponding to lengths of the mouse DOR-1 were 
subsequently used to 'fish' for other opioid receptor DNA by hybridizing with cDNA 
libraries from other sources. The rat 5-opioid receptor was cloned and shown to 
comprise 372 amino acid residues with a 97% amino acid identity between the two 
(Abood et al., 1994; Fukuda et al., 1993). Human 5-opioid receptor has also been 
cloned (Knapp et al., 1994).
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While screening a mouse cDNA library for somatostatin receptor subtypes, a receptor 
with a high homology to the mDOR-1 was found and when expressed in COS cells 
showed binding characteristics of the K-opioid receptor (Yasuda et al., 1993). Later, 
isolation and chromosomal assignment was documented (Nishi et al., 1994). There 
followed several independent reports of the cloning of the rat K-opioid receptor (Chen 
et al., 1993; Li et al., 1993; Meng et al., 1993; Minami et al., 1993; Nishi et al.,
1993). The sequence of 380 amino acids (in both rat and mouse) showed 98% amino 
acid identity. However, there are two amino acid differences in the primary structure of 
the protein as reported by the five groups. A guinea pig K-opioid receptor was shown 
to have 89% homology with the mouse and rat K-receptors (Xie et al., 1994). An early 
report of a putative human K-opioid receptor from placenta suggested that it comprised 
440 amino acid residues (Xie et al., 1992) but subsequently a 380 amino acid residue 
with a 91% homology with the rat K-opioid receptor was identified (Mansson et al., 
1994; Simonin gf a/., 1995).
|i-opioid receptor cDNA has also been cloned and expressed (Chen et al., 1993; 
Fukuda et al., 1993; Wang et al., 1993) and a cDNA clone from rat brain coding a 367 
residue protein showing opioid receptor homology but not opiate binding when 
expressed (Chen et al., 1994; Fukuda et al., 1994; Wang et al., 1994). A human 
receptor showing ji-selective DAMGO binding has been cloned and expressed (Raynor 
etal., 1995).
No distinct subtypes of the three individual gene products, the |X-, 6 - and K-opioid 
receptors, have yet been identified. However an isoform of the rat |i-opioid receptor 
rMORl has been isolated, rMORlB, in which 386 residues are identical. The small 
differences in the C-terminal end were shown to have little effect on the ligand binding 
profile or the ability of the receptor to inhibit adenylate cyclase when expressed in 
CHO-Kl cells but the receptors were more resistant to agonist induced desensitization 
(Zimprich et al., 1995a). Both were also shown to increase [Ca^+J by IP3 mediated
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release from internal stores (Zimprich et a l, 1995b). Also reported is a 367 residue 
protein the cloned cDNA of which was used to produce a 20 base antisense 
oligonucleotide which was demonstrated to block K3 -mediated naloxone 
benzoylhydrazone (NalBzOH) analgesia in vivo in the mouse (Pan et al., 1994). 
When expressed in COS-7 cells, opioid binding and inhibition of adenylate cyclase 
proved difficult to demonstrate and the exact nature of the receptor remains 
unconfirmed. Other putative members of the opioid receptor family have been 
tentatively identified principally on the basis of their homology with the known |i-, 5- 
and K-opioid receptors but little definitive opioid mediated function has been observed 
in the expressed receptors (Mollereau et al., 1994; Wang et al., 1994; Bunzow et al., 
1994; Keith et a l, 1994). There is, at present, insufficient evidence that the putative 
subtypes of the |i-, 6 - and K-opioid receptors suggested by their pharmacology and by 
binding studies are separate gene products.
1,4.2 Structural features of the opioid receptors
Guanine nucleotide-binding regulatory proteins (G-proteins) have been established as 
mediators of transmembrane signalling. Many receptors are linked to G-proteins and a
ut
number of intracel^ effector systems are in turn influenced by them. (For reviews see 
Bimbaumer et al., 1990; Graziano and Gilman, 1987; Stryer and Bourne, 1986). 
Early observations of opioid binding to brain membranes indicated that binding was 
influenced by the presence of ions and GTP (Blume, 1978; Blume et al., 1979; 
Childers and Snyder, 1980; Pasternak et al., 1975). Therefore when the role of G- 
proteins in signal transduction began to be understood there were already indications 
that the opioid receptors may be similar to other membrane bound receptors which 
interacted with G-proteins.
Hydropathy analysis of the amino acid sequences of the cloned opioid receptors 
suggested that there would be seven transmembrane helices and in these transmembrane
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regions the amino acid sequences were between 73-76% identical in the three gene 
products. The first and second extracellular loops each had cysteine residues, probably 
critically involved in preserving the approprite conformation by disulphide bonding, 
which are typically conserved in G-protein-linked receptors. The intracellular loops 
show 63-66% homology in the three receptors, typically have several potential 
phosphorylation sites on the 2nd and 3rd loop and the C-terminal domain and cysteine 
residues that may undergo palmitylation. The extracellular regions exhibit only 34-40% 
identity but all have potential sites for N-linked glycosylation. Compared with other G- 
protein coupled receptors, closest homology is with somatostatin receptors (34-42%) 
(Evans et al., 1992; Kieffer et al., 1994; Minami and Satoh, 1995).This is significant 
since somatostatin and its analogues will bind to opioid receptors (Mulder et al., 1991). 
Overall, the closest homology is with other peptidergic receptors (Evans et al., 1992).
1.4.3 Second messenger systems and the opioid receptors.
The principle effector systems associated with G-proteins identified at present are the 
stimulation or inhibition ' * of adenylate cyclase, the stimulation of phosphoinositol 
turnover and direct G-protein coupling to a K+ channel or to a Ca^+ channel 
(Bimbaumer et al., 1990). Opioid effects have been observed on all these effector 
systems. The most frequently used criteria to confirm that opioid mediated 
responses are coupled to effector systems via G-proteins are the demonstration of 
specific guanine nucleotide regulation of agonist binding, agonist stimulation of 
GTPase activity and inhibition of adenylate cyclase activity which is sensitive to (a) 
pertussis toxin which covalently modifies Gi by ADP ribosylation and thus blocks 
opioid inhibition of adenylate cyclase and (b) cholera toxin which has the same effect on 
Gg causing persistant activation of adenylate cyclase and overrides any opioid inhibitory 
effects. (Inhibition may be measured against basal levels of cAMP or by reduction of 
direct forskolin stimulated increases in cAMP). While opioid effects on K+ and Ca^+ 
fluxes have been observed evidence suggests that there are a number of mechanisms
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involved, among them, direct G-protein interaction with membrane ion channel protein, 
interaction of the adenylate cylase system with membrane ion channel protein and 
release of Ca^+ from the endoplasmic reticulum via the inositol phosphate system. 
Some of the published evidence for 5- and K-opioid - G-protein - effector links is 
shown in Table 7.
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1.5 DISTRIBUTION OF OPIOID RECEPTORS IN THE CNS
1.5.1 An overview.
The presence of opioid receptors was originally established using homogenate binding 
techniques on whole brain or spinal cord and then on homogenatesfrom specific 
regions. The developmentdf in vivo and in vitro receptor autoradiography allowed 
more accurate determination of the anatomical distribution of opioid receptors. Early 
studies were hampered by the lack of selective ligands which made the identification 
and quantification of the |X-,6- and k-subtypes difficult. The development of more 
selective ligands ( see 1.2) made discrimination possible but whether the receptors 
were located in the membrane of cell bodies or were present on fibre terminals fi'om 
distant cells was and still is, difficult to determine. Immunohistochemical techniques 
have improved discrimination between subtypes and with the cloning of the three 
principle opioid receptors, in situ hybridization has enabled the identification of 
receptor specific mRNA expression (George etal., 1994; Mansour et al., 1994). The 
combination of techniques and comparison of the data has enabled some detailed 
mapping of the receptor distribution and helped to rationalise some of the 
pharmacological effects of opioids by showing the receptor to be located in the 
hypothesised pathways or closely associated with the brain areas thought to be
Ol
involved in the responses. This is particularly true of the hypothalmic-pituitary axis. 
The putative endogenous opioid ligands and their precursors have also been mapped 
using immunocytochemical techniques and in situ hybridization and have been used 
for comparison with receptor mapping (Arvidsson et al., 1995; Mansour et al., 
1993a). Detailed reviews of the anatomical distribution of opioid receptors can be 
found in Mansour, 1995; Mansour and Watson, 1993.
It is not possible to generalise across species because the opioid receptor subtype 
densities and also their distribution have been shown to differ markedly between
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species (Blackburn efû/., 1988; Robson era/., 1985; Rothman er a/., 1992; Yobum 
et al., 1991). Futher discussion will centre on studies in the rat and in particular 
identification of receptors in pathways and areas associated with the perception of 
pain.
1.5.2 The d istr ib u tion  o f  K -opioid receptors.
Initially it was reported that there was no evidence for separate K-opioid receptors in 
rat brain and spinal cord (Harris and Sethy, 1980; Hiller and Simon, 1979). These 
studies used [^H]EKC, the unlabelled form of which had, from it's in vivo 
pharmacology implicated the existence of an opioid receptor at which EKC did not 
show cross tolerance with morphine (Martin et al., 1976). Very soon afterwards there 
were reports of biphasic displacement curves for EKC v. dihydromorphine (DHM) 
suggesting that DHM did in fact label at least two sites distinguished by EKC 
(Wolozin et al., 1982). The rat brain was shown to contain K-receptors measured 
using [3H]bremazocine with p- (DAGO) and 6- (DADLE) suppression (Gillan and 
Kosterlitz, 1982). Subsequent studies showed that of the four species investigated, 
the mouse, the rabbit, the guinea pig and the rat, the rat exhibited the lowest 
proportion of K-receptors: GP 44%, rabbit 37%, mouse 20% and rat IZ% (Robson et 
al., 1985). This study made regional estimates of K-binding and showed it to be 
highest in the midbrain, hypothalamus and striatum. The paucity of K-binding as 
measured with EKC was further demonstrated, being 39 fmol/mg protein as compared 
with 179 fmol/mg for DHM (p,-) and 205 fmol/mg for DPDPE (6-) (Weyhenmeyer 
and Mack, 1985). However^ the importance of giving due consideration to the 
methods used by different research groups is illustrated by the report that in the 
presence of p,-selective (BIT) and 6-selective (FIT) ablating agents, at 0°C and in the 
presence of 0.4M sodium chloride, pH]bremazocine labelled K-sites were measured 
at 378 fmol/mg protein in rat brain membranes (minus cerebellum) (Rothman etal..
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1985). Almost all other reports suggested that K-sites in the rat brain were relatively 
low being 1/3 to 1/5 of the fx- and 5- levels (Mansour e ta l, 1986).
There has been general agreement that there is a concentration of K-receptors in the 
nuclei of the hypothalamus (Mansour et al., 1987; Mansour et al., 1988; Morris and 
Herz, 1986; Sharif and Hughes, 1989). Conflicting evidence (Desjardins et al., 1990) 
may have arisen as a result of using different ligands as 'K-selective' particularly since 
K-sites have been shown to be a mixed population all having affinity for the 
benzomorphans but only a proportion, K%-, being recognised by the benzacetamides 
(see 1.2). Other areas where it has been generally demonstrated by autoradiographic 
ligand binding studies that there is a concentration of K-receptors include the nucleus 
accumbens and olfactory tubercule and moderate levels are reported in the deeper 
cortical layers V and VI, the caudate putamen, the thalamus and periaquAductal grey 
(Mansour, 1995; Mansour and Watson, 1993; Nock et al., 1988a; Zukin et al., 
1988). The neural lobe of the pituitary is reported to have exclusively K-sites 
(Herkenham et al., 1986).
Identifying receptor sub type-specific mRNA can be a more selective method for 
identifying receptor protein expression. Given the high degree of homology between 
the receptor sub types the oligonucleotide probe should be chosen with care and high 
stringency conditions applied to the hybridization to reduce the possibility of any 
cross-recognition. The density and location of receptor mRNA has been shown to 
correspond well with previous identification of K-receptors using ligand 
autoradiography (George et al., 1994). Moderate levels were demonstrated in the 
somatosensory cortex, periaqueductal grey, nuclei of the thalamus and hypothalamus 
and the amygdala. High levels were described in the claustrum, hippocampus, the 
caudate putamen and nucleus accumbens of the corpus striatum, the substantia nigra 
in the brain stem and additional nuclei in the thalamus and hypothalamus (Mansour et 
al., 1994JÈJ. Direct comparisons have been made between K%-receptor mRNA, Ki-
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receptor binding and prodynorphin mRNA (Mansour et al., 1994a). Good correlation 
was found and discrepancies between for example, ligand binding and receptor 
mRNA expression can be explained by receptor transport to the distal nerve terminal. 
The detailed findings of this study are beyond the scope of this commentary but in 
summary, K-receptor mRNA was expressed in the claustrum, nucleus accumbens, 
amygdala, hypothalamic and thalamic nuclei, raphe nuclei and nuclei in the solitary 
tract. The presence of K-receptors in the periaqueductal grey and raphe nuclei in 
particular are of significance in the possible role of K-receptors in modulation of pain 
sensation,for these are sites at which descending pain inhibition pathways may be 
modulated.
The history of K-receptor location and quantification in the spinal cord has paralleled 
the studies in the brain with the same limitations e.g. ligand selectivity. In the rat 
pHjbremazocine with |x- and 5-su^ession was shown by autoradiography to label K- 
receptors in the dorsal part of the substantia gelatinosa (SG) of the dorsal horn in both 
the cervical and thoracic regions (Slater and Patel, 1983). Homogenate binding was 
used to identify K-binding at all levels in the spinal cord (Gouarderes and Cros, 1984) 
and subsequently autoradiography indicated K-binding to be denser in the cervical and 
lumbar regions (Gouarderes et al., 1985) . Reports differed and uniform binding at 
all levels was also recorded (Krumins, 1987). The K-binding sites were demonstrated 
to be only about 7% of total opioid binding at the cervical (C7) level and it was 
suggested that these sites represented an approximately equal distribution pre- and 
post-synaptically in laminae I and II of the dorsal horn (Besse et al., 1990). Using the 
Ki-selective ligand pH]U69593, even lower levels of K%-sites were recorded, being 
only approximately 2% of total opioid binding in lamina I-II and V and X of the 
lumbosacral spinal cord (Stevens et al., 1991). This picture was refined by the use of 
^^S-labelled probes for K-receptor mRNA. The mRNA was shown to be present in 
20-24% of neurones (mostly small and intermediate fibre) in sections of dorsal root 
ganglia (DRG) being highest in those from the thoracic region. There were numerous
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dorsal horn neurones throughout the cervico-thoracic and lumbar cord in which k - 
receptor mRNA was identified. Labelling was strongest in the superficial laminae but 
also found in Vl/VII and VIII (Schafer et al., 1994). These findings were supported 
by other groups in relation to the lumbosacral spinal cord (Maekawa et al., 1994) but 
another report, although confirming K-receptor mRNA expression in cells of small 
diameter fibres in the DRG from the thoracic region, found it in few cells in the cord 
at this level (Mansour etal., 1994).
Table 8 summarises some of the reported distribution of K-receptors in the rat central 
nervous system
Functional responses mediated by K-agonists can be demonstrated at the spinal and 
supraspinal level and individual neurones of the SG can be shown to respond to k- 
agonists, confirming the presence of K-receptors (Randic et al., 1995). The functional 
aspects of k-mediated antinociception will be introduced with the report of the 
experimental investigations into antinociceptive responses in the neonatal rat which 
form part of the basis of this thesis.
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1.5.3 Distribution of 5-opioid receptors.
A relatively 5 -selective ligand, DPDPE, was available before a correspondingly 
selective K-ligand but because it exhibited high levels of non-specific binding it was 
difficult to detect low levels of receptor. Although there is rather less interspecies 
variation in the distribution of 5-receptors (Mansour and Watson, 1993) as in 1.5.1, 
the emphasis in this commentary will be placed on the rat as a model. An interspecies 
comparison showed the rabbit to be relatively poor in 5-receptors, 5-binding in brain 
minus cerebellum representing some 19% of total opioid binding, whereas in the rat it 
was 42%, the guinea pig 32% and the mouse 29-35% (two strains) (Robson et al.,
1985). In an almost contemporary study in the rat, 42% of the binding in the striatum 
and 32% in the cortex was shown to be 5- and none was detectable in the brainstem 
(Castanas et al., 1986). Autoradiography using DPDPE located the highest 
density of 5-receptors in the cortical layers II, HI, V andVI, the caudate putamen and 
nuclei of the amygdala. There was only low level diffuse binding in the thalamus and 
hypothalamus and none in the PAG or raphe nuclei but relatively dense binding in the 
pons (Blackburn et al., 1988; Mansour et al., 1986). In a combined saturation and 
autoradiographic study using [^HjDPDPE, 5-receptors were reported to be 1/5 of the 
density of jx-receptors ( k - not measured) and to be concentrated in the forebrain, 
particularly the olfactory lobe, nucleus acumbens, striatum and cortex layer I-II and 
V-VI. 5-receptor binding was also visualised in the SG of the spinal cord (Sharif and 
Hughes, 1989). A more detailed study using pH]DSTBULET broadly confirmed the 
previous findings. This ligand has selectivity comparable to DPDPE but with about 
four-fold greater affinity, therefore receptors were detected at a lower level. There 
was diffuse binding in the substantia nigra, PAG and raphe nucleus and thalamus. 
Substantial binding was again observed in the cortex, neostriatum and nucleus 
acumbens. At all levels there was low level binding in the SG of the spinal cord 
(Delay-Goyet et al., 1990). The ventromedial nucleus was the only part of the 
hypothalamus to show significant binding (Desjardins et a i,  1990). The very highly
69
6-selective antagonist NTI (Portoghese et al., 1988) also indicated high levels in the 
somatosensory cortex, claustrum and caudate putamen (Drower et al., 1993). This 
distribution was generally observed using peptide agonists [D-Ala^jdeltorphin I 
labelled with either or 125 the greater resolution afforded by the latter allowing 
the visualisation of diffuse binding throughout the grey matter of the cord 
(Gouarderes etal., 1993; Renda eta l., 1993). As was described in 1.5.2, the 
identification of opioid-receptor mRNA has proved an even more sensitive method of 
locating receptor expression and the results correlate well with the binding studies. 
There are some discrepancies particularly in the p^s/medulla areas where Ô-receptor 
mRNA is visualised but little 0-binding. This could be simply a reflection of the 
greater sensitivity of the in situ hybridization tecnique (George et al., 1994; Mansour 
etal., 1994; Mansour etal., 1993a).
Specific studies in the spinal cord at first indicated uniform distribution throughout 
the cervical, thoracic and lumbar regions (George et al., 1994; Krumins, 1987; 
Mansour et al., 1994; Mansour et al., 1993) and suggested ô-binding was 
^proximately 12% of total opioid binding (Kowalski et al., 1989). Both studies used 
pHjDADLE with DAGO (x-suppreÿon. The 6-receptors were subsequently more 
precisely located in the d ^a l horn. [^H]DTLET gave a level of 24% 6-receptors in 
laminae I-II in control animals and 9% post-rhizotomy indicating that approximately 
60% of the sites were pre-synaptic (Besse et al., 1990). Differential distribution of 
opioid receptor types within the laminae of the dorsal horn of the lumbosacral spinal 
cord has been demonstrated using ligand binding autoradiography. Laminae I-II 
showed only 7% 6-binding, V showed 28% and adjacent to the central canal it was 
33% (|i-binding dominated throughout) (Stevens etal., 1991). A more detailed study 
demonstrated the presence of 6-sites in laminael-II of the cervical spinal cord and 
after rhizotomy showed that the loss of 6-receptors was not confined to the one 
segment i.e. the afferent fibres projected and synapsed in adjacent segments (Besse et 
al., 1991). Thus, 6-receptors have been identified in sensory pathways in the spinal
70
cord, in the somatosensory cortex and other areas of the brain which may play a part 
in the perception of pain (Fields, 1993; Porreca and Fields, 1993).
Table 9 summarises some of the reported distribution of 6-opioid receptors in the rat 
central nervous system.
1.6. THE ONTOGENY OF THE K- AND Ô-OPIOID RECEPTORS.
The ontogeny of the k - and ô-opioid receptors forms the basis of the investigations 
reported in this thesis. A review of the current understanding in this area will be 
presented at the introduction of the relevant experimental sections.
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1.7 AIMS OF THE THESIS.
1. To investigate the ontogeny o f  the K-opioid r e c e ^ r  in  the rat by hom ogenate  
binding and functional studies using K -selective ligands.
2. To quantify the development of the 6-receptor in the neonatal rat brain and spinal 
cord using 6-selective ligands in homogenate binding studies and to investigate the 
role of weaning in the regulation of 6-receptor development
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CHAPTER 2
QUANTITATIVE ONTOGENY OF THE KAPPA OPIOID 
RECEPTOR IN THE RAT BRAIN
75
2.1 INTRODUCTION
2.1.1 Total opioid receptor ontogeny in the rat: non-selective ligands.
The ligand binding study has been the principle method used to investigate opioid 
receptor development in the foetus and the neonate. There are only small amounts of 
brain tissue available, particularly prenatally and so whole brain homogenates have 
been primarily used to provide membrane fractions. Although the technique has been 
used on grossly dissected brain regions, the quantity of tissue available even from a 
large number of foetuses was generally inadequate for the generation of a full 
saturation curve which is necessary to fully characterise the binding within those 
regions. The earliest investigations preceded the realisation that there were distinct 
opioid receptor subtypes and used what are now known to be relatively non-selective 
ligands, so reported levels generally represent the total receptor population. 
Expressed as fmol/mg wet weight, pHjnaloxone binding was first detected in the rat 
brain at E15 (embryonic day 15) and shown to increase to 40% of adult binding at 
birth, adult levels being reached at 28 days (Coyle and Pert, 1976). This study also 
reported that the regional distribution of binding changed between birth and 
adulthood. pHJNaltrexone binding was used to demonstrate stereospecific binding at 
E13 and expressed as fmol/mg protein, an approximately four-fold increase between 
E14 and PN21 (postnatal day 21) with a further doubling by 20 weeks was observed 
(Clendeninn et al., 1976). The comparison of these two studies and of subsequent 
reports is hampered by the different methods used to express the results since 
maximum binding capacity expressed per milligram wet weight, per milligram protein 
and per brain will all present different profiles of the rate of development and the 
timing of peak values will change e.g. as the protein to wet weight ratio changes. 
However, both the above reports showed no significant difference in ligand affinities 
over the developmental period studied. [3H]Diprenorphine binding in the embryonic 
and neonatal rat brain expressed per mg. protein (Kirby, 1981) gave results similar to
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the p  HJnaltrexone study (Clendeninn et aL, 1976) in that receptors were first 
detected at E14 and were shown to have increased some six-fold by 15-30 days, 
further increasing by a factor of 1.2 in the adult. The study also suggested a different 
developmental profile in the spinal cord where [^HJdiprenorphine binding could be 
detected at E l6, rising rapidly to E22 but falling by some 40% at parturition. 
Subsequently, another rapid increase resulted in peak binding at PN6 but was followed 
by a gradual decrease to adult levels by PN15.
Some early studies indicated a mixed population of opioid binding sites by 
demonstrating a differential development of high and low affinity sites. For example, 
pH]naloxone was shown to bind to a high affinity site which at PN5-10 represented 
20% of total binding and which doubled to 40% at PN30 (Augey-Valette et al., 
1978). The low affinity site over this time only increased by a factor of 1.3 thus 
falling from 80% to 60% of the total binding sites. Further, H]D-Ala^-Met^ - 
enkephalinamide, pH]morphine and pH]EKC were shown to exhibit both high and 
low affinity binding in 2 day-old and 14 day-old rats (Zhang and Pasternak, 1981). 
The high affinity binding increased rapidly over this period from 21% of adult high 
affinity binding levels to 68% while the low affinity binding, which was already at 
PN2 closer to the adult levels, showed a much smaller percentage rise fi*om 63% to 
77% of adult levels. A similar pattern was observed in the spinal cord using pH]D- 
Ala^-Met^-enkephalinamide. With this ligand, in the brain, the time course of the 
development of the two sites was shown to differ over the period PNl to PN28. The 
low affinity sites remained almost unchanged as a percentage of the adult levels until 
PN l8 when there was a rapid increase to approximately adult levels at PN21 but 
throughout the period PN3 - PN21, the high affinity sites rapidly increased. It was 
also demonstrated that the low affinity [^HJD-Ala^-Met^-enkephalinamide binding 
was more easily displaced by DADLE than by morphine. The different binding 
profile was also linked to different pharmacology and indicated that the opioid 
receptor population was heterogeneous with respect to development and function.
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2.1.2 Opioid receptor ontogeny in the rat: selective ligands.
The use of relatively selective ligands has allowed the comparative study of the 
ontogeny of the |i-, 6- and K-opioid receptor subtypes and different developmental 
patterns have been established. Naloxone has an affinity for |x-receptors fifteen-fold 
greater than for 6-receptors (Magnan et aL, 1982), therefore if binding is carried out 
at an appropriate [^HJnaloxone concentration it can be considered |i-selective. 
Morphine is selective for the p-receptor over the DADLE labelled 6-site by a factor of 
48 (Paterson et aL, 1983). DADLE has about a four-fold greater affinity for 6- 
receptors than it has for p-receptors (Chang and Cuatrecasas, 1979). Using these 
properties of the ligands in rat brain homogenates, a naloxone binding site was shown 
to increase seven-fold between PNl and PNl2 and a further three-fold by PN26 
(Wohltmann etal,, 1982). During the whole of this time, inhibition of [^Hjnaloxone 
binding by morphine showed monophasic displacement curves. In contrast, 
pH]DADLE binding was some 50% lower than pH]naloxone binding between PNl 
and PN l2, although they rose in parallel. A six and a half-fold increase in 
pHjDADLE binding between PN12 and PN26 brought the levels to approximately 
the same as the [^HJnaloxone p-binding. Inhibition studies with morphine showed a 
monophasic displacement up to PNl2 but after this time biphasic plots were seen. 
These results suggested that prior to PN12 pHjDADLE was probably binding to p- 
receptors (because it was readily displaced by morphine) but not to saturation because 
of the level of [^HJDADLE chosen, hence the binding observed was less than that 
with pH]naloxone but they were binding to a common site. After PN l2 the rapid 
[^HjDADLE binding increase was probably to a second site, less sensitive to 
morphine displacement, possibly the 6-receptor. Another comparative study in the six 
day-old rat pup and the adult using [^H]dihydromorphine, pHJDADLE and pH]EKC 
confirmed that pH]DADLE binding in the neonate differed from that in the adult 
probably representing p-binding in the neonate and 6-binding in the adult (Leslie et 
aL, 1982). From the competitive displacement of pHjEKC by the p-selective agonist
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FK33-824 (see 1.2.4.1) this study also indicated that the ratio of K/p binding was 
greater at PN6 than in the adult. Hill et al. (1984) reported that the overall pattern of 
development of the binding of the p/K-ligand pH]EKC in the rat cerebral cortex over 
the period PN1-PN90 showed a steady increase to adult levels at about PN28 
confirming the pattern in whole brain established with naloxone (Coyle and Pert, 
1976) but again indicating the relatively high K/p ratio in the neonate compared to the 
adult since tifluadom, a K-selective agonist (see Table 3), was a more potent displacer 
of [^H]EKC binding at PNl than in the adult. The emerging picture of opioid 
receptor development in the rat brain was of early development of p- and K-receptors 
with a more significant increase in p-receptors than of K-receptors postnatally but 
both having reached adult levels by four weeks posmatally. In contrast the Ô-receptor 
appe ared to show delayed development, possibly not appearing before PN7 and 
reaching adult levels later than the p- and K-receptors.
The development of the p-selective agonist DAGO (Corbett et al., 1984; Kosterlitz
and Paterson, 1980) allowed a clearer distinction between p- and 6-opioid receptors
and as DADLE has been shown to discriminate between 6- and K-sites by a factor of
6000 (James and Goldstein, 1984) it was possible to use [3H]EKC binding with p- 
Pand 6-suïjression to quantify K-receptors. Spain et al. (1985) measured opioid 
receptor development in the rat over a period PNl to PN35 and demonstrated a clearly 
different ontogeny for the p-, 6- and K-receptors. p-binding ([^HjDAGO) appeared to 
decline by about 20% over the first 4 postnatal days but rapidly increased to adult 
levels over the period PN7 to PN21. 6-binding (pH]DADLE with DAGO p-
p
supression) was difficult to detect in the first posmatal week but steadily increased 
eight-fold over the period PN7 to PN28 to adult levels. K-binding ([^H]EKC with FK
p
33-824 p-suÿession and DADLE 6-supression) was lower by 80% compared to the 
p-binding at birth but did not exhibit the drop observed in the p-binding and slowly
f
increased, doubling by PN35. In spite of the suÿession conditions there was some 
evidence that [^HJEKC was binding to more than one site. Subsequent studies using
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su^essor ligands to improve discrimination, largely confirmed these findings. For 
example Petrillo et al. (1987) reported p-binding expressed as pmol/g of brain to be 
53% of total opioid binding at PN3 and to treble between PN7 and PN21 falling 
slightly from this peak in the adult. 6-binding was undetected at PN3, appeared at the 
end of the first posmatal week and trebled from this point fcpPN21. The increase 
continued slowly  ^doubling the PN21 levels in the adult. K-binding at PN3 represented 
20% of total opioid binding and doubled by PN14 after which there was no apparent 
increase. This peak of K-binding was somewhat earlier than reported by Spain et al. 
(1985) and when related to total protein levels, K-binding varied little between PN3 
and PN 14 and fell in the adult. This pattern was very similar to that previously 
observed in the mouse (Tavani et al., 1985). Using a different su^ession protocol 
Komblum et al. (1987) reported a similar developmental profile and recorded no 
significant difference between K-binding, this time expressed per wet w ^h t, at PN3 
and in the adult. Conversely Volterra et al. (1986) failed to detect significant 
PH]DYN(^_8) K-binding in the pre-weanling period. The development of DPDPE, a 
specific 6-agonist (Mosberg etal., 1983), which was selective for 6- over |a-receptors 
by a factor of 260 and over K-receptors by >5000 (Corbett et al., 1984) made it 
possible to more directly measure 6 -receptor density. In the rat  ^6-receptors were 
found to increase by a factor of 3 between PNIO and PN25 when expressed per 
milligram protein or by a factor of 6.5 if expressed per brain (McDowell and Kitchen,
1986). At PN 25 the levels were equivalent to those in the adult (50 days) and the 
affinity remained unchanged throughout. No specific binding was detected before 
PNIO.
In the spinal cord of the rat K-receptor levels in pooled tissue from animals PN9-PN16 
were shown to be 5-6 times higher than in the adult when measurd by [^H]U69,593 
binding (Allerton et al., 1989). These sites probably represent the Ki-receptor (see 
1.3.1) thought to be a relatively small proportion of the K-receptor population in the 
rat (Zukin et al., 1988). In the spinal cord as opposed to the brain, K-receptors have
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been shown to be the predominant site and to show a different developmental profile 
to that of the |i-receptor while 8-receptors have generally been a(^ . very low
levels (Attali et al., 1990). K-receptors detected at E15 were demonstrated to rise 
rapidly, peaking at E20 when they represented 80% of total opioid binding expressed 
relative to protein levels. |i-receptors also detected at E l5, lagged only slightly 
behind K-receptors and peaked at PNl. Both sites had fallen in density by PN3, k- 
receptors by 20% and p,-receptors by 50%. The |i-receptors subsequently remained 
unchanged to adulthood but in contrast, the K-receptors peaked again at PN7 where 
they once more represented 75-80% of total opioid binding but levels then decreased 
to the adult level by PNl5 at which time p- and K-receptors were approximately equal 
in density (Attali et al. 1990). These results substantiated the much earlier 
observation of a fall in total opioid binding in the spinal cord at parturition followed 
by a peak at PN6 and a gradual decreaese to adult levels (Kirby, 1981). The 
predominance of K-receptors in the neonatal spinal cord has been confirmed by others. 
Barr era/.^recorded K-sites as 80% of opioid binding at birth. These levels, expressed 
per milligram protein, remained unchanged to PNIO when there was a rapid doubling 
to reach adult levels at PN14. p,-receptor density, 20% of total opioid receptors at 
birth, showed a continuous steady increase reaching adult levels at about PN l6 and 
being approximately equal in density to the K-receptor at this time. While confirming 
the absence of measurable levels of 8-receptors in the rat at PNl, the k- to p,-receptor 
ratio has been reported to be almost the reverse of that reported by Attali et al. (1990). 
Being measured with [^HJDAGO (p-) and with [^HjEKC+DAGO suj&ession (k-), p,-
A
receptors were found to be 70% and K-receptors to be 30% of total opioid binding 
(Dray et al., 1989). Subsequent data from the same group confirmed the 7:3 ratio of 
p.- to K- binding but also showed that K%-binding measured with pH]U69,593 was 
only 50% of the total K-binding (James et al., 1990). The postulated Kg-receptor 
which was originally identified in calf brain (Price et al., 1989) has also been 
demonstrated in the rat and the mouse (Clark et al., 1989). Labelled by naloxone 
benzoylhydrazone, this putative K-receptor in the rat is reported to be at ’moderate'
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le v e ls  (6 fm o l/m g  w et w eigh t) at PN2 and to doub le to adult le v e ls  b y  PN21 thus 
sh ow in g  a sim ilar profile the K-receptor population in general.
O v era ll th e ob serv a tio n s su g g est that in the rat brain there is  a s ig n ific a n t  
developm ent o f  |i -  and K -opioid receptors prenatally. jx-receptor d ensity  continues to 
increase m ore significantly than K-receptor density in the early postnatal period  and in  
the adult K -receptors m ay actually  be at a low er density  than in  the n eon ate. Ô- 
receptors have proved d ifficu lt to quantify before the end o f  the first posm atal w eek , 
partly for m eth od olog ica l reasons and partly b ecause they are at lo w  lev e ls . T he  
d evelopm ent o f  the 6 -receptor is  delayed when com pared to the |i -  and K-receptor and 
the ev id en ce  suggests they reach their m axim um  density at a later stage.
Table 10 summarises the reports considered here. It should be noted that the period of 
maximum rate of increase of receptor density may fall outside the times at which 
experimental observations were made in any particular study. This is particularly true 
of smdies which do not include prenatal tissue. Functional smdies can also be used to 
demonstrate the presence of opioid receptors and are used in parallel with specific 
binding smdies to investigate the ontogeny of the receptors. These will be discussed 
in the introduction to Chapter 3.
The aim o f  this study is to quantify the developm ent o f  the K-receptor in the neonatal 
rat brain usin g  the h ig h ly  K%-selective b enzacetam ide ligand s pH]U-69,593 and 
pH]CI-977 for saturation binding in hom ogenates o f  w h ole  brain (m inus cerebellum ).
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2.2 MATERIALS AND METHODS.
2.2.1 Animals.
Wistar Albino rats (University of Surrey strain) of mixed sexes were used in all ligand 
binding experiments. Animals were housed eight to a cage as adults, ten to a cage 
post weaning (21 days ) to 30 days, or as litters, one to a cage. The day of birth was 
designated as day 0. Litters were culled to ten and cross-fostered where possible 
except those used at 1,3 or 5 days. These litters were left as bom in order to maximise 
the available brain tissue. It was assumed that litter size would not significantly affect 
development at these early ages. The animals were housed in an air conditioned unit 
maintained at 20-22°C and 50-60% humidity and were allowed free access to 
standard rodent chow and water. Lighting was controlled on a twelve hour cycle, 
lights off 19.00h - OT.OOh.
2.2.2 Preparation of tissue homogenate.
Animals were equilibrated in a quiet laboratory 24h before experimentation and 
experimental procedures begun between 08.30h and 09.00h. Preweanling pups were 
removed fi*om the maternal cage immediately before killing. Animals were killed by 
decapitation and the whole brain removed. The cerebellum was removed and the 
remaining tissue weighed and put into 50mM Tris HCl buffer, pH 7.4 at 0°C. The 
tissue was coarsely chopped with scissors and homogenised in 10 volumes Tris HCl 
buffer at 0°C using a Kinematica Polytron homogeniser for 45 sec at speed 6. The 
homogenate was centrifuged at 49,000g for 15 min at 4°C using a 45TI rotor carrying 
100ml capped tubes in a Beckman L5-65B ultracentrifuge. The resulting pellets were 
re-suspended in 100 vol. 50mM Tris HCl buffer, pH 7.4 at 37°C, using the Polytron 
homogeniser at speed 6 for 15 sec. The suspension was divided into four equal 
aliquots which were placed in 100ml Beckman polyallomer tubes and incubated in a
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shaking water bath at 37°C for 45 min in order to remove any endogenous ligand. 
The homogenate was re-centrifuged and the pellets re-suspended as above in Tris HCl 
buffer, pH 7.4 at 25°C, at a density of 40 mg (original wet weight)/ml. For each 
saturation assay pooled brain tissue was used, the number of brains used depending on 
the age of the animals as follows:
Age/Days 1 3 5 10 15 20 25 30 Adult
Number of 
brains
15-16 13-15 10-11 6-8 5-6 4-6 5-6 4-5 3-4
For competition studies, where the volume of homogenate was sufficient, it was used 
to obtain K; values for two different competing ligands.
2.2.3 Ligands.
2.2.3.1 [^H]-labelled ligands.
pH]U-69,593, specific activity 40 Ci/mmol , 1 mCi/ml in ethanol, purchased from 
New England Nuclear Corporation, was evaporated to dryness under a stream of 
nitrogen and re-dissolved in 200 |xl of 80 parts 6.25% glacial acetic acid, 0.25% 
ammonia in distilled water (solvent A) to 20 parts acetonitrile (solvent B). This was 
purified in two 100 |xl aliquots by reverse phase HPLC using a linear acetonitrile 
gradient, 20%-90%, in solvent A, over 20 min at 1 ml /min through a Bondapak Cig 
column assembly. Preliminary experiments with this system had established that the 
retention time for pH]U-69,593 was 9-10 min. The firont was relatively discrete but 
there was some trailing over 10 -12 min. The bulk of the [^H]U-69,593 was therefore 
calculated to be in the fraction collected over 8.5 - 12 min. A 5 |xl sample of this 
fraction was diluted 1:1000 in 1:1 solvent A:B and the [^H] activity of 10 jil samples 
of this solution determined after the addition of 5.0 ml of Unisolve E scintillation 
fluid. The concentration of the recovered pH]U-69,593 was calculated and the
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solution stored at - 20°C to be diluted as required to provide solutions for the 
saturation assays.
pH]CI-977 at 1 mCi/ml (specific activity 21 Ci /mmol) in ethanol was custom 
synthesized by Amersham International (U.K.) according to the method of Boyle et 
al. (1990). The ligand was used without further purification.
2.2.3.2 Cold competing ligands.
The cold competing ligands used were U69593, PD117302, DAGO, DPDPE and 
naloxone (See Fig.3, Table 4 and section 1.2.4.1 for chemical identity). DAGO and 
DPDPE were purchased from Cambridge Research Biochemicals. Naloxone 
hydrochloride was a gift from Dupont and U69593 a gift from Upjohn.
2.2.4 Saturation studies.
22.4.1 [3H]U-69,593
A minimum of four saturation assays were carried out at each age. Saturation binding 
was determined in triplicate in 50 mM Tris HCl, pH 7.4 at 25°C. Reaction mixtures 
were prepared in 5 ml polypropylene tubes (Sarstedt product no. 55.526). 1.9 ml of 
homogenate at 40 mg wet weight/ml was used, the final volume of the reaction 
mixture being brought to 2.0 ml after the addition of ligand solutions, displacer 
solutions and Tris HCl buffer. For each level of [^H] ligand used a parallel set of 
three tubes was prepared containing 1 |xM diprenorphine as a displacer in order to 
determine non-specific binding. The reaction was initiated by the sequential addition 
of varying volumes of two freshly prepared stock solutions of [^H]U69593 in Tris 
HCl buffer to produce a series of 11 concentrations from 0.1 nM - 7 nM. Incubation 
was for 75 min at 25°C in a Julabo SW shaking water bath (110/min) The reactions
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were initiated over a period of 60 min. and subsequently terminated over the same 
period by phase separation effected by individual filtration under vacuum through a 
Whatman GF/B filter on a sintered glass filter. The individual filters were soaked for 
2 h in 1% v/v polyethylenimine in 50 mM Tris HCl buffer, pH 7.4 at 0°C to minimise 
the non-specific binding to the filters. The membranes were washed three times with 
4.0 ml volumes of 50 mM Tris HCl buffer, pH 7.4 at 0°C. The individual filters plus 
membranes were placed in 5 ml polythene scintillation vials. After the addition 
of 0.5 ml 20% Triton X-100 in toluene and 4.5 ml Unisolve E scintillation fluid, the 
tubes were capped, shaken and left for a minimum of 17 h in order to allow 
solubilization of the membranes plus bound ligand and dispersion into the scintillant. 
The [^H] emissions were counted over a 5 min period for each sample using a 
Rackbeta II Liquid Scintillation Counter. Samples of the ligand solutions were 
counted on each occasion in order to determine the exact concentrations in the 
reaction mixtures. A pH]hexadecane standard was counted in order to establish the 
efficiency of the counter.
2.2.42 [3H]CI-977
pH]CI-977 saturation assays were carried out as for pH]U69593 except for the 
following details.
A range of 8 - 10 concentrations of pH]CI-977 between 0.04 nM and 4.0 nM were 
used. Non-specific binding was determined in the presence of 1 |xM naloxone. The 
reaction was terminated by phase separation using Whatman GF/B glass fibre strips 
presoaked in 1% polyethylenimine in 50mM Tris buffer pH 7.4 at 0°C, in a Brandel 
M24 cell harvester.
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2.2.5 Competition studies.
Competition studies were carried out for the binding of pH]CI-977. These were 
carried out in triplicate using brain homogenates at 40 mg wet weight per ml from 3 
day old animals and a concentration of [^H]CI-977 approximating to the equilibrium 
dissociation constant obtained from the saturation studies. The concentration range of 
competing ligands was initially chosen with reference to the published data from 
inhibition studies in the adult rat (Boyle et al., 1990) After the initial investigation 
with each competing ligand the concentration range was modified where necessary to 
produce inhibition of pH]CI-977 binding in the range 0 - 100% where possible.The 
following concentration ranges were used:-
U69593 0.3 nM -105 nM
PDl 17302 2.5 nM - 525 nM
DAGO 0.05 |iM -18 |iM
DPDPE 0.09 ^lM-28 |XM
Naloxone 2.5 nM - 210 nM
In all cases the concentrations were obtained by adding variable volumes of 2 - 4 
stock solutions of displacing ligand to a reaction mixture, final volume 2.0 ml. 
Maximum binding was determined in triplicate in the absence of any competing 
ligand and non-specific binding was determined by the addition of naloxone at a final 
concentration of 1 |xM to a further set of three reaction mixtures containing no 
displacing ligand and a parallel set of three containing the highest level of displacing 
ligand. Incubation temperature was 25°C and incubation time was increased to 90 
min since the presence of inhibiting drug has been shown to increase the time for 
equilibrium binding to be achieved (Weiland and Molinoff, 1981) All other aspects 
of the assay were as for the saturation studies using pH]CI-977. U69593 inhibition of 
pH]CI-977 binding was also measured in brain homogenate from 1 day old rats.
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22.6 Protein analysis.
Samples of homogenate were retained and stored for up to 12 weeks at -20°C. The 
samples were thawed and diluted 1/4 in Tris HCl buffer, pH 7.4,25°C to a level of 10 
mg wet weight /ml. 0.5 ml samples were assayed in triplicate against a bovine serum 
albumin standard, fraction V (Sigma product no. A4503) between 50 |ig/ml and 500 
[Xg/ml also prepared in the same buffer. The method of total protein analysis used was 
a modification of that of Lowry (Lowry e ta l,  1951).
To the 0.5ml samples was added 2.5 ml freshly prepared copper/tartrate reagent (98 
parts 2% w/v sodium carbonate in O.IM aqueous sodium hydroxide: 1 part 2% w/v 
aqueous cupric sulphate: 1 part \% w/v aqueous potassium sodium tartrate). The 
mixture was vortexed and left for 10 min. 0.25 ml Folins/Ciocalteu’s phenol reagent 
(Sigma product no. F9252) diluted 1:1 with distilled water was added and the mixture 
vortexed. The colour was left to develop for 30 min and the optical density measured 
at 690 nm. against a Tris HCl buffer/reagent blank.
2.2.7. Data analysis.
The data obtained was used to plot saturation binding curves and further analysed by 
means of Scatchard plots. Slopes and intercepts were calculated from linear 
regression analysis of the Scatchard plot and values of Kd and Bmax derived. 
Measures of B^ax were calculated per brain, per mg wet weight and per mg protein. 
Values of Bmax andK© were compared using ANOVA and Duncan's New Multiple 
Range post hoc analysis for the comparison of all means. Data from the competition 
studies was used to plot percentage inhibition of specific binding against log 
displacing ligand and analysed by means of Hill plots. The K; values for the 
unlabelled competing ligands were calculated according to the method of Cheng and 
Prussoff using the IC5 0  values obtained from the Hill plots, the free tritiated ligand 
concentration used and the Kd for the tritiated ligand from the Scatchard analysis of 
the saturation study (Cheng and Prusoff, 1973).
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2.3 RESULTS
2.3.1 [^H]U-69,593 Saturation binding.
pH]U-69,593 binding produced linear Scatchard plots at all ages studied (Figure 8). 
Throughout the postnatal period the binding affinities for [^H]U-69,593 were not 
significantly different (ANOVA and Duncan's post hoc P > 0.05). Table 11 shows 
the binding capacities and affinities for pH]U-69,593 during postnatal development. 
Saturable binding was detected at 5 days and between 5 and 10 days there was a rapid 
increase representing a 4.3*fold increase when expressed per whole brain, a 2.7-^old 
increase when expressed per^wet weight and a 2.3-fold increase when expressed per 
mg protein. At day 10 the number of sites (expressed per mg wet weight or per brain) 
was equivalent to that observed in adults. When expressed per mg protein, a 
progressive fall was observed from day 10 to day 25 when the adult levels were 
reached. Reproducible binding was not always observed at 5 days and therefore 
earlier ages were not studied. Table 12 shows the brain weights and protein 
concentrations throughout development. From day 5 to 15 there was a marked 
increase in protein levels relative to brain mass but thereafter protein concentrations 
and brain weight increased in parallel to adulthood.
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Figure 8. Representative saturation curves with Scatchard transformations 
(inset) for specific binding of [%]U-69^93 to homogenates of whole brain 
(minus cerebellum) from rats of various ages.
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Table 12. Postnatal changes in brain weight and total protein levels measured
during the quantification of K-receptor development using [^H]U-69^93.
AGE
(days)
BRAIN WEGHT 
(g)
PROTEIN CONCENTRATION 
(mg/g wet weight tissue)
5 0.52 ±0.05 29 ±2.8
10 0.91 ±0.02 35 ±1.0
15 1.18 ±0.06 49 ±3.6
20 1.22 ±0.03 51 ±7.2
25 1.30 ±0.02 50 ±2.9
30 1.40 ±0.04 59 ±4.3
ADULT 1.62 ±0.04 55 ±2.0
Values are means ± SE of 3-6 observations.
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2.3.2 [3H]CI-977 Saturation binding.
In equilibrium binding studies pH]CI-977 demonstrated high affinity saturable 
binding with linear Scatchard plots being observed at all ages. Figure 9 illustrates 
representative saturation curves and Scatchard plots (inset) obtained at 1,5 and 10 days 
and in the adult rat. There was no significant difference in binding affinity across all 
the neonatal ages (ANOVA and Duncan’s post hoc P > 0.05). Reproducible k - 
binding was measured at day 1 and the number of sites, when expressed per wet 
weight, was equivalent to that observed in the later ages and in the adult. Table 13 
shows the derived measures of and Kd and Table 14 the increasing brain weight 
and protein levels across the age range studied. When expressed per mg protein the 
levels of [3H]CI-977 binding were some three times higher at 1 day than in the adult, 
a result of the greater increase in protein levels relative to brain weight.
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Figure 9. Representative saturation curves with Scatchard transformations
(inset) for binding of [^H]CI-977 to homogenates of whole brain (minus
cerebellum) from rats of various ages
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Table 14. Postnatal changes in brain weight and total protein levels measured
during the quantification of K-receptor development using [3IQCI-977
AGE
(days)
BRAIN WEGHT 
(g)
PROTEIN CONCENTRATION 
(mg/g wet weight tissue)
1 0.256 ±0.014 14.0 ±0.96
3 0.355 ±0.015 20.0 ±0.56
5 0.502 ±0.034 17.95 ±1.5
10 0.899 ±0.014 22.53 ±2.1
20 1.190 ±0.090 27.8 ±2.3
30 1.520 ±0.030 40.25 ±2.3
- ADULT 1.642 ±0.044 47.8 ±3.5
Values are means ± SE of 4 observations. Brain weights represent weights of pooled 
brain samples divided by the total number of brains for each assay.
1 0 0
2.3.3 [^H]CI-977 Competition studies.
Competiton studies versus pH]CI-977 in brain homogenates from 3 day old animals 
with unlabelled ligands selective for |i-, 6- and K-receptors showed potent inhibition 
by the K-ligands U-69,593 and PDl 17302. The Kj for the |x-ligand DAGO was 
greater by a factor of 10  ^demonstrating it s poor affinity for the site and the even 
weaker affinity of the 6-ligand DPDPE was shown by a K% greater by a factor of 10"* 
than those of the K-ligands. The antagonist naloxone also inhibited [^H]CI-977 
binding at day 3. Data obtained on day 1 using U-69,593 versus pH]CI-977 
demonstrated very similar displacement parameters to those obtained on day 3, the Kj 
for U-69,593 versus pH]CI-977 was 6.96 ± 1.56nM and the Hill coefficient was 0.86 
± 0.10. The displacement curves are illustrated in Figure 10. The Hill coefficients for 
the competing unlabelled ligands were not significantly different from unity (Table 
15).
1 0 1
Table 15. Inhibition constants (Kj) obtained for reference opioid ligands versus 
pH]CI-977 labelled K-opioid receptor in 3 day-old ra t whole brain (minus 
cerebellum) homogenates
Unlabelled ligand
Ki versus [3HJCI-977 
(nM) Hill coefficient
U69593 5.70 ±0.74 0.91 ±0.08
PDl 17302 3.17 ±0.15 1.1 ±0.10
Naloxone 25.8 ±3.7 1.01 ±0.09
DAGO 1289 ±407 0.90 ±0.07
DPDPE > 30,000
Each value represents the mean ± SE of four experiments
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Figure 10. Inhibition of specific [^H]CI-977 binding in homogenates of 
neonatal rat brain (minus cerebellum) by U-69^93, PD 117,302, DAGO,
Naloxone and DPDPE,
100-,
90-
80-
70-
X 60—
I
§  - “  50-
40-
30-
20-
10-
[Displacing ligand]: Log M
(•)U69593, (O) PDl 17302, (A) Naloxone, (♦) DAGO, (□) DPDPE in 3 day- 
old rat brain homogenate (■) U69593 in 1 day-day old rat brain homoge. nate. 
Points are the mean of 4 determinations in triplicate and error bars are ± SE
mean. SB = [^H]CI-977 bound (fmol/mg wet weight), Bmax = [^H]CI-977 bound 
(fmol/mg wet weight) in the absence of competing ligand, (for ligand acronyms,
see Section 1.2)
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2.4 DISCUSSION.
The binding of pH]U-69,593, which was quantifiable down to PN5, was shown by 
Scatchard analysis to be typical of binding to a single population of receptors. Over 
the neonatal period studied and in the adult there was no significant change in the 
affinity of the receptor. This property is characteristic of all opioid receptors during 
development. (For a review see McDowell and Kitchen, 1987). There have been 
conflicting reports on the development of the K-opioid receptor system from studies 
using less selective ligands or non-selective ligands with \i- and 5-displacers. 
pH]EKC (|Li-/K-) binding was demonstrated to continually rise postnatally to reach 
adult levels at 28 days suggesting that \i- and/or K-receptor density was increasing 
throughout this period (Leslie et a i, 1982). However tifluadom, k  »  ji (Romer et al., 
1982) was a potent inhibitor of pH]EKC binding in the 1 day-old rat brain than 
in the adult which suggested that the ratio of K-/ja- was greater in the neonate (Hill et 
al., 1984). K-binding measured with [^H]EKC and ji/ô-suppression has been reported 
to be considerably higher than the measures recorded in the present study being 80 
fmol/mg protein at PNl (Barr et al., 1986). No increase was observed until PNIO 
when an approximate doubling to adult levels was observed over the period PNIO to 
PN14. Spain et al. (1985) also reported a doubling of K-binding between PNl and 
adulthood when expressed relative to wet weight but expressed as [^HJEKC bound 
per mg protein under |i/S-supression conditions, the level of 50-60fmol/mg protein 
showed no increase after PNl. Komblum et al. (1987) also reported an approximate 
doubling of pH]EKC binding(vith ji/5-suppressioi^between PN6 and adulthood from 
0.94fmol/mg wet weight to 1.8fmol/mg wet weight but this difference was found not 
to be statistically significant. Very similar figures have been reported by PetriUo et al. 
(1987) indicating a doubling of K-binding between PN3 and PN14 fi*om 0.71 to 
1.5fmol/mg wet weight measured with [^H]bremazocine and |i/5-suppression. Levels 
exceeded those in the adult when expressed relative to total protein being 
33.3fmol/mg protein at PN3 and 37.5fmol/mg protein at PN14 compared with 
23.1fmol/mg protein in the adult.
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In the results presented here, only at 5 days did the total specific binding of [^H]U-
69.593 per brain show any significant difference from that observed in the adult. 
Expressed relative to wet weight or total protein there was no significant difference at 
any age studied. This suggests that K-receptor development is already complete at 5 
days. The apparent fall in receptor density between 10 days and the adult when 
expressed relative to protein is not statistically significant and therefore probably does 
not represent a loss of receptor protein but arises from a general increase in protein 
levels in the brain. These observations are in accordance with a study which 
compared 9-16 day and adult rat spinal cord where it was found that at 9-16 days the 
density of pH]U-69,593 binding sites was significantly higher than in the adult but 
the total binding per cord showed little difference (AUerton et a l , 1989).
CI-977 has been demonstrated in animal models to be a highly selective K-opioid 
agonist (Hunter et a l, 1990) and this study confirms it s advantage of higher affinity 
by a factor of 2-3. Like U69,593 it binds to a single population of sites in rat brain 
throughout the postnatal period but the high affinity binding is detected at an earlier 
age being measurable at day 1. The negligible affinity of the p- and 6-ligands in the 
competition studies confirms the labeling of K-sites and the overall displacement 
profile is similar to that obtained in adult tissue (Boyle et al., 1990). The Ki measured 
at 3 days for DAGO and naloxone is some five times higher than that observed in the 
adult by Boyle et al., (1990) and correlates with the reported characteristics of pH]- 
dynorphin binding in the 4 day-old rat in comparison with the adult (Volterra et al.,
1986). The major difference observed using [^H]CI-977 compared with [^HJU-
69.593 was the ability to demonstrate reproducible specific binding at days 1, 3 and 5. 
Expressed relative to protein levels, the specific binding was at a maximum at day 1 
and there was no significant difference observed until day 30 when the specific 
binding per^protein fell to adult levels. That this again reflects the general increase in 
total brain protein rather than a loss of K-receptor protein is indicated by the failure to 
demonstrate any significant difference in the specific binding when expressed per^wet
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weight and the consequent parallel increase of receptor protein per brain and brain 
weight
Both ligands recognised a lower density of K-sites than previous studies using 
pHJEKC or [^Hjbremazocine with p/6-su^ression. As discussed in 1.2.2.1, both 
U-69,593 and CI-977 are benzacetamide ligands thought to recognise the putative Ki- 
receptor subtype rather than the total K-receptor population as defined by 
benzomorphan-type ligand binding (Attali et a/., 1982). Zukin et al. (1988) have 
identified the [^HJEKC recognised K-population in rat brain as a mixed population of 
high affinity, low density sites (Bmax 16fmol/mg protein) and low affinity, high 
density sites (Bmax lllfmol/mg protein). U-69,593 has been shown to selectively 
displace the high affinity K-binding (k i)  and to be inactive at the low affinity, K2, site 
whereas EKC and bremazocine competed for both. The predominant site in the rat 
brain is suggested to be the U-69,593 insensitive K2 -site which is readily recognised 
by EKC and bremazocine (Zukin et al., 1988). The present study therefore represents 
the profile of development of the Ki-site whereas earlier studies indicating higher 
levels of K-binding probably represent the sum total of K%- and Kz-opioid binding 
sites. Further, the putative Kg-opioid receptor characterized by pH]NalBzoH binding 
is reported to be at relatively high density in the rat brain. This receptor is also 
recognised by EKC (Clark et al., 1989) but the affinity of U-69,593 for this receptor 
is some 200 times less than the affinity of EKC (Cheng et al., 1992). However, when 
using pH]EKC with DAGO p-su^ession, the levels of DAGO required to block 
pH]EKC at p-receptors are sufficient to block Kg-receptors (Clark etal., 1989) so 
these are less likely to contribute to the higher estimates obtained in earlier studies 
and although they do double in density between PN14 and PN30 when expressed 
relative to wet weight (Cheng et a l, 1992) the figures would be unlikely to indicate 
any change expressed relative to protein levels (not quoted). It is more probable that 
the higher levels observed using [^HjEKC under su^ession conditions and the 
increases in K-receptor binding observed over the postnatal period represent increase
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in K2 -receptor density which can only be confirmed when a K2 -selective ligand 
becomes available.
Whichever way the data are expressed, [^H]CI-977 consistently recognises a higher 
density of K-sites than pH]U-69,593. [^H]CI-977 recognises a single population of 
sites with the characteristics of those demonstrated in the adult (Boyle et al., 1990) 
and there is no immediately obvious reason why they are not all recognised by [^H]U- 
69,593. Possibly the membrane environment is sufficiently different at the very early 
ages to interfere to some extent with agonist binding so that the increased affinity of 
pH]CI-977 when compared with [^H]U-69,593 makes it possible to detect specific 
binding with the former. Results indicate that CI-977 would be the preferred k- 
selective ligand for use in binding studies and similar methodologies.
The results with highly selective ligands for the K-receptor confirm the early full 
development of the K-site and that they precede the significant development of the Ô- 
receptor population which is not thought to occur until PN week 2 (de Vries et al., 
1990; Leslie et al., 1982; Tavani etal., 1985). Although p-receptors have been 
detected in spinal cord from the 15th. prenatal day (Attali et al., 1990) and p-mediated 
effects observed in cortical slices at E17 (de Vries et al., 1990), p-receptor 
development is not complete until day 21 (PetriUo et al., 1992). The quantitative 
measurement of the K-opioid receptor revealed by this study are predicted from the 
observation of K-mediated behavioural responses in whole animals at 5 days (Jackson 
and Kitchen, 1989a), antinociceptive effects in isolated spinal cord/tail preparations at 
1 day (Dray et al., 1989), inhibition of dopamine release in striatal slices at E17(de 
Vries et al., 1990) and support the observation of prenatal peak K-receptor levels at 
E20, only slightly exceeded by a postnatal peak at PN7 in rat spinal cord (Attali et al., 
1990).
Functfonal aspects of K-receptors are discussed in more detail in Chapter 3.
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CHAPTER 3
KAPPA-MEDIATED ANTINOCICEPTION IN THE 
NEONATAL RAT
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3.1 INTRODUCTION
3.1.1 K-mediated antinociception
There is no doubt that opioid receptors mediate antinociception although the relative 
importance of the p-, 5- and K-receptors is still a topic for investigation. The 
discovery of the opioid receptors and the endogenous opioid peptides suggested the 
existence of an endogenous pain control system and much effort has been made to 
clarify the endogenous mechanisms. Work in this field has been reviewed since it’s 
beginnings (Basbaum and Fields, 1984; Gillman and Lichtigfeld, 1985; Luttinger et 
al., 1984; Millan, 1986; Terenius, 1978; Zeiflgansburger, 1984). However, 
discussion here will be limited to the experimental investigation into the 
antinociceptive effects mediated by the K-opioid receptor.
Early investigations into the antinociceptive effects of agonists showing a degree of 
specificity for the K-opioid receptor indicated that K-agonists were more effective in 
producing antinociception when the noxious stimulus was pressure. Antinociception 
with respect to heat stimuli was absent or reduced (Tyers, 1980). It has been 
suggested that the relative potencies in thermal/pressure antinociceptive tests could be 
used to classify opioid agonists, the K-agonists being more effective in pressure tests 
than the |i-agonists and vice versa. Comparing agonists using matched response times 
as an indication of matched stimuli of different modalities, it was proposed that 
different antinociceptive profiles were the result of qualitative and not quantitative 
differences between noxious stimuli (Upton et al., 1982). This concept was further 
supported by the demonstration of distinct pharmacological profiles of \V; ô- and k- 
opioid receptors in the spinal cord of the rat (Schmauss and Yaksh, 1984). The 
populations were shown to be differentially associated with visceral, chemical and 
cutaneous thermal stimuli Later observations by the same group led to the suggestion 
that spinal K-opioid-mediated antinociception was functional only in response to 
pressure stimuli and that should a putative K-agonist show any effect against thermal
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stimuli it should be interpreted as an indication of poor K-selectivity since thermal 
antinociception could only be mediated by \i- or 6-receptors (Schmauss, 1987) The 
idea of stimulus specificity persisted for some time. An interspecies/stimulus specific 
profile was suggested as a means of classifying opioid agonist activity (Hayes et al. ,
1987) and failure to produce antinociception against thermal noxious stimuli 
continued to be accepted as typical of K-selective agonists (Leighton et al., 1987). 
Subsequently a more selective K-agonist U-69,593, was shown to produce 
antinociception in the rat using the hot-plate test (La Regina et al., 1988) although 
paradoxically another K-agonist, CI-977, was demonstrated to be effective in the 
mouse against mechanical and chemical but not thermal stimuli and yet activity was 
observed in the tail-immersion test in the Rhesus monkey (Hunter et al., 1990). 
Contrary to the findings of Upton (1982), K-agonists U-50,488H and U-69,593 were 
shown to produce antinociceptive effects against mechanical and thermal stimuli 
which were matched in terms of their basal response times (Millan, 1989a). 
However, their action against heat was shown to be stimulus intensity-dependent, the 
effect being lost as the intensity increased whereas this was not observed using the 
pressure stimulus. This was suggested to reflect the presence of two sub-populations 
of K-receptors, one involved in the responses to heat and the other in the responses to 
painful mechanical stimuli.
Additional evidence of K-opioid receptor involvement in thermal nociceptive 
responses has been obtained by recording the firing rate of motoneurones in the 
spinalized rat in response to thermal or mechanical stimuli (Dong et al., 1991; 
Parsons and Headley, 1989a; Parsons and Headley, 1989b). The effectiveness of the 
K-agonists U-50,488H and tifluadom in inhibiting the firing of the neurone was 
shown to be dependent on the frequency of the spikes generated. As the firing rate 
increased in response to either stimulus, the agonists became less effective. Further, 
when the effect of a non-noxious tap (vibration) stimulus was compared with the 
noxious heat stimulus in the same motoneurone, the U-50,488H reduced the response
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(HPA=hypothalamic/pituitary/adrenal)
rate to the noxious heat stimulus but not to the non-noxious stimulus. Naloxone 
reversibility was also demonstrated. Other electrophysiological investigations using 
isolated spinal cord/tail preparations to record depolarization in the spinal ventral root, 
demonstrated a greater inhibitory effect when capsaicin was applied to the tail than 
when the stimulus was heat (James et ai, 1990). Over-all, the electrophysiological 
measurements suggested that the concept of stimulus specific effects was not 
accurate. It had been suggested that non-naloxone reversible flaccidity observed with 
higher doses of U-50,488H (Hayes et al., 1988), the frequently observed paralysis 
induced by dynorphin analogues, also non-opioid (Caudle and Isaac, 1988; Long et 
al., 1988) and supraspinally mediated sedative effects (Millan et al., 1989) 
contributed largely to the "antinociceptive" effects of K-agonists. However, the 
recording of K-opioid effects and naloxone reversal in neurones involved in a spinal 
reflex in spinalized animals or in isolated preparations indicated a K-mediated spinal 
antinociceptive pathway.
3.1.2 Observed K-mediated responses in the developing rat.
Pharmacological responses mediated by the opioid system during ontogeny have been 
reviewed by McDowell and Kitchen (1987). There is a considerable amount of data 
which indicates the stimulation of the HP A axis via K-receptors. Raised 
corticosterone levels in response to K-agonists and other opioids have frequently been 
recorded (Eisenberg, 1980; Hayes and Stewart, 1985; Iyengar gf a/., 1986; Iyengar 
etal., 1987; Lahti and Collins, 1982). K-mediated responses have been observed as 
early as PN2 (Adamson et al., 1991). K-mediated diuretic effects are also well 
documented, centrally mediated effects probably being due to the inhibition of anti­
diuretic hormone (ADH) release (Leander, 1983a; Leander, 1983b; Leander et al., 
1985). Peripherally mediated K-agonist-induced diuresis has also been reported 
(Blackburn et al., 1986). K-opioid mediated diuresis has been demonstrated in 10 
day-old rat pups whereas p-mediated diuresis was not observed even in water-loaded
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pups (Jackson and Kitchen, 1989c). Behavioural effects have also been recorded in 5, 
10 and 20 day-old rats. At 5 and 10 days, U-50,488H, PDl 17302 and tifluadom all 
produced hyperactivity, sedation only appearing at higher doses in the older animals 
in contrast to the sedative effects of p-agonists at all ages (Jackson and Kitchen, 
1989a). U-50,488H also produced increased vocalization, activity levels and hot plate 
response latency in isolated 10 day-old rat pups (Kehoe and Boylan, 1994). Rear- 
limb, trunk and tail movements have been observed at E21 following IT injection of 
U-50,488H (Petrov et al., 1994). In the neonate, milk has been shown to reduce 
responses to tactile stimuli via the K-opioid system and this response has been 
recorded as early as E19 induced by the administration of U-50,488 (Anderson et al., 
1993; Smotherman and Robinson, 1992a; Smotherman and Robinson, 1992b)
K-antinociception has also been recorded at an early age. It has been demonstrated at 
PN3 rising to adult levels at PN7 (Barr et al., 1986) although this study used the rather 
poorly selective ketocyclazocine. Ketocyclazocine-induced antinociception has also 
been shown at PN7, suggested to be spinal^mediated and dependent on the type of 
noxious stimulus as well as body topography (Giordano and Barr, 1987). Using a 
preparation of spinal cord with tail attached from 1 day-old rats, recordings have been 
made from cutaneous polymodal nociceptors known to behave similarly to those in 
the adult (Fitzgerald, 1985). When the spinal cord was superfused with DAGO (p-), 
U-50,488H ( k -) or DPDPE (Ô-) no change was recorded in response to an innocuous 
stimulus but a reduced response was seen to exposure to heat and the irritant 
capsaicin (Dray et al., 1989). The reduction was partially reversed by naloxone in 
the case of DAGO but higher levels were required to reverse the effects of U- 
50,488H. This demonstrated opioid antinociception via p- and k- receptors at PNl in 
spinal cord. At this time there were thought to be no Ô-receptors in the spinal cord at 
PNl and the DPDPE effects were suggested to be mediated via p-receptors. Parallel 
antinociceptive (paw pressure) and electrophysiological studies on dorsal horn 
neurones showed naloxone reversible depression of electrical activity and
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antinociception in 9-16 day-old rats using U-69,593 (Allerton et aL, 1989). 
Conversely in the adult, l.V.benzeneacetamide K-agonists were shown to have no 
antinociceptive (paw pressure) activity suggesting that the neonate possessed higher 
levels of spinal Ki-sites although supraspinal Ki-sites were demonstrated in the adult 
by i.c.v.injection of the same agonists (Leighton et al., 1988). Further evidence of 
functional Ki-receptors in PNl spinal cord was demonstrated using U-69,593 and 
PDl 17302 in the spinal cord/tail preparation recording antinociceptive responses 
against capsaicin and heat (48°C) (James et al., 1990).
Having established the full development of the K%-opioid receptor in the neonatal rat 
at PN 3, in terms of receptor-protein density, and demonstrated that the affinity 
remains unchanged throughout the period of development obseved (Chapter 2), this 
study is designed to identify a functional K % -opioid-mediated antinociceptive response 
in the whole animal as early as possible using Ki-selective agonists PDl 17,302, U-
69,593 and CI-977.
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3.2 METHODS.
3.2.1 Animals.
Animals were reared and kept as descibed in 2.2.1. Only male animals were used in 
the experiments which were carried out at 3,5 and 10 days.
3.2.2 Experimental conditions.
Mothers and litters were equilibrated in a quiet laboratory for 24h before experimental 
procedures began. Between 08.30h and 09.30h, pups were removed from the mother, 
weighed, tail marked for identification and placed in a separate cage. Warmth was 
provided using a 60W lamp bulb positioned 20cm above the cage.
3.2.3 Antinociceptive models.
Antinociceptive effects were evaluated by the application of two different types of 
noxious stimuli. A mechanical stimulus was applied separately to both hind paws 
using a modified Analgesymeter, Ugo Basile, Milan (Kitchen, 1984). Withdrawal of 
the limb, flinch response or vocalization were accepted as indications of nociception. 
The preselected cut-off point was 250g which was designed to prevent any tissue 
damage. A thermal stimulus was applied by the immersion of the tail in a 
thermostatically controlled water-bath. Conditions were modified according tOj the 
age of the animals under investigation as shown below
AGE TEMPERATURE WHERE STIMULUS APPLIED
3 and 5 day 43.5°c Distal 1.0 - 1.5cm
10 day 50.0°C Distal 2.0 - 2.5cm
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Response time was measureiusing a hand held stopwatch. The response time was 
recognised as the withdrawal of the tail from the water in the 10 day-old animals but 
at 3 and 5 days of age efforts to withdraw were accepted since their responses were 
not so well co-ordinated. A cut-off time for exposure to the thermal stimulus was set 
at 10s in order to avoid possible tissue damage. During the application of the stimuli, 
the animals were gently restrained by 'swaddling' in folded paper tissue as they were 
found to be more relaxed when held in this manner than when held directly in the 
hand. Both stimuli were applied on each occasion that the tests were made, but not 
always in the same order. The random application was made to avoid any possible 
systematic stress-induced antinociceptive efects between stimuli although it has been 
demonstrated that the order in which the stimuli are applied has no significant effect 
(Millan, 1989a)
3.2.4 Preparation of drug solutions.
CI-977 and naloxone were dissolved in 0.9% saline. 25mg of U-69,593 was dissolved 
in 0.5ml IM hydrochloric acid and approximately 20ml of 0.9% saline was added. 
The pH was adjusted to pH 7.0 with IM sodium hydroxide solution and the solution 
made up to a final volume of 25ml with 0.9% saline. PDl 17302 required warming to 
37°C in order for it to go into solution in 0.9% saline.
3.2.5 Route of administration of drugs.
All drugs and saline were injected intrapeiitoneally (ky]). A range of drug solutions 
was prepared such that the dose required could be administerd in a volume of not 
more than 0.1ml.
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3.2.6 Dose-respotise determinations.
Published data relating to antinociception in the adult rat were used as a guide to the 
appropriate dose range that should be chosen for each drug (Hunter et al., 1990; 
Leighton et al., 1987; Millan, 1989a). Pilot studies were carried out to determine the 
time course of the action of each drug before the full dose-response investigations. 
The dose range was modified as necessary after the preliminary investigations Pre­
treatment values were measured for paw-pressure withdrawal threshold and tail- 
immersion withdrawal latency in each animal. A single dose of drug was 
administered IP and the responses measured at 15 minutes post injection in the case of 
U-69,593 and 20 minutes post injection in the case of PDl 17302 and CI-977. The 
following dose ranges were used in the 5 and 10 day-old animals:
AGE (days) DOSE RANGE (mg/kg)
PDl 17302 U-69,593 CI-977
5 0.3 -10.0 0.3-40 0.025 -1.0
10 0.3-20 0.3-40 0.025 - 2.0
3.2.7 Time course and reversal of antinociceptive effects.
The data obtained from the dose-response investigations were used to define a 
suitable dose for the investigation of the time course of the antinociceptive effects of 
the drugs. Pretreatment values were measured for paw pressure withdrawal threshold 
and tail immersion latency in each animal at - 15 minutes. At -10 minutes each 
animal received either 0.1ml saline or naloxone at l.Omg/kg administered j.p. At time 
0, each animal was dosed i.^.with either 0.1ml saline or an agonist at the following 
dose levels, CI-977 0.05mg/kg, U-69,593 l.Omg/kg, PDl 17302 l.Omg/kg. 
Antinociceptive testing was then carried out at 5,10, 20, 30, 45, 60 and 120 minutes 
post injection. Each animal was tested at each of the times specified. At each age, six
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control treatment measurements were made ie saline/saline injected animals and eight 
determinations of the effect of drug treatments ie saline/agonist, naloxone/saline and 
naloxone/agonist. No more than two values in each data set were obtained on the 
same day or from animals in the same litter.
3.2.8 Data analysis.
Dose response curves were constructed from non-transformed data. From the dose- 
response curves a suitable dose for use in the time course investigations was chosen 
using the following criteria:
(i) The response produced should approximate to 50% of the maximum possible 
effect observed or 50% of the pre-determined cut-off point, whichever was the smaller 
ie a clearly sub-maximal response.
(ii) The dose levels of the different drugs should be chosen to produce approximately 
die same absolute value of withdrawal threshold and response latency.
For the individual agonists, the data for each of the four treatments at the individual 
time points in the time course and reversal of antinociception studies were subjected 
to ANOVA and Duncan’s post hoc procedure for the comparison of all means. 
Statistical comparisons were not made between time points.
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3.3 RESULTS.
3.3.1 Dose-response relationships.
Antinociceptive dose-response relationships were established to both mechanical and 
thermal stimuli for all three K-agonists, PDl 17302, U-69,593 and CI-977 in both 5 
and 10 day-old animals (Figures 11-16). For each agonist^ both paw pressure 
withdrawal threshold and tail immersion withdrawal latency increased in parallel over 
the same dose range. At the lower end of the dose ranges all agonists produced 
increased activity in the form of 'paddling' and 'wall climbing'. PDl 17302 at doses of 
10.0 and 20.0mg/kg produced pronounced sedation and loss of righting reflex. U-
69,593 at doses above 20.0mg/kg also produced pronounced sedation, loss of righting 
reflex and loss of muscle tone which lasted for more than Ih. CI-977 at l.Omg/kg 
produced sedation with intermittent activity and the retention of the righting reflex but 
at 2.0mg/kg there was more complete sedation. Straub tail was frequently observed. 
It was not found possible to apply the nociceptive tests to 3 day-old pups. The short 
length of the tail and the tendency to carry it closely against the body made it difficult 
to immerse the tip in water. Similarly the small size of the hind limb made it 
impossible to use the Analgesymeter. In addition the limb and the tail were 
withdrawn in response to the initial non-noxious tactile stimulus however slowly the 
bar was lowered onto the foot or contact was made with the water surface. In pilot 
experiments a specific response could not be distinguished from intermittent tremors 
and random motor activity which all three agonists produced post injection.
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Figure 11. Dose-response relationship in the 5 day-old neonatal rat
between IP PD117302 and (a) tail immersion response latency at
43.5°C and (b) paw pressure withdrawal threshold.
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Figure 12. Dose-response relationship in the 10 day-old neonatal rat
between IP PD117302 and (a) tail immersion response latency at 50®C and
(b) paw pressure withdrawal threshold.
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Figure 13. Dose-response relationship in the 5 day-old ne(^tal rat between
IP U-69,593 and (a) tail immersion response latency at 43.5°C and (b) paw
pressure withdrawal threshold.
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n
Figure 14. Dose^'esponse relationship in the 10 day-old neo^tal rat
between IP U-69,593 and (a) tail immersion response latency at
50°C and (b) paw pressure withdrawal threshold.
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Figure 15. Dose response relationship in the 5 day-old neoatal rat
between IP CI-977 and (a) tail immersion response latency at
43.5°C and (b) paw pressure withdrawal threshold.
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Figure 16. Dose-response relationship in the 10 day-old neoatal rat
between IP CI-977 and (a) tail immersion response latency at
50°C and (b) paw pressure withdrawal threshold.
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3.3.2 Time course and reversal of antinociception.
At l.Omg/kg PDl 17,302 produced pronounced antinociceptive effects to both 
mechanical and thermal stimuli in 5 day-old and 10 day-old animals (Figures 17 and 
18). The antinociceptive effect was at a maximum at 20 minutes post injection. 
There was a significant antinociceptive effect measured against the mechanical 
stimulus for 2  hours (maximum observation time) in the 5  day-old animals and 
against both stimuli in the 10 day-old animals. A very similar profile was observed 
with U-69,593 at a dose level of 1 mg/kg (Figures 19 and 20). However, the 
antinociceptive effects peaked at 1 0  minutes and the responses were not significantly 
different from the controls at 2 hours. In the 5 day-old animals, the antinociceptive 
effect against the pressure stimulus was maintained at the peak value up to 45 minutes 
post-injection whereas at this time the response latency to the thermal stimulus had 
fallen from the peak measure of 5.5 seconds to approximately 2 seconds compared 
with the control measure of Is. CI-977 at 0.05mg/kg produced antinociception 
against both stimuli peaking at 1 0  minutes post injection in the 5  day-old animals and 
20 minutes in 10 day-old animals (Figures 2 1  and 22). Animals receiving injections 
of saline and/or the antagonist naloxone at Img/kg showed no evidence of significant 
stress-induced antinociception. Complete reversal of each agonists antinociceptive 
effects was achieved by prior injection of Img/kg naloxone. Complete reversal was 
not always maintained throughout the time course of the experiments. In a 
preliminary study to determine the time of peak antinociception appropriate to use in 
the establishment of dose-response relationships, CI-977 was used at 0 .2 mg/kg. 
Img/kg naloxone did not completely abolish the agonist induced antinociception but 
complete reversal was observed with an antagonist dose of 3mg/kg (Figure 23).
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Figure 17. Time course and reversal of PD117302 induced antinodception 
in the 5  day-old neonatal rat measured as (a) tail immersion withdrawal 
latency at 43.5°C and (b) paw pressure withdrawal threshold.
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Figure 18 Time course and reversal of PD117302 induced antinociception
in the 10 day-old neonatal rat measured as (a) tail immersion withdrawal
latency at 50.0°C and (b) paw pressure withdrawal threshold.
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Figure 19. Time course and reversal of U-69,593 induced antinodception
in the 5 day-old neonatal rat measured as (a) tail immersion withdrawal
latency at 43.5°C and (b) paw pressure withdrawal threshold.
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Figure 20. Time course and reversal of U-69,593 induced antinodception
in the 10 day-old neonatal rat measured as (a) tail immersion withdrawal
latency at 50.0°C and (b) paw pressure withdrawal threshold.
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Significantly different from controls (ANOVA and Duncan'^oj^r hoc test for the
comparison of all means) # #  P < 0.01 #  P < 0.05
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Figure 21. Time course and reversai of CI-977 induced antinodception in
the 5 day-old neonatal rat measured as (a) tail immersion withdrawal
latency at 43.5°C and (b) paw pressure withdrawal threshold.
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Significantly different from controls (ANOVA and Duncan'spoj? hoc test for the
comparison of all means) P < 0.01 # P  < 0.05
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Figure 22. Time course and reversal of CI-977 induced antinociception in
the 10 day-old neonatal rat measured as (a) tail immersion withdrawal
latency at 50.0°C and (b) paw pressure withdrawal threshold.
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(□) naloxone Img/kg: saline (■) naloxone Img/kg: CI-977 0.05mg/kg
Significantly different from controls (ANOVA and Duncan'spojr hoc test for the
comparison of all means) # #  P < 0.01 #  P < 0.05
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Figure 23. Dose related effects of CI-977 and naloxone on k-mediated
antinociception in the 10 day-old neonatal rat measured as (a) tail immersion
withdrawal latency at 50°C and (b) paw pressure withdrawal threshold.
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3.4 DISCUSSION
The dose-response curves for each agonist in both 5 and 10 day-old animals indicated 
an agonist potency against a mechanical noxious stimulus equivalent to that reported 
in adults (Hunter et al., 1990; Leighton et al., 1987). U-69,593 was found to be 
approximately equipotent with PDl 17,302 whereas CI-977 potency was of the order 
of 100 times greater. It is particularly important in an antinociceptive test with an 
endpoint dependent on a motor response that possible agonist induced motor 
impairment does not result in apparent lack of response which might be attributed to 
antinociceptive effects and similarly, hyperactivity may mask antinociceptive effects. 
Therefore^ the dose levels chosen in this study were designed to produce 
approximately 50% of the maximum possible effect. In contrast to some observations 
which suggest dose-dependent sedation over approximately the same dose range as 
that required to produce antinociception (Hunter et a/., 1990), these results indicate 
that hyperactivity in the form of paddling/wall climbing is induced over a 
considerable dose range. Sedative effects were only observed at higher levels, 
lOmg/kg for PDl 17,302 and U-69,593 and l.Omg/kg for CI-977. This observation is 
in agreement with results reported in mice which indicated that the dose of U- 
69,593 required to produce sedation was significantly higher than that needed to 
produce antinociception (Horan et al., 1991) although another study suggested there 
was only a small separation between antinociceptive and sedative doses (Leighton et 
at., 1987). Hyperactivity has been recorded in behavioural studies with PDl 17,302 in 
5 and 10 day-old rats, sedative effects only appearing at higher doses in older animals 
(20 day-old) (Jackson and Kitchen, 1989a). More recently, CI-977 at 0.03 and 
0.05mg/kg has been reported to increase locomotor activity in 3 and 15 day-old 
neonatal rats, an effect lost by 21 days (McLaughlin et at., 1995). The time course of 
the antinociceptive activity of the agonists was similar to that observed in the adult 
(Hunter et al., 1990). The rapid onset, antinociception being observed at 5 minutes 
and the peak values at 1 0 - 2 0  minutes are predicted since the arylacetamide ligands are
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lipophilic. Although complete reversal of the agonist effects by naloxone was 
observed initially the antagonist effect in some cases could be seen to decline with 
time. This is expected since the half-life of naloxone by various routes of 
administration is reported to be of the order of 13-20 minutes (Heyman et al., 1986; 
Porreca et al., 1981) and in these experiments naloxone injection preceded agonist 
injection by 10 minutes. The partial reversal of the antinociception produced by CI- 
977 at 0.2mg/kg by Img/kg naloxone and the complete reversal by 3mg/kg naloxone 
demonstrated a dose-dependent antagonist effect and confirmed that the agonist- 
induced antinociception was entirely due to opioid mediated effects.
Dose-dependent responses were observed in the thermal tail immersion test. The dose 
ranges over which these were observed were the same as those in the paw pressure 
(mechanical) test. This observation of antinociceptive effects against a thermal 
stimulus conflicts with some previous reports. Using the hot-plate test in adult mice, 
all three agonists were reported to be inactive (Hunter et al., 1990) and there have 
been numerous other reports that a failure to produce antinociception against a 
thermal stimulus or a much reduced potency in comparison with other tests, is typical 
of K-agonists (Giordano and Barr, 1987; Hayes et al., 1987; Schmauss, 1987; 
Schmauss and Yaksh, 1984; Upton et al., 1982). However, \ U-69.593 in mice
has been demonstrated to have antinociceptive effects against tail immersion (55°C) 
(Horan et a i ,  1991) and in rats U-69,593 prolonged the reaction time on the 55°C 
hot-plate (La Regina et al., 1988). It has been demonstrated by recording responses 
in individual spinal neurones that K-opioid inhibition of electrical activity induced by 
noxious stimuli is intensity-dependent. In particular^it was recorded that comparable 
firing rates elicited by either noxious heat or pressure stimuli were both dose- 
dependently reduced by K-agonists (Dong et al., 1991; Parsons and Headley, 1989a; 
Parsons and Headley, 1989b). In the whole animal, K-agonist activity has been 
demonstrated to be stimulus-intensity-dependent in the thermal test but not in the 
mechanical test (Millan, 1989a). It was observed during preliminary experiments to
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establish experimental parameters for the study reported here that there was a 
small 'window' of temperature suitable to use in the tail immersion test, i.e. the 
temperature at which the heat stimulus was tolerated as apparently non-noxious was 
never more than 5°C lower than the temperature which elicited instantaneous 
withdrawal and latency could not be quantified. It is possible therefore that the 
stimulus parameters chosen in fact produced matched responses in the spinal neurones 
and it was thus possible to observe k-agonist antinociceptive effects against thermal 
and mechanical noxious stimuli. It is suggested that focused radiant heat and a water 
temperature of 55°C, which are frequently used thermal stimuli, are likely to represent 
more intense stimuli. The apparent lack of concensus in the literature relating to k- 
agonists and their ability to mediate antinodception is probably a reflection of the 
variety of techniques and animal models used. There are clearly species differences 
in the density and distribution of the K-receptors relative to the total opioid receptor 
population (Robson etaL, 1985) and in the relative proportions of the putative Ki- 
and K2 -sites (Boyle era/., 1990; Zukine/c/., 1988). For a comprehensive review see 
Mansour and Watson, 1993. Further anomalies may arise because of the route of 
administration of drugs. For example up. injection of opioid agonists and antagonists 
does not specifically target a particular opioid receptor population therefore the 
experiments reported here cannot distinguish between spinally and supraspinally k- 
mediated responses both of which are reported in the rat (Leighton et al., 1988; 
Mansour and Watson, 1993; Millan et al., 1989; Parsons and Headley, 1989b; 
Pelissier et al., 1990; Schmauss and Yaksh, 1984). The route of administration may 
markedly affect the subsequent observation of antinociception and the 
pharmacokinetics of distribution may differ between the neonate and the adult e.g. the 
blood brain barrier does not fully develop until about PN14 (Davson, 1972) and the 
lipid layer in the dorsal horn is reduced in the neonate (Sullivan and Dickenson, 1991) 
allowing drugs easier access than in the adult.
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In the adult, K-agonists have been shown to both facilitate and inhibit the responses of 
lumbar dorsal horn neurones in response to C-fibre inputs which may cancel each 
other out in terms of overall effect on the receptor population so that antinociception 
may not be produced (Knox and Dickenson, 1987). It has also been reported that the 
antinociceptive effects of U-50,488H and U-69,593 (observed at the neuronal level by 
electrophysiological studies) can be reversed by the selective K-antagonist nor-BNI in 
the rat pup but not in the adult (Sullivan and Dickenson, 1991) and that U-69,593 was 
some 19-fold more potent in the pup whereas U-50,488H showed only a 6 -fold higher 
potency. This may be due to the presence of a heterogeneous K-receptor population 
differing in relative numbers between the neonate and the adult or to agonist effects at 
another opioid receptor. It has been reported that a heterogeneous population of k - 
receptors can be distinguished using a variety of K-agonists in the spinally sectioned 
and spinally intact rat (Herrero and Headley, 1993). No conclusion is drawn as to the 
nature of the difference within the population. There is binding and functional 
evidence for K-receptor subtypes (see Section 1.3.1) and the rat is reported to have 
very low levels of the benzaceËmide sensitive K%-opioid receptor subtype (Zukin et 
al., 1988) although to date only a single K-opoid receptor has been cloned from any 
one species (see Section 1.4.1).
Reports do suggest that k -mediated antinociceptive responses are more easily
observed in the neonate (Allerton et al., 1989) and that this may reflect the relatively 
higher levels of K-binding in the neonate compared with the adult. There are a 
number of opioid-mediated responses in the whole animal which are observed to 
change during development K-agonists have been shown to produce hyperactivity in 
the neonate and sedative effects in the adult (Jackson and Kitchen, 1989a). K- 
antinociception precedes p-antinociception (Barr et al., 1986) allowing the 
possibility that p-mediation may supercede K-mediation with age. A similar switch in 
relative functional importance is seen with the change from p-mediated to 5-mediated 
swim-stress-induced antinociception on weaning (Jackson and Kitchen, 1989b;
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Kitchen and Pinker, 1990). As discussed in Section 3.1.2 there are many K-mediated 
responses observed in the neonatal ra t, even as early as E l9.
The K-mediated antinociception reported in this study confirms that K-mediated 
antinociception to both thermal and mechanical stimuli induced by the highly 
selective Ki-agonists PDl 17,302, U-69,593 and CI-977 can be observed in the whole 
animal as early as PN5. This correlates with the report in Chapter 2 of full 
development of the benzacetamide sensitive K%-opioid receptor at PNl with recorded 
levels exceeding the adult levels. The reports of failure to demonstrate K-mediated 
thermal antinociception may reflect methodological differences e.g. the use of more 
intense thermal stimuli, together with the decreasing significance of K-opioid 
receptors in the nociceptive pathways of the adult which may parallel the relative 
decrease in K-receptor density with respect to the total opioid receptor population.
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CHAPTER 4
QUANTITATIVE ONTOGENY OF THE DELTA-OPIOID 
RECEPTOR IN THE RAT BRAIN AND THE EFFECT OF 
WEANING ON DELTA-RECEPTOR DEVELOPMENT
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4.1 INTRODUCTION.
A general review of opioid receptor ontogeny has been presented in Section 2.1. The 
earliest '5-selective' ligands, although having a low affinity for K-receptors, showed 
relatively poor discrimination between 6 - and p-receptors (Table 5). e.g. DADLE (for 
acronyms please see Table 4) has only approximately a four-fold greater affinity for
5-receptors over p-receptors (Chang and Cuatrecasas, 1979) compared with a 
selectivity for 5-receptors over K-receptors of the order of 6000-fold (James and 
Goldstein, 1984). (The selectivity of opioid ligands is reviewed in Section 1.2). 
However, used in conjunction with ligands such as naloxone and moiphine which are 
selective for p-receptors over 5-receptors by factors of about fifteen and forty-eight 
respectively (Magnan et a i,  1982; Paterson et al., 1983) it was possible to 
demonstrate that significant 5-receptor binding in homogenates of the rat brain did not 
appear until the second postnatal week (Leslie et al., 1982; Wohltmann et al., 1982). 
DPDPE was shown to be a 5 -receptor-selective ligand with a reported 5-/p- 
preference of 14.3 in calf brain (Clark et al., 1986), 175 in rat brain (Mosberg et al., 
1-983) and 260 in guinea-pig brain where 5-/k- selectivity was >5000-fold (Corbett et 
al., 1984). The 5-selective properties of this ligand allowed the direct quantification 
of 5-receptors in the developing rat brain and a six-fold increase in 5-binding between 
PNIO and PN25 was reported (McDowell and Kitchen, 1986) after which there was 
little or no increase observed. The relatively low affinity of DPDPE (Kd = lOnM) 
and a decreasing specific binding ratio with decreasing age resulted in a failure to 
detect any specific 5-receptor binding earlier than PNIO at which age a Bmax of 34.5 
fmol/mg protein was recorded (McDowell and Kitchen, 1986). The availability of the 
tritiated forms of the highly selective, high affinity 5-agonists Ile^.^Deltorphin II 
([3H]ne5.6DELT H) (Bûzâs et al., 1992) and Deltorphin I (pHjDELT I) (Erspamer et 
al., 1989) and the highly selective, high affinity 5-antagonist Naltrindole ([^HjNTI) 
(Yamamura et al., 1992) has allowed the further investigation of 5 -receptor 
development in the rat.
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In vivo functional studies of opioid-mediated responses in the rat have indicated 
differences between the adult and the neonate. \i- and K-agonists produced 
behavioural responses in 5-20 day-old animals which were dissimilar to those in the 
adult whereas 0-agonists did not elicit a behavioural response in 5,10 and 20 day-old 
rat pups (Jackson and Kitchen, 1989a). Opioid -mediated, stress-induced 
antinociception involving |Lt-opioid receptors up to PN20 has been shown to be Ô- 
receptor-mediated at PN25 (Jackson and Kitchen, 1989b; Kitchen and Pinker, 1990). 
Further, if animals are not weaned at PN21, the switch from p,-receptor to 6 -receptor 
mediation of the stress-induced antinociception does not occur (Muhammad and 
Kitchen, 1993). Other observations have indicated that directly agonist-mediated 
antinociception differs between weaned and non-weaned 25 day-old rats. The 
putative 0 2 -agonist DSLET produces antinociception in 25 day-old weaned rats but 
not in 25 day-old non-weaned rats whereas antinociception is observed in both 
weaned and non-weaned animals in response to DELTI (Kitchen et al., 1994). These 
observations suggest that weaning is a stimulus for the development of a DSLET- 
sensitive 6 -opioid receptor. The 6 -opioid receptor population has been shown to be 
heterogeneous in 25 day-old rats (Crook et a i, 1992) since antinociceptive responses 
to DPDPE and DSLET were observed to be some ten times more sensitive to NTI 
antagonism than those of DELT I.
Although the agonist/antagonist profiles are not entirely consistent with those in the 
rat, there is evidence that 6 -receptor subtypes exist in the mouse and on the basis of in 
vivo studies involving differential antagonism and cross tolerance the subtypes have 
been designated 6 i- and 6 2  (Horan et al., 1993b; Jiang et al., 1991; Mattia et al., 
1992; Mattia era/., 1991; Sofuoglu a/., 1991a; Sofuoglu ef a/., 1991b). A single
6 -opioid receptor has been cloned (Evans et a i, 1992; Kieffer et al., 1992) with a 
high sequence homology between the rat and the mouse. Treatment with antisense 
oligodeoxynucleotide to this receptor has been demonstrated to differentially reduce 
the antinociceptive effects of 6 -agonists indicating 6 -receptor multiplicity in the
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mouse (Bilsky et al., 1994; Lai et al., 1994) and to differentially affect selective 
ligand binding in the rat brain (Cha et al., 1995). Homogenate binding studies in the 
mouse (Sofuoglu et al., 1992; Xu et al., 1993) and in the rat (Negri et al., 1991) also 
suggest 6 -receptor heterogeneity as do autoradiographic studies in the rat (Hiller et 
al., 1995). It has been suggested that 6 -opioid receptor subtypes can be distinguished 
in rat brain on a chemical basis dependent on their susceptibility to the sulphydryl 
reagent N-ethylmaleimide (NEM) (Tam and Rafferty, 1994). 6 1-receptor binding is 
reduced to a greater extent than 6 2 -receptor binding and it is proposed that this 
indicates non-equivalent cysteine residue sulphydryls in the receptor protein which 
differ in their reactivity with the NEM due to their differing molecular environments.
Based on the evidence that suggests 6 -receptor heterogeneity and in particular the 
observations that in vivo 6 -receptor mediated responses differ in weaned and non- 
weaned 25 day-old rats the highly 6 -selective radioligands [^HjDELT I, 
pHjlÊe^’^ DELT II and pH]NTI were used to quantify 6 -receptor density in both the 
brain and the spinal cord of 25 day-old weaned and non-weaned rats. Development in 
the brain was followed throughout the preweanling period with all three ligands and 
postweaning development with [^HjDELT I.
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4.2 MATERIALS AND METHODS.
4.2.1 Animals.
Wistar Albino rats were bred and reared under the conditions described in 2.2.1. The 
day of birth was designated as day 1. Litters were cross-fostered and litter size was 
standardised to ten animals, all males where possible. Only male animals were used 
in the experiments. Preweanling pups (up to day 20) were removed from the cage 
immediately before killing and weaning was carried out on day 21 by the removal of 
the mother from the cage. In groups of animals which were not weaned, the mother 
remained with the litter at all times until the pups were removed for killing. In all 
other respects both weaned and non-weaned groups were housed under identical 
conditions in the same room. Further groups of animals were weaned at day 25 (late 
weaning) and were killed at days 30, 35 and 40 for comparison of 5-receptor binding 
with animals of the same age weaned at 21 days. For the measurement of 6-receptor 
binding in adults, animals weaned at 21 days were killed at an age of between 60 and 
90 days.
4.2.2 Preparation of tissue homogenate.
Membrane homogenates were prepared as described in 2.2.2 except that the final 
homogenate was prepared at 10 mg wet weight per ml in 50 mM Tris-HCl buffer 
designed to be at pH 7.4 at the temperatures appropriate to the subsequent binding 
procedures which were 25°C and 35°C. For all post-weaning studies, the minimum 
number of brains used to prepare an homogenate was two, in order to avoid possible 
individual variation. For the study of preweanling 6-ontogeny measures were made at 
20, 15, 10, 5 and 3 days and the number of brains used at each age was 2, 2, 3, 4-5 
and 8-10 respectively. For the comparison of weaned and non-weaned animals at day 
25, pooled tissue from 2 animals was used in the case of the brain and from 10
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animals in the case of the spinal cord. The brain tissue was obtained from 2 of the 
group of 10 animals which were used for the spinal cord tissue.
4.2.3 Ligands.
4.2.3.1 [^H] Labelled ligands.
pH]-Deltoiphin I (pH]DELT I), 35 Ci/mmole was custom synthesised by Cambridge 
Research Biochemicals (Cheshire, U.K.)
pH]-Ile^’6-Deltorphin II ([^HJ-Ile^’^ -DELT II), 49 Ci/mmole and [^HJ-Naltrindole 
d^HJ-NTI), 19.5 Ci/mmole were provided by Izinta (Budapest, Hungary).
4.2.3.2 Unlabelled ligands
Unlabelled Deltorphin I was purchased from Cambridge Research Biochemicals and 
naloxone hydrochloride was purchased from Sigma Chemicals.
(DELT I, DELT II and NTI are fully identified in Section 1.2.3, Table 4 and naloxone 
illustrated in Section 1.1.1, Figure 1).
4.2.4 Saturation assays
4.2.4.1 [^H]-Ile^>^-Deltorphin II
Based on the value of Kd for H]-Ile^'^-DELT II binding published in the literature 
(Bùzâs et al., 1992) preliminary time-course experiments were carried out using a 
final ligand concentration of 1.82 nM at a temperature of 35°C (Bûzâs et al., 1992) 
and homogenate of brain minus cerebellum from 25 day-old rats at lOmg/ml
143
(ww/vol), 11 replicate sets of tubes in triplicate were prepared and harvested at 10 
time points between 5 and 120 minutes. Non-specific binding was determined using 
one set of tubes to which had been added naloxone at a final concentration of 10|iM at 
time 0 and which was harvested at 120 minutes. The experiment was repeated three 
times. Based on these experiments, saturation binding studies were carried out as 
described in 2.2.4.2 using 12 ligand concentrations between 0.2 - 10 nM, an 
incubation temperature of 35°C, an incubation time of 45 minutes and using 10 jiuM  
naloxone to determine non-specific binding. A minimum of four determinations were 
made for each group of animals. Preweanling m e ^ e s  were made using pHj-Ile^'^- 
DELT n  at 20 days and successively earlier ages until no specific binding could be 
detected. Measures were also made in weaned and non-weaned rats at 25 days in both 
brain and spinal cord.
4.2.4.2 pH]-Naltrindole
Preliminary experiments were carried out based on published data characterising 
pH]-NTI binding to rat brain homogenates (Contreras et a l, 1993; Yamamura et al., 
1992) The time course of pH]-NALT binding at 25°C was established over a period 
of 5 to 120 minutes as described for [^Hj-Ile^’^ -DELT II using a ligand concentration 
of 0.4 nM. The experiment was repeated three times. Subsequent saturation studies 
in triplicate were carried out as described in 2.2.4.2 using a ligand range of 14 
concentrations between 0.02 - 2.0 nM, an incubation temperature of 25°C, an 
incubation time of 60 min and 10 |iM naloxone to determine non-specific binding. 4- 
6 determinations were carried out at 20 days and successively earlier ages down to 3 
days. 3 determinations were made in the adult. 4-6 determinations were also made in 
weaned and non-weaned rats at 25 days in both brain and spinal cord.
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4.2.5 [^H]-Deltorphin I homologous displacement studies.
Unlabelled DELT I solution was prepared at 20 pg/ml in absolute alcohol and stored 
at - 20°C. This stock was used throughout the whole series of experiments being 
diluted on the day into 50 mM Tris-HCl buffer, pH 7.4 at 35°C. Initial experiments 
were carried out to confirm the suitability of the published experimental parameters 
for use in this study (Negri et al. , 1993). The time course of pH]-DELT I binding at 
35°C was determined using a final ligand concentration of 0.3 nM. Assays were in 
triplicate and non-specific binding was measured at each time point by the addition of 
naloxone to give a final concentration of 10 |xM to a replicate set of tubes. Binding 
was measured at intervals from 5 to 180 minutes. After establishing the time needed 
to reach saturation the time course of displacement was investigated. Homogenate 
samples in triplicate were incubated at 35°C with 0.3 nM [3H]-DELT I for 90 min. 
One set of tubes was used to determine non-specific binding by the addition of 10 pM 
naloxone. Unlabelled DELT I was added to all tubes to give a final concentration of 
168 nM and the reactions terminated by filtration at intervals of up to 3 hours. The 
experiment was repeated four times. From the time courses of binding and 
displacement an incubation time of 90 min was chosen for further studies. Reaction 
mixtures were prepared containing 0 - 168 nM cold DELT I by the addition of 
varying volumes of three stock solutions of different concentrations. Within 10 
minutes of these additions [^H]-DELT I was added at a final concentration of 0.3 nM 
and the incubation temperature was 35°C. Non-specific binding was determined in 
replicate sets of tubes at levels of displacer of 0 and 168nM by the addition of 
naloxone to give a final concentraion of 10 pM. The reactions were terminated and 
the radioactivity determined as described in 2.2.4.1. In the preweanling study 4-6 
determinations were made at 20 days and successively earlier ages until reproducible 
binding could not always be detected. 4-12 determinations were carried out in 
homogenates of brain and spinal cord from weaned and non-weaned rats at 25 days.
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1C 50 =  the concentration o f  co ld  displacer w hich  reduces the sp ecific  binding o f  the 
labelled  ligand by 50%.
3-4 determinations were made in brain homogenates from animals greater than 25 
days after normal weaning (21 days) or late weaning (25 days) and in the adult.
4.2.6 Protein analysis.
In order to avoid freezing the homogenate samples, protein analysis was carried out 
within 24 hours of preparation. The homogenates were diluted by half in the 50mM 
Tris buffer in which they had been prepared and the total protein measured by the 
modified Lowry method as described in Section 2.2.6. Measures were made against a 
BSA standard prepared in the Tris buffer corresponding to that in which the 
homogenates had b& prepared.
4.2.7 Data analysis.
Data from saturation experiments were used to construct saturation curves. From 
Scatchard analyses K© values were calculated for the ligands at each age and 8 - 
receptor density was calculated as Bmax expressed as fmol [^Hjlle ’^^ -DELT II or [^H] - 
NTI bound per milligram wet weight. From these values receptor density was 
calculated as fmol [^HJIle ’^^ -DELT II or pH]-NTI bound per milligram protein or 
pmol per brain. Data from the [^HJ-DELTI homologous displacement studies were 
analysed by means of Hill plots from which were derived IC5 0  values. A modified 
form of the Cheng and Prussoff equation (IC5 0  = Kc(l+L/Kh) where IQ and Kh are the 
dissociation constants of the cold (unlabelled) ligand and hot (labelled) ligand and L 
is the concentration of radioligand used) was used to calculate the and to derive 
the Bmax- On the assumption that hot and cold ligand have the same affinities for the 
receptor, there is only one class of binding site, there are no cooperative effects and 
the fraction of ligand bound is so small that the firee ligand concentration may be 
assumed to be the same as the total ligand concentration, then B^ax = Bq x IC5 0 /L
w here B q =  total binding o f  radiolabelled ligand in the absence o f  com petitor
m inus n on-specific  binding o f  the hot ligand under conditions o f  100%
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displacement of specific binding. The principle of this approach is discussed in 
DeBlasi et al. (1989). B^ax values were calculated per wet weight, per protein and 
per brain. The data from pH]-DELT I homologous displacement experiments in 
brain homogenates were also analysed by LIGAND, a non-linear regression analysis 
program (Munson and Rodbard, 1980). Kd values for the individual ligands were 
compared across the age groups by 1-way ANOVA and Duncan's post hoc test for 
the comparison of all means. Comparison of Bmax values was carried out using 2-way 
ANOVA to analyse the interaction between age and ligand. The Kd values for the 
individual ligands in the 25 day weaned and non-weaned groups were compared using 
Student t - test. The Bmax values measured by all three ligands in both weaned and 
non-weaned groups were compared by 1-way ANOVA and Duncan's post hoc test 
for the comparison of all means. Brain weights and protein levels at each age were 
compared across the experiments with the three ligands by 1-way ANOVA and 
Duncan's post hoc test for the comparison of all means.
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4.3 RESULTS
4.3 1 Preliminary time course experiments
4.3.1.1 pHJIle^’^ -Deltorphinll
The specific binding of [^HJIle^’^ DELT II at a concentration of ligand of 1.82nM at 
35°C expressed as fmol/mg protein was found to have reached equilibrium at 25-30 
minutes in good agreement with the published data (Bûzâs et a i, 1992). This is 
illustrated in Figure 24. The equilibrium at 25 minutes was maintained over the time 
period of the experiment, 120 minutes, there being no significant difference in the 
binding observed at 25, 30, 60, 90, 100 and 120 minutes (1-factor ANOVA and 
Duncan's post hoc test for the comparison of all means). This was accepted as an 
indication that there was no significant enzyme degradation of [^HJIle^’^ DELT II and 
that its stability in crude rat brain membranes prepared in 50mM tris buffer, pH 7.4 
was comparable to that of D-Ala^-Deltorphin n  which has b ^  shown to undergo very 
slow hydrolysis, < 10% after 50 minutes incubation at 37°C (Erspamer et al., 1989). 
An incubation time of 45 minutes was therefore considered suitable for saturation 
assays.
4.3.1.2 pHJNaltrindole
pH]NTI binding to homogenates of whole brain minus cerebellum from the 27 day- 
old rat at 25°C and at a ligand concentration of 0.40nM, reached an equilibrium at 60 
minutes, the Bmax of which expressed as fmol pH]NTT bound/mg protein, was not 
significantly different fi*om the values at 90 and 120 minutes (1-factor ANOVA and 
Duncan's post hoc test for the comparison of all means). This is illust fated in Figure 
25.
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Figure 24, Time course of [^]He^’^ Deltorphin H binding in homogenate of
whole brain (minus cerebellum) from the 25 day-old rat
45-,
'S  40 -
K :
E 3 5 -
30 -
S  2 5 -
a  20-:
«  10-:
CO
40 60 1200 20 80 100
Time (minutes)
Error bars are ± SB, n = 3. There is no significant difference between 
measures at 25,30,60,90,100 and 120 minutes. (P > 0.05,1-factor 
ANOVA and Duncan’s post hoc test for the comparison of all means)
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Figure 25. Time course of [^]Naltrindole binding in homogenate of 
whole brain (minus cerbelium) from the 25 day-old rat.
70-,
A
^ 5 0 -
12060 10040 800 20
Time (minutes)
Error bars are ± SB, n = 3. There is no significant difference between 
measures at 60,90 and 120 minutes. (P > 0.05,1-factor ANOVA and 
Duncan’s post hoc test for the comparison of all means).
150
4.3.1.3 [^HJDeltorphin I
pH]DELT I binding to homogenates of whole brain (minus cerebellum) from 25 day- 
old rats at a ligand concentration of O.SOnM and a temperature of 35°C, reached an 
equilibrium at 90 minutes which was maintained to the limit of the observation time, 
180 minutes. After 90 minutes there was no significant difference in the Bmax of 
pH]DELT I measured as fmol/ mg protein (1-factor ANOVA and Duncan’s post hoc 
test for the comparison of all means). Following the addition of cold DELT I at a 
final concentration of 168nM at 90 minutes, [^HJDELTI binding reached a minimum 
after a further 90 to 120 minutes. There was no significant difference in the Bmax for 
pHjDELT I binding expressed as fmol/mg protein after 120 minutes in the presence 
of cold DELT I and subsequent measures at 150 and 180 minutes (1-factor ANOVA 
and Duncan’s post hoc test for the comparison of all means). At these times there 
was incomplete displacement of [^H]DELT I binding, residual binding representing 
some 15% of the maximum binding observed. The enzymatic degradation of 
Deltorphin I under these conditions has been shown to be very slow (Erspamer et al. ,
1989) and there was no evidence of the equilibrium maximum binding changing over 
90-150 minutes. Therefore 90 minutes was accepted as suitable for the subsequent 
experiments.
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Figure 26. Time course of pHjDeltorphin I binding and homologous 
displacement in homogenate of whole brain (minus cerebellum) from 
the 25 day-old rat.
100
00
0 50 300100 200 250150
Addition of cold Deltorphin
l<
. Î
Time (minutes)
#  = [ H]Deltorphin I binding O = [ HJDeltorphin I displacement
SB = [ H]Deltorphin I bound in fmol/mg protein
Bmax = [^EQDeltorphin I bound in fmol/mg protein in the absence of competing ligand. 
There is no significant difference between measures at 90,120 and 150 minutes for 
the binding or between 210,140 and 270 minutes for the displacement
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4.3.2 Preweanling 6-receptor development
pHjNALT and pHJIle^’^ DELT II showed high affinity saturable binding at all ages 
where there was measurable specific binding. Specific [^HJNALT binding was 
detectable down to day 3 which was the earliest age that was investigated. At day 5 
pH]Ile^'^DELT II total binding was not distinguishable from non-specific binding 
(n=2). Representative binding curves and Scatchard transformations for pHJNALT 
binding at days 5, 10, 15 and 20 are shown in Figure 27 and for [^Hjlle^ ^DELT II 
binding at 10, 15 and 20 days in Figure 28. Monophasic homologous displacement 
curves for the binding of [^HJDELT I were obtained down to day 5 at which time 
binding was detected only in 50% of experiments (n = 6). The slopes of the Hill plots 
derived from the displacement data were never significantly different from 1. 
Displacement curves and corresponding Hill plots obtained at 5, 10 15 and 20 days 
are shown in Figure 29. Derived measures of Kq for pH]DELT I did not differ from 
day 5 at any age and for pH]Ile^’^ DELT II no change was found with age. At day 3 
the antagonist [^HJNALT was the only 5-ligand with which specific binding could be 
detected and the Kd value was higher at 3 days than at all other ages. The percentage 
of non-specific binding increased at younger ages for all ligands. Table 16 
summarises 5-receptor binding affinities and specific binding ratios recorded during 
preweanling development and includes the postweaning values measured at 25 days. 
There was no significant difference in the brain weights after the removal of the 
cerebellum between the groups of animals used at any one age (Table 17). At 10,15 
and 20 days, expressed as fmol/mg wet weight or pmol/mg brain, there was no 
significant difference between Bmax values for all three ligands nor at 5 days between 
those of [^HjNALT and pH]DELT I. Expressed as fmol/mg protein, significantly 
lower values of Bmax measured with pH]NALT, reflected the significantly higher 
protein levels recorded in the homogenates used in these experiments (Table 17). 
These results are summarised in Table 18.
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Figure 27. Representative saturation binding curves with Scatchard
analyses (inset) for [^H]naltrindole binding in homogenate of whole brain
(minus cerebellum) from five, ten, fifteen and twenty day-old rats.
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Figure 28. Representative saturation binding curves with Scatchard
analyses (inset) for pH]He^’^ DeItorphin II binding in homogenate of whole
brain minus cerebellum from ten, fifteen and twentyfive day-old rats
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Figure 29. Representative homologous diplacement curves with Hill plots inset
for [^H]Deltorphin I binding in homogenates of whole brain (minus cerebellum) 
from five, ten, fifteen and twentyfive day-old rats.
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4.3.3 The effect of weaning on 6-receptor density in the 25 day-old rat brain and 
spinal cord
In both the brain and spinal cord of the weaned and non-weaned 25 day-old rat, 
pH]NTI and [^Hjlle^ ^DELT II showed saturable high affinity binding (Figures BO­
SS). Monophasic displacement curves were obtained for [5H]DELT I and the slopes 
of the derived Hill plots were not significantly different from 1 (Figures S4 and S5). 
Comparison of the derived Kq values for each ligand in both brain and spinal cord 
showed no significant difference between the weaned and non-weaned groups (Table 
19). The specific binding ratios, at Kd for [^HjNTI and [^HJIle^’^ DELT II and at 
O.SnM for [^EJDELT I, were not significantly different in the weaned and non- 
weaned groups (Table 19). The brain weights after the removal of the cerebellum 
were not significantly different between the groups except for the NTT non-weaned 
group which just reached significance at P < 0.05 (Table 20). There was no 
significant difference between the weaned and non-weaned protein ratios across all 
ligands in the brain or spinal cord.(Table 20). pH]NTT and [^Hjlle^^DELT II 
recognised an equivalent number of sites in the brain of both weaned and non-weaned 
25 day-old rats (Figure S6). The Bmax obtained using [^HjDELT I in non-weaned 
animals was similar but in weaned animals it was S5% higher expressed per wet 
weight or per protein (Figure S6). The numerical values derived from Hill analysis of 
the homologous displacement data were 9S.S fmol/mg protein in the weaned group 
and 68.8 fmol/mg protein in the non-weaned group. Corresponding figures from 
LIGAND analysis were 89.9 fmol/mg protein and 65.8 fmol/mg protein. From 
approximately one third of both weaned and non-weaned groups the preliminary 
analysis within the program (EBDA) produced parameter estimates for both 1-site and 
2-site models but subsequent LIGAND analysis either would not fit a 2-site model or 
preferred the 1-site model. A similar profile was observed in the spinal cord where 
there was no significant difference in the Bmax measured with [^HjNTI and 
pH]De5’6DELT II in weaned and non-weaned animals and with [^HJDELTI in non­
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weaned animals (Figure 37). However, in weaned animals the Bmax of [^HJDELTI 
was 25% higher than in the non-weaned animals (Figure 37).
4.3.4 Post-weaning 0-receptor development and the effect of delayed weaning.
At 30 days, in animals weaned at day 21, ô -receptor density as measured by 
pH]DELT I displacement studies still exceeded the levels observed in animals which 
had not been weaned until day 25 (Table 21). However, by the age of 35 days both 
groups had the same measure of 6-binding and at 40 days the late weaned group 
showed a significant increase over the normally weaned group (Table 21), the Ô- 
receptor density being the same as in the adult (>60 days, weaned at 21 days). At no 
time was any significant difference observed between the derived Kd for pH]DELT I 
binding in the normally and late weaned groups nor between the protein levels of each 
group at any one age (Table 21). In animals weaned normally at 21 days, there was 
an approximately 20% increase in [^HJDELT I binding expessed per milligram 
protein between 25 days and the adult in which the Bmax recorded was 114 ± 
7.6fmol/mg protein. However, statistical analysis of the levels of binding at 25, 30, 
35 and 40 days and in the adult showed no significant difference (1-factor ANOVA 
and Duncan's post hoc test for the comparison of all means, P > 0.05).
pH]NTI saturation binding in the adult brain showed a Kd of 0.34 ± 0.06 nM. A 
comparison of Kd across the age groups including the adult showed this was not 
significantly different from any other age (1-factor ANOVA and Duncan's post hoc 
test for the comparison of all means, P > 0.05). The Bmax was 4.96 ± 0.78 fmol/mg 
wet weight or 75.4 fmol/mg protein, not significantly different from the levels at 25 
days in the weaned and unweaned rat which were 73.88 fmol/mg protein and 78.48 
fmol/mg protein respectively (1-factor ANOVA and Duncan's post hoc test for the 
comparison of all means, P > 0.05).
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Table 19. The effect of weaning on 5 -opioid receptor binding affinity and 
specific binding ratios in the brain and spinal cord of the 25 day-old rat.
KD(nM) Specific Binding Ratios (%)
Weaned Non-weaned Weaned Non-weaned
Brain
NT! 0.16 ±0.02 0.14 ±0.01 15 72
DELT I 0.97 ±0.15 0.74 ±0.07 88 87
DELTI 0.67 ±0.08 0.72 ±0.07
fle5*6DELTn 1.08 ±0.40 2.30 ±0.20 49 49
Spinal cord
NT! 0.13 ±0.03 0.13 ±0.02 46 48
DELTI 1.03 ±0.11 1.18 ±0.12 81 78
He5.6DELTn 2.33 ±0.58 2.13 ±0.23 31 31
Values represent the mean of 6-11 determinations (brain) or 4-6 determinations 
(spinal cord) ±SE. There was no significant difference in the binding affinity of any 
ligand between the weaned and non-weaned groups or between the brain and spinal 
cord (1-factor ANOVA and Duncan's post hoc test for the comparison of all means P 
>0.05)
Figures in italics are from LIGAND analysis.
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Table 20. Brain weights and protein ratios in the brain and spinal cord of 25 
day-old weaned and non-weaned rats.
Brain Weight (g) Protein/Wet Weight Ratios (%)
Weaned Non-weaned Weaned Non-weaned
Brain
NTT 1.36 ±0.08 1.44 ±0.12* 5.1 ±0.08 4.7 ±0.01
DELTI 1.31 ±0.11 1.29 ±0.10 5.8 ±0.13 5.9 ±0.06
ne5.6DELTn 1.34 ±0.09 1.25 ±0.00 5.2 ±0.20 5.2 ±0.17
Spinal cord
NTI 7.2 ±0.29 8.0 ±0.68
DELTI 6.4 ±0.23 6.5 ±0.18
ne5.6DELTn 7.8 ±0.54 7.1 ±0.54
Values represent the mean of 6-11 determinations (brain) or 4-6 determinations 
(spinal cord) ±SE. Significantly different from all other means (1-factor ANOVA and 
Duncan's post hoc test for the comparison of all means ) * P < 0.05.
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Figure 30. Representative saturation curves with Scatchard anlyses (inset) for
the binding of [^H]Naltrindole in homogenate of whole brain (minus
cerebellum) from the 25 day-old weaned or non-weaned rat
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Figure 31. Representative saturation curves with Scatchard anlyses (inset)
for the binding of [^H]Naltrindole in homogenate of spinal cord from the 25
day-old weaned or non-weaned rat
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Figure 32. Representative saturation curves with Scatchard analyses
(inset) for the binding of [^ H]IIe ’^^ Deltorphin II in homogenate of whole
brain (minus cerebellum) from the 25 day-old weaned or non-weaned rat
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Figure 33. Representative saturation curves with Scatchard analyses (inset) 
for the binding of [^H]IIe^’^ Deltorphin II in homogenate of spinal cord from the 
25 day-old weaned or non-weaned rat.
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Figure 34. Representative homologous displacement curves for[^H]Deltorphin I 
with Hill plots (inset) in homogenates of whole brain (minus cerebellum) from 
25 day-old weaned or nonweaned rats
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Figure 35. Representative homologous diplacement curves for [^H]Deltorphin I 
with Hill plots (inset) in homogenates of spinal cord from 25 day-old weaned or 
nonweaned rats.
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Figure 36. The effect of weaning on 0-receptor bindng in whole brain minus 
cerebellum homogenates from 25 day-old weaned and non-weaned rats.
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Binding is expressed as Bmax (a) per wet weight and (b) per protein, measured by 
saturation binding of the pH] labelled 5-selective ligands Naltrindole and 
Ile^.^Deltophin II or homologous displacement of pHjDeltorphin I. Values represent 
the mean of 4-12 determinations ± SE. Significantly different from all other values 
*P < 0.05 (1-factor ANOVA and Duncan's post hoc test for the comparison of all 
means).
H  Deltorphin I H  Ile^.^Deltorphin II ^N altrindole
170
Figure 37. The effect of weaning on 5-receptcr binding in the spinal cord 
from 25 day-old weaned and non-weaned rats.
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Binding is expressed as Bmax (a) per wet weight and (b) per protein, measured by 
saturation binding of the pH] labelled 5-selective ligands Naltrindole and 
Ile^’^ Deltophin II or homologous displacement of pHjDeltorphin I. Values represent 
the mean of 4-6 determinations ± SE. Significantly different from all other values *P 
< 0.05 (1-factor ANOVA and Duncan's post hoc test for the comparison of all 
means).
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4.4 DISCUSSION.
The data obtained from the preweaning ontogeny study (Table 18) clearly 
demonstrate the presence of 5-opioid receptors as early as PN3 in the case of pHjNTI 
specific binding and PN5 when using pH]DELT I. The failure to detect specific 
binding of [^Hjlle^’^ DELT II before PNIO is probably a reflection of the relatively 
high non-specific binding experienced using this ligand, the non-specific binding 
being some 80% in this age group. In this respect the properties of [^Hjlle^’^ DELT II 
as a ligand for homogenate binding studies are very similar to pH]DPDPE 
(McDowell and Kitchen, 1986). Given that the ligands used have a very high 
selectivity for 5-receptors over p- or K-receptors: NTI > 100-fold (Portoghese et al., 
1988; Rogers et al., 1990; Traynor et a l, 1990): DELT I > 3000-fold (Dupin et al., 
1991; Erspamer et al., 1989): DELT II > 3000-fold (Nevin et al., 1993a; Sasaki et 
al., 1991) it is highly probable that the receptors quantified are 5-receptors as distinct 
from |x- or k-opioid receptors both of which are known to be substantially developed 
relative to the adult levels in the neonatal rat brain and spinal cord (AUerton et al., 
1989; Komblum era/., 1987; Milligan era/., 1987; Petrillo era/., 1987). There is 
very good correspondence between the measures recorded with all three ligands at 10, 
15 and 20 days when expressed relative to wet weight and the figures are in good 
agreement with those reported using pH]DPDPE (McDowell and Kitchen, 1986).
pr»^
Expressed per^protein a significant difference is recorded in the level of binding at 
PN20 measured with [3H]NTI compared with pH]DELT I and [^HjEeS ^DELTE. 
This arises from a significantly higher protein level observed in this group of animals. 
There is no obvious explanation for this discrepancy. At PN5 both [^HjNTI and 
[^HjDELT I gave similar measures although in some experiments [^HjDELT I 
specific binding was not quantifiable. [^H]NTI has been shown in binding studies in 
mouse brain (Fang et ah, 1994) to be insensitive to the presence or absence of 
guanyl-5'-6’-imidodiphosphate and Na+ which suggests both G-protein coupled and 
uncoupled receptor states are equally well recognised by this ligand. (The 
significance of coupled and uncoupled receptor states in relation to ligand binding is
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discussed in the introduction to Chapter 5). It is possible therefore, that the binding of 
pH]NTI at 3 and 5 days, with a significantly lower affinity, represents binding to an 
uncoupled receptor state and the ability to detect measurable pHJDELT I binding in 
only 50% of experiments at PN5 may suggest that G-protein coupling or final 
processing of the receptor molecule e.g. glycosylation, may be developing at this 
time. [3H]DPDPE binding sensitive to 5'-guanylylimidophosphate has been reported 
in rat brain at PN5 (Szücs and Coscia, 1990) but the modulatory effects were shown 
to differ from the adult, suggesting the neonatal receptors/G-protein system differed in 
some way from the adult form.
The overall picture of 6-receptor development from PN3 to the adult shows very low 
levels of 5 -receptor at PN3, approaching the limits of detection by homogenate 
binding techniques. Receptor levels expressed relative to wet weight increase by a 
factor of 2-3 between PN5 and PNIO, and approximately double between PNIO and 
PN15 after which the rate of increase gradually declines. Over the 10-day period 
PN15-PN25 there is a further increase by a factor of 2-3 and subsequently only a very 
gradual increase to adult levels. Due to the rapid increase of total protein levels over 
the period to PN25, the rate of increase of 6-receptor protein relative to total protein 
appears less than when measured against wet weight and after PN25, the proportion of 
6-receptor protein relative to total protein shows no significant change. The 
developmental pattern is therefore clearly distinct from that established for the K- 
receptor in Section 2.3. The K-receptor shows no increase with age over the value at 
PNl relative to wet weight and relative to total protein levels is some three times 
higher at PNl than in the adult. The relative levels per protein show the K-receptors 
exceeding the 6-receptors by a factor of 1.5-2 at PN5 and being approximately equal 
in density at PNIO. By PN25 the 6-receptor population is 7-10 times greater than the 
K-receptor population. Numbers alone cannot be assumed to indicate functional 
significance but the changes in the density of the two receptors do correlate with 
observations of 6- and K-mediated responses during this period. Putative Ki-spinally
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mediated responses are observed in the 9-16 day-old rat which are absent in the adult 
where the Ki-receptor binding is also reduced compared with the neonate (Allerton et 
al., 1989) and 6 -mediated behavioural responses are not evident until after day 20 
(Jackson and Kitchen, 1989). Evidence for K-mediated antinociception at PN5 has 
been presented in Chapter 3 of this thesis and 5-mediated swim-stress-antinociception 
has been reported not to be demonstrable before PN25 (Kitchen and Pinker, 1990).
In the bain of the 25 day-old rat, both weaned and non-weaned, [^HjNTI and 
pHJIle^’^ DELT II label between 69 and 77 fmol/mg protein. These values are 
consistent with other reported levels for 6 -binding in adult rat brain, [^H]NTI, 63.5 
fmol/mg protein (Yamamura e ta l,  1992) and [^HJDSTBULET, 6 8  fmol/mg protein 
(Delay-Goyet et al., 1988) and [%]TIPP(H-Tyr-Tic-Phe-Phe-OH where Tic = 
tetrahydro-3-isoquinoline carboxylic acid), 82 fmol/mg protein (Nevin et a l ,  1993b). 
In the non-weaned rat [^H]DELT I labelled an equivalent number of sites, 69 fmol/mg 
protein. However in the weaned 25 day-old rat a higher Bmax for [^HJDELT I. 93 
fmol/mg protein, suggested that weaning may have activated the development of a 6 - 
receptor subtype which represents about 25% of the 6 -receptor population recognised 
by this ligand. This B^ax at PN25 is not significantly different from adult levels and 
corresponds to other reported measures of 6 -receptor in adult rat brain; pH]DPDPE, 
103 fmol/mg protein (McDowell and Kitchen, 1986), pH]DELT n. 92 fmol/mg 
protein (Bùzâs et a l ,  1992), [^HJDADLE (high affinity site) and [^HJDSLET, 110 
fmol/mg protein (David et a l, 1982). The close correspondence in the values 
obtained from LIGAND analysis of the pHjDELT I data confirms the measures 
derived from the IC50 values according to the method of DeBlasi et a l, (1989) and 
suggests that the differences observed between weaned and non-weaned groups has 
not arisen firom the means of data analysis chosen which can markedly influence the 
derived values (Delay-Goyet et a l, 1988). The literature provides a number of 
measures for 6 -receptor density in rat brain which vary with the ligand used and the 
laboratory, in the latter case the variation may largely be due to the strain of animals
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used since there are marked strain differences (Cotton et al., 1985; Traynor et al., 
1990)
Evidence suggesting 6-receptor subtypes comes predominantly from in vivo studies 
of cross-tolerance an differential antagonism (Jiang et al., 1991; Mattia et al., 1991; 
Mattia era/., 1991; Sofuoglu a/., 1991b; Stewart and Hammond, 1993; Vanderah 
et al., 1994). However it cannot be assumed that the implications of a 
pharmacological study will necessarily be directly supported by binding studies but 
there are homogenate binding studies which indicate the existence of Ô-receptor 
subtypes. In the mouse brain [^H]DSLET labels 35% more 6-receptors than either 
pHJDADLE or [^HJDPDPE (Sofuoglu etal., 1992). Non-equivalent 6-binding sites 
have been demonstrated in rat and mouse brain (Xu et al., 1992; Xu et al., 1993) and 
Bmax values for [125i]dPDPE (Knapp etal., 1991) are reported to be considerably 
lower than for pH][4’-Cl-Phe^]DPDPE (Vaughan et al., 1989) in rat brain 
membranes.
A difference in 6 -receptor density between weaned and non-weaned 25 day-old 
animals has also been observed by autoradiography with [^HJDELTI (Kitchen et al., 
1995). The difference was not apparent with pHjlle^'^DELT II. The significantly 
higher density of 6-receptors labelled with [^HjDELT I in weaned animals was not 
generally distributed throughout those areas of the brain where 6-receptors are found 
but was localised in the deeper layers of the frontal parietal cortex. In situ 
hybridization to identify 6-receptor mRNA did not show the same quantitative 
differences (Kitchen et al., 1995) but parallel changes in mRNA and receptor protein 
may not be observed if there is significant receptor transport (Mansour, 1995; 
Mansour et al., 1993a). There are other reports of quantitative differences in 6- 
binding between the deep (layers IV-VI) and superficial layers (layers I-BI) of the rat 
cortex, the difference being recognised only by some ligands. [i^I]DELT I 
(Gouardères etal., 1993) and [^HJDADLE (Komblum etal., 1987) label more sites
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in the deep cortex whereas pHJDPDPE (Mansour et al., 1987; Sharif and Hughes,
1989) and [^HJNTI (Drower et al., 1993) label uniformly. Denser binding of 
pHJDSLET compared with that of pH]DPDPE has been recorded in lamina VI but 
not in laminae I-IV of the rat cortex (Hiller et al., 1995). A comparative study of 
pH]DPDPE and [^H]DADLE binding (Blackburn et al., 1988) also identified 
quantitative differential binding of the two ligands, [^HjDADLE binding being denser 
in the frontal cortex, layer IV. Differential development of 6 -receptor binding has 
been observed in the rat brain (Komblum et al., 1987), binding appearing in the deep 
layers prior to binding in the superficial layers.
In the spinal cord of the 25 day-old weaned and non-weaned rat [^HjNTI and 
pHjlle^’^ DELT II label equivalent numbers of ô-receptors at a level consistent wth 
those recognised by [^HjDELT I in the non-weaned rat and at approximately the level 
recorded using pHJDADLE (Attali et al., 1990). However, the level of Ô-receptor 
measured in the weaned rat with pH]DELT I is significantly greater and consistent 
with the levels reported in the adult rat spinal cord using pH]DPDPE (Traynor et al.,
1990). The different Bmax 5-binding values recorded by others, depending on the 
ligands used (Attali et al., 1990; Traynor et al., 1990) give support to in vivo 
evidence for 5-receptor subtypes in the rat spinal cord (Stewart and Hammond, 1993; 
Tiseo and Yaksh, 1993). The apparent weaning-induced activation of a population of
5-receptors coincides with the observations of differences in stress-induced 
antinociception between weaned and non-weaned rats (Muhammad and Kitchen,
1993) and differential agonist-induced antinociception in the two groups (Kitchen et 
al., 1994). The observed differences in the brain and spinal cord may both contribute 
to the observations in vivo.
If weaning is delayed to PN25, the 5-receptor levels in late-weaned animals approach 
those in the normally weaned animals by PN 30 and are not significantly different 
from them by PN35. This observation is matched by the appearance of 5-receptor-
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mediated antinociception (a response absent at PN25 in unweaned rats) in 30 day-old 
rats which had not undergone enforced weaning (Muhammad and Kitchen, 1993). 
This suggests that the change in the ô-receptor population apparently promoted by 
weaning will eventually occur without the stimulus of weaning.
The weaning-induced expression of 5-receptors recognised by [3H]DELT I may be 
hypothesised to represent either the development of a receptor subtype or the 
establishment of G-protein coupling, perhaps different to that in the preweaned state. 
The high degree of discrimination for 5-receptors over [L- and K-opioid receptors 
shown by this ligand (Erspamer et al., 1989) makes it very unlikely that the increase 
is due to binding to \L- or K-opioid receptors which are fully developed at this time 
(Spain et al., 1985). The failure of [^Hjlle^’^ DELT H to recognise the difference in 
the 5-receptor population at 25 days in weaned and non-weaned rats may indicate that 
it does not discriminate between the possible subtypes. Alternatively, the binding 
qualities of the ligand e.g. the relatively high non-specific binding, may make it a less 
precise ligand particularly in saturation studies where high concentrations of 
radiolabelled ligands are used. NTI shows little or no discrimination between the 
putative 5-subtypes in vivo (Sofuoglu etal., 1991; Takemori and Portoghese, 1992) 
or in homogenate binding studies (Fang etal., 1994), therefore if the increase in Bmax 
measured with pH]DELT I at PN25 in normally weaned animals represents the post- 
weaning develpment of a 5-receptor subtype, it is expected that it would also be 
recognised by [^HjNTI. The failure to identify any increase in 5-receptor mRNA in 
weaned groups over non-weaned groups (Kitchen et al., 1995) also argues against the 
difference being due to new receptor protein. The failure of the pH]DELT I study to 
indicate more than one binding site is not surprising since it is difficult to resolve 
multiple binding sites by homologous diplacement unless there is a considerable 
difference between the number and/or the affinity of the sites (DeBlasi et al., 1989; 
Swillens gf a/., 1995a; Swillens etal., 1995b)
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There is much evidence that jx-, 6 - and K-opioid mediated responses depend on a G- 
protein coupled signal transduction system (see Table 7 and for a review see Childers,
1991). There is evidence for multiple conformational states of the ô-receptor and for 
coupling to different G-proteins, in particular to Go or Gi \  protein subspecies 
(Georgoussi and Zioudrou, 1993; Prather et a l, 1994a; Prather et al., 1994b; 
Richardson etal., 1992; Roerig et al., 1992) but also to Gg (Cruciani etal., 1993). 
During development there have been demonstrated differences in opioid binding 
sensitivity to guanine nucleotides and cations (Getting et al., 1987; Szucs et al., 
1987) and developmental changes in GTP binding proteins in rat brain homogenates 
(Szücs and Coscia, 1990). The binding of 5-agonists has been shown to have 
different sensitivities to GTP analogues and Na+ (Wild et al., 1993). In particular [D- 
Ala^-Glu^jDeltorphin II consistently shows smaller G-shifts than DPDPE. Therefore 
the failure to demonstrate a difference in 5-binding between weaned and non-weaned 
rats with [^Hjlle^’^ DELT II may be because it shows less discrimination between the 
coupled and uncoupled receptor states than [^H]DELT I although it would be 
expected to match the higher Bmax observed in weaned animals rather than the lower 
unweaned value. The binding of the antagonist pHJNTl in mouse brain homogenates 
has been shown to be insensitive to the presence or absence of guanyl-5'-6’- 
imidodiphoshate (GppNHp) and Na+ indicating that it has no preference for the 
coupled or uncoupled receptor (Fang et al, 1994). Therefore if the increased Bm ax  
for pH]DELT I in the weaned animals over the non-weaned animals represented 
newly effected or different G-protein coupling the [^HJNTI would be predicted to 
recognise the same higher levels in both weaned and non-weaned groups. Although it 
does demonstrate equal levels of 5-receptor binding in both groups the receptor 
density is equivalent to the lower value recorded in the non-weaned group using 
pH]DELT I. This is difficult to explain in the light of the recorded behaviour of 
agonists and antagonists in relation to their binding to coupled/uncoupled receptors. 
There is the possibility that this discrepancy arises from the two different methods 
used to quantify the radioligand binding. The concentration of [3H]DELT I used was
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0.3nM which is approximately one third of the Kp (Table 16). This is possibly low 
enough for ligand depletion to occur at the lower levels of displacer. The ligand 
depletion will become less significant as the concentration of the displacing ligand 
increases resulting in a shift to the right of the displacement curve but the change in 
shape is not likely to be distinguished (Hulme and BirdsaU, 1992). This will lead to 
an overestimate of the IC5 0  and since Bm ax is derived from B q x  IC5 0/L (Section 4 .2 .7 )  
this in turn will result in an overestimate of Bmax. This discrepancy would apply 
equally to all determinations with [3H]DELT I in both groups and therefore would not 
affect the difference established between the weaned and non-weaned groups but may 
shift them both relative to the maximum binding recorded with [^H]NTI and 
pHJIle^’^ DELT H. This suggests that it is possible that the weaned pHJDELT I Bm ax 
is comparable with the [^HjNTI and pHjlle^'^DELT EI.levels while the non-weaned 
[3R]DELT I Bmax is some 30% lower.
The highly selective 6 -ligands [3H]DELT I, pH]Ile5.6DELT B and [^HJNTI have been 
used to follow the postnatal develoment of the 6 -opioid receptor in the rat and it is 
clear that while 6 -receptor binding can be detected as early as PN3 with pH]NTI, 
substantial development takes place in the following three weeks, adult levels being 
reached by PN25-30. Weaning clearly stimulates the development of a population of
6 -opioid receptors in both the brain and the spinal cord which are recognised by 
pH]DELT I but not by pH]He^»^DELT II and pH]NTI. This quantitative difference 
observed to take place in response to weaning is paralleled by previously reported 5- 
opioid receptor-mediated behavioural changes associated with the weaning process. 
Quantitative autoradiography in the brain supports the proposition of weaning- 
stimulated 6 -opioid receptor development although the response appears to be very 
localized and in situ hybridization studies do not indicate an increase in receptor 
message. Therefore it seems most likely that the change in the 6 -opioid receptor 
population may be a result of functional coupling to G-protein or a change in G- 
protein coupling to which [^HJDELTI is sensitive but [^EQIle ’^^ DELT II and pH]NTI
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are not. In order to investigate the sensitivity of the binding of three 5-ligands to the 
different coupled states of the 6 -receptor and to establish whether there is any 
difference in response to modified binding conditions in brain tissue from the weaned 
and non-weaned rat, saturation binding studies with pHJDELT I, [^HJIle^’^ DELTII 
and [3H]NTI have been carried out in conditions designed to modify receptor-G- 
protein coupling and are reported in Chapter 5.
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CHAPTER 5
THE EFFECTS OF SODIUM IONS 
AND GUANYLYL-5'-6'-IMIDODIPHOSFHATE 
ON THE SATURATION BINDING OF 5-SELECTIVE LIGANDS 
IN HOMOGENATES OF THE BRAJN OF THE WEANED AND 
NON-WEANED 25 DAY-OLD RAT,
1 8 2
5.1 INTRODUCTION
It is now generally accepted that opioid receptors are G-protein coupled to second 
messenger systems (see Table 7). (For reviews of receptor-effector coupling by G- 
proteins see Stryer and Bourne, 1986; Graziano and Gilman, 1987; Neer and 
Clapham, 1988; Bimbaumer et al., 1989 and Bourne et al., 1990). Opioid receptor - 
G-protein interactions are reviewed in Childers, 1991, Childers, 1993 and discussed in 
Cox, 1993. Briefly, early studies indicated that guanine nucleotides and Na+ 
specifically decreased opioid agonist binding in both brain membranes (Blume, 
1978a; Childers and Snyder, 1979) and NG108-15 cells, a mouse neuroblastoma- 
glioma hybrid which expresses 6 -receptors • . (Chang et al., 1981b;
Blume, 1978b). More specifically, the 6 -opioid binding sites in guinea pig and rat 
brain membranes were shown to be regulated by guanine nucleotides (Pfeiffer et al., 
1982; Werling et al., 1984; Zajac and Roques, 1985). It had already been observed 
that guanine nucleotides regulated interaction with hormonal receptors which in turn 
mediated the activation of adenylate cyclase and that this involved a receptor, 
adenylate cyclase and other separate membrane components identified as a family of 
G-proteins (Rodbell, 1980). The opioid inhibition of adenylate cyclase in NG108-15 
cells was demonstrated to be dependent on both guanine nucleotides and Na+ (Blume 
et al., 1979) and opioid agonists were found to inhibit adenylate cyclase by 
stimulating GTP-ase activity in cells and membranes containing opioid receptors 
(Koski and Klee, 1981). Opioid activity in the brain was shown to be GTRdependent 
(Cooper et al., 1982; Law et al., 1981). These interlinked effects suggested the 
functional linkage opioid receptor - G-protein/GTPase - adenylate cyclase and 
eventually purification and reconstitution of the separate components confirmed 
opioid receptors as part of the famly of G-protein coupled receptors (Ueda et al., 
1990). Further evidence for this became available with the cloning of |X-, 6 -,and k- 
opioid receptors (see Section 1.4.1). It was possible to predict from the amino acid 
sequence of the receptor protein the preferred conformation of the molecules and this
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was predicted to include the seven transmembrane segments typical of G-protein 
linked receptors (see Section 1.4.2).
As a G-protein coupled receptor, the very simplest model of the opioid receptor must 
allow for ’ an agonist binding site and an allosteric site for association with the G- 
protein. The G-protein may in turn be associated with GDP or GTP. A number of 
receptor states are therefore predicted, among them free receptor, receptor + G- 
pnotein/GDP, receptor + G-protein/GTP, ligand + receptor, ligand + receptor + G- 
protein/GDP and ligand + receptor + G-protein/GTP (Cox, 1993). The equilibrium 
will be complex and some of the predicted states more transient than others. The 
affinity state of the receptor with respect to agonist binding will vary and the multiple 
affinity states reported for opioid receptors (Costa et a l,  1985; Law et al., 1985; 
Spain and Coscia, 1987; Werling et al., 1988; Wong et al., 1994) are possibly 
associated with the longer lived receptor states of the model (Cox, 1993). In 
particular, receptors functionally uncoupled from G-proteins by various means e.g. 
pertussis toxin ADP-ribosylation of the a-subunit and treatment with antisera to 
^ecific subunits (Costa et al., 1983; McKenzie et al., 1988; McKenzie and Milligan, 
1990; Werling et al., 1988), show low agonist affinity. The uncoupling of G-protein 
firom receptor can also be accomplished by the use of a non-hydrolysable analogue of 
GTP such as guanylyl-5'-6'-imidodiphospate (GMPPNP Boehringer Mannheim 
catalogue (1996), most usually Gpp(NH)p (Prather et al., 1994; Szücs and Coscia, 
1990) but also abbreviated to GMPP(NH)P (Blume, 1978a) and p(NH)ppG 
(Richardson etal., 1992)). GTP and its analogues have been frequently observed to 
substantially reduce agonist binding to |X- and 6 -opioid receptors by increasing both 
agonist-receptor association rates and dissociation rates with a much greater effect on 
the latter which results in an increase in the equilbrium dissociation constant i.e. 
decrease in agonist affinity (Blume, 1978a; Childers and Snyder, 1979; Werling et 
al., 1984; Zazac and Roques, 1985). GTP or GMPPNP binding to G-protein 
promotes the breakdown of receptor - G-protein complex resulting in the conversion
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of the receptor to the low affinity state. Normally the hydrolysis of GTP on the 
separated G a-subunit would regenerate Ga-GDP which would reassociate with the 
GPy subunits and the trimer could reassociate with receptor. The binding of non- 
hydrolysable GMPPNP effectively prevents the regeneration of GaGDP and therefore 
G-protein - receptor association which essentially inactivates the effector system by 
forcing the accumulation of low affinity free receptors (Wong et a l , 1994).
The influence of cations on opioid receptor binding has also been frequently recorded 
(Blume, 1978a; Getting e ta l, 1987; Pfeiffer e ta l, 1982) but the mechanismsdf the 
interactions are less well understood than the guanine nucleotide interactions. Na+ in 
particular has been demonstrated to potently reduce agonist binding (Blume, 1978a; 
Pfeiffer e ta l,  1982; Puttfarken e ta l,  1986; Szucs e ta l,  1987). The extent of the 
reduction of agonist binding by GTP or its analogues alone varies between reports 
from small for DAGO in rat brain (Wong et a l , 1994) to a 50% reduction in binding 
of [^HJDADLE in rat brain (Chang et a l, 1983). There appear to be quantitative 
rather than qualitative differences between the effects on the opioid receptor subtypes 
but this may reflect the experimental systems, not least the ligands used (Cox, 1993). 
It is universally observed that in the presence of Na+ and GTP or stable analogue there 
is a dramatic reduction in equilibrium binding of agonist which may approach 1 0 0 % 
(Werling et a l, 1984). The mechanism by which Na+ regulates opioid binding is still 
a matter for investigation. There is evidence that the regulatory site at which Na+ 
exerts its effects is intracellular. At 6 -receptors in guinea pig cortical membranes the 
concentration of Na+ producing half maximal binding was shown to be 10-30nM 
(Werling et a l ,  1986). Under physiological conditions the high extracellular Na+ 
concentration of 118nM (Zajac et a l, 1990) would result in permanent activation at 
such a site whereas intracellularly the resting level Na+ concentration would be close 
to or lower than these levels. Also the Na+-selective ionophore monensin, while 
having no effect on agonist binding in intact NG108-15 cells, in the presence of 
extracellular Na+ did reduce agonist binding (Puttfarken et a l ,  1986). It was
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suggested that this was a result of rising intracellular Na+ concentration promoting the 
interaction of Na+ with an intracellular site which effectively reduced agonist binding. 
Data consistent with the influence of intracellular Na+ levels on opioid binding in 
Waio. kiS'Sue. V\oviL also been recorded (Zajac et al., 1990). It is reported that Na+ does not 
alter the intrinsic activity of purified Gi and Go which suggests that it does not react 
with the G a subunit (Higashijima et al., 1987) and others suggest that the influence of 
Na+ is neither directly on the receptor or on the G-protein but at a third 
membrane protein unit which interacts with the G-protein (Ott et al., 1988) Although 
promoting the association of empty receptor and G-protein/GDP (Costa et al., 1990) 
there is evidence that in the agonist-occupied receptor the Na+ reduces the ability of 
agonist binding to promote the dissociation of GDP from G-protein (Cox, 1993; 
Wüster et al., 1984). However direct interaction of Na+ at a specific residue in the G- 
protein linked a-adrenoceptor has been recorded (Horstman et a i, 1990). The site is 
on an intracellular loop and given the similarities in G-protein-linked receptors it is 
possible that a similar effect may be observed in opioid receptor protein.
Very early reports indicated that opioid antagonist binding was stimulated in the 
presence of Na+ (Pert et al., 1973) and a 'sodium dependent' form of the receptor with 
a higher affinity for antagonists was proposed (Simon et a l ,  1975). Subsequent 
evaluation of the effects of Na+ and guanine nucleotides on equilibrium binding of 
antagonists suggested that they had very little effect (Childers and Snyder, 1980; Law 
et a l ,  1985; Werling et a l, 1988). More recent reports demonstrate that purified \i- 
receptors in the absence of G-proteins bind opioid agonists with low affinity and 
antagonists with high affinity only in the presence of a high concentration of Na+ (Li 
et a l, 1992). Further investigations led to the hypothesis that Na+ favours a low 
affinity receptor conformation, is essential to antagonist high affinity binding and 
recruits completely unassociated free receptors into a low affinity pool (Wong et a l ,
1994) effectively increasing the population recognised by the antagonists. Based on 
these observations of apparent receptor affinity states and their rclcvaocfilcb agonist
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and antagonist binding, it is possible to modify binding conditions in order to force 
the receptor population into a low affinity state. This should theoretically largely 
remove a significant variable from a compariÊve binding study using a number of 
ligands in that the receptor population affinity state should be stabilized. Antagonists 
are predicted to bind with high affinity to all states of the receptor and therefore to 
recognise the entire population even in the low affinity state possibly recording a 
larger Bmax in the presence of Na+. Agonists will bind with low affinity and 
maximum binding will be reduced under these conditions.
The evidence presented in Chapter 4 suggests the weaning-stimulated development of 
a 6-receptor population that is recognised by [^H]DELT I but not by [^ElJDe ’^^ DELT 
n  or [3H]NTI. As discussed in Section 4.4, a difference in the G-protein coupled state 
of the receptors to which only pH]DELT I is sensitive may give rise to the 
discrepancy in the 6-receptor density measured by the three highly selective 6-ligands. 
In order to investigate how the state of G-protein coupling affects the recognitionof 6- 
receptors by the three ligands and to establish whether modified binding conditions 
differentially affect the population of 6-receptors recognised in the weaned or non- 
weaned 25 day-old rat, saturation binding studies have been carried out in 50mM 
Tris-HCl alone and in the presence of 50|iM GMPPNP, lOOmM Na+ or both. In order 
to confirm that the difference in 6-receptor density between weaned and non-weaned 
animals, seen only by pH]DELT I, was not a result of the different methodology used
i.e. homologous displacement for [^HJDELT I studies vs. saturation binding for 
pHjlle^'^DELT II and [^HJNTI, all measures were derived from saturation binding 
studies.
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5.2 MATERIALS AND METHODS.
5.2.1 Animals.
Wistar albino rats were bred and reared under the same conditions as described in 
2.2.1. The day of birth was designated PNl, litters were cross-fostered and litter size 
standardized to 10. The litters were weaned on PN21 by removal of the mother from 
the cage. Unweaned animals were left with the mother until the day required. The 
brain tissues from both weaned and non-weaned animals was taken at PN25. Only 
male animals were used in the study.
5.5.2 Preparation of tissue homogenate.
Homogenate of whole brain minus cerebellum was prepared at lOmg wet weight/ml 
in 50mM Tris-HCl buffer designed to be at pH 7.4 at the temperature appropriate to 
the subsequent saturation binding assays as described in 2.2.2 and 4.2.2. A minimum 
of four brains was used to prepare each sample of homogenate. For binding assays in 
the presence of lOOmM Na+, the final homogenate of brain tissue was prepared in 
50mM Tris-HCl buffer containing lOOmM sodium chloride (AR) and allowed to 
equilibrate at room temperature for 60 minutes before use.
5.2.3 Materials.
pH]NTI, [^HJDELT I, pHjlle^’^ DELT II and naloxone were as described in 4.2.3. 
Guanylyl-5'-6'-imidodiphoshate (GMPPNP) was purchased from Boehringer 
Mannheim UK. Product No.106 402.
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5.2.4 Saturation assays.
Saturation assays for and [^HjDELT II were carried out as described in 4.2.4.
Saturation binding assays for [^HjDELT I were also carried out as described for 
pH]NTI and pHJDELT II in 4.2.4 with the following modifications of the method: 
pHJDELT I was used at 10 concentrations over the range 0.1 - S.OnM, the incubation 
temperature was 35°C and the incubation time was 90 minutes. The saturation 
binding of each ligand was measured under four conditions:
(1) control conditions, 50mM Tris-HCl buffer pH 7.4
(2) 50mM Tris-HCl buffer pH 7.4 in the presence of 50|xM GMPPNP,
(3) 50mM Tris-HCl buffer pH 7.4 with lOOmM NaCl
(4) 50mM Tris-HCl buffer pH 7.4 with lOOmM NaCl in the presence of 
50|XM GMPPNP.
In each case a single pooled brain homogenate in 50mM Tris-HCl buffer pH 7.4 was 
used for (1) and (2) and a single pooled brain homogenate in 50mM Tris-HCl buffer 
pH 7.4 with lOOmM NaCl was used for (3) and (4). The final level of 50|xM 
GMPPNP was achieved by the addition of 20p,l of a 5mM freshly prepared aqueous 
solution to each reaction mixture immediately prior to the addition of radiolabelled 
ligand.
5.2.5 Protein analysis.
Protein analysis was carried out as described in 4.2.6 except that homogenates 
prepared in 50mM Tris-HCl buffer pH 7.4 with lOOmM NaCl were assayed against a 
BSA standard prepared in the same medium.
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5.2.6 Data analysis.
Data from saturation binding experiments was analysed by means of LIGAND (see 
Section 4.2.7) to provide values for Bmax and Kp for each ligand under each binding 
condition. The Bmax values for all ligands under control binding conditions were 
compared by 1-factor ANOVA and Duncan's post hoc test for the comparison of all 
means. All Bmax and Kp> for individual ligands for both treatment groups (weaned 
and non-weaned) under the four binding binding conditions were compared (ANOVA 
and Duncan's post hoc test for the comparison of aU means).
Bmax values in the presence of GMPPNP, Na+ or both were also expressed as 
percentage change from the respective mean control value for Bmax in weaned and 
non-weaned groups.
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5.3 RESULTS.
In 50mM Tris-HCl buffer (control conditions) all three ligands showed saturable high 
affinity binding (Figures 38, 40 and 42). and there was no significant difference in 
their Kd values between the weaned and non-weaned groups (Table 22) P > 0.05 
(ANOVA and Duncan's post hoc test for the comparison of all means). Under 
control binding conditions, when expressed as specific binding in fmol/mg protein or 
pmol/brain (Tables 23 and 24), the Bmax for [^HJDELTI in non-weaned animals was 
significantly lower than all other measures of Bmax in both weaned and non-weaned 
animals P < 0.05 (ANOVA and Duncan's post hoc test for the comparison of all 
means). There was no significant difference in the brain weights and protein levels 
recorded in any group of animals used in the study (Table 25). LIGAND analysis 
would fit only a one-site model.
Representative saturation binding curves for each ligand under each of the four 
binding conditions are illustrated with Scatchard graphs inset in Figures 38-43. Under 
control binding conditions and in the presence of 50|xM GMPPNP, lOOmM Na+ or 
both there was no significant difference in the affinity of the antagonist [^HJNTl 
(Table 22). The affinity of the agonist pHJDELT I was not significantly different 
from the control values in the presence of 50 ^ iM GMPPNP or lOOmM Na+ in either 
the weaned or non-weaned rat (Table 22). The Kd of the agonist [^HJIle^’^  DELTII 
was not affected by the presence of 50|xM GMPPNP in weaned or non-weaned brain 
but in homogenate of weaned brain in the presence of lOOmM Na+ the Kowas 
significantly different from the control value, P < 0.05, the critical difference only just 
being reached. In homogenates of both weaned and non-weaned brain in the presence 
of 50|xM GMPPNP and lOOmM Na+ there was a significant decrease in the affinity of 
both agonists, P < 0.01.
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The Bmax for pHJNTI showed significant increases in the presence of lOOmM Na+ 
and both 50 jiM GMPPNP and lOOmM Na+ when expressed per milligram wet weight 
and per brain but when expressed per milligram protein the only value seen as 
significantly different from the control value was the Bmax in homogenate of weaned 
brain in the presence of both 50|xM GMPPNP and lOOmM Na+ (Tables 23 and 24). 
The Bm ax values for [^HJDELTI and [^HJIle^’^  DELT II were significantly reduced in 
the presence of either lOOmM Na+ or both 50|iM GMPPNP and lOOmM Na+ (Tables 
23 and 24). The Bmax of pHJHe^*^ DELT II expressed relative to protein was 
insensitive to the presence of 50p,M GMPPNP in both weaned and non-weaned brain 
(Table 24). The Bmax value for pHJDELT I relative to protein in non-weaned brain 
in the presence of 50|iM GMPPNP also showed no significant difference to the 
control value whereas the Bm ax in weaned brain showed a significant decrease in 
Bm ax (Table 24). The percentage changes in Bmax with respect to the control values 
induced by the the differing binding conditions are illustrated in Figure 44. In the 
non-weaned brain in the presence of GMPPNP, LIGAND would only fit a single site 
model. In the weaned brain in the presence of GMPPNP the LIGAND analysis was 
inconclusive.
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Figure 38. Representative saturation binding curves with Scatchard analyses
(inset) for the binding of [^HJNaltrindoIe to homogenates of whole brain (minus 
cerebellum) from the weaned and non-weaned 25 day-old ra t measured in
(a) 50mM Tris buffer (control conditions)
(b) 50mM Tris buffer + SO i^M GMPPNP
(a) 50mM Tris buffer (control conditions) 
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Figure 39. Representative saturation binding curves with Scatchard analyses 
(inset) for the binding of pHJNaltrindoIe to homogenates of whole brain (minus 
cerebellum) from the weaned and non-weaned 25 day-old ra t measured in
(a) 50mM Tris buffer + lOOmM Na"*"
(b) 50mM Tris buffer + lOOmM Na+ + SOjiM GMPPNP
(a) 50mM Tris + lOOmM Na"^  
WEANED NON-WEANED
3.5-1
#  2.5- 20 n
15-
DO
Oo1 0 -
00
0.5-
SB (fmol/mg wet weight)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
4-1
3.5-
DÛ
2.5-
2 -
1.5-
0.5 SB(fmol/mg wet weight)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
[ H]Naltrindole (nM) [ H]Naltrindole (nM)
(b) 50mM Tris + lOOmM Na"^  + 50pM GMPPNP 
WEANED NON-WEANED
3.5-
oo
^ 2.5-
60
0.5-
SB(fmol/mg wet weight)
0 0.20.40.60.8  1 1.21.41.61.8 2
4.5-1
4 -
3.5-
20 -2.5-
60
1 0 -
1.5-
0.5- SB (fmol/mg wet weight)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
[ HjNaltrindole (nM) [ H]Naltrindole (nM)
194
Figure 40. Representative saturation binding curves with Scatchard 
analyses (inset) for the binding of pH]Deltorphin I to homogenates of
whole brain (minus cerebellum) from the weaned and non-weaned 25 day-
old ra t measured in
(a) 50mM Tris buffer (control conditions)
(b) 50mM Tris buffer + 50|iM GMPPNP
(a) 50mM Tris buffer - (control conditions) 
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Figure 41. Representative saturation binding curves with Scatchard analyses 
(inset) for the binding of pHJDeltorphin I to homogenates of whole brain (minus 
cerebellum) from the weaned and non-weaned 25 day-old ra t measured in
(a) 50mM Tris buffer + lOOmM Na"*"
(b) 50mM Tris buffer + lOOmM Na+ + SOpM GMPPNP
(a) 50mM Tris buffer + lOOmM Na"*"
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Figure 42. Representative saturation binding curves with Scatchard analyses
(inset) for the binding of [^H]Ile^’^ Deltorphin H to homogenates of whole 
brain (minus cerebellum) from the weaned and non-weaned 25 day-old rat 
measured in
(a) 50mM Tris buffer (control conditions)
(b) 50mM Tris buffer + 50|iM GMPPNP
(a) 50mM Tris buffer (control conditions) 
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Figure 43. Representative saturation binding curves with Scatchard analyses 
(inset) for the binding of [^H]He^’^ DeItorphin n  to homogenates of whole brain 
(minus cerebellum) from the weaned and non-weaned 25 day-old ra t measured
(a) 50mM Tris buffer +100mM Na'*’
(b) 50mM Tris buffer + lOOmM Na^ + 50jiM GMPPNP
(a) SOmM Tris buffer + lOOmM Na"^  
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Table 22. The effect of 50|iM GMPPNP, lOOmM Na+ or both on the Kd for the 
saturation binding of pH]Naltrindole, pH]DeItorphin I and [^HjDe '^^Deltorphin n  
in homogenate of whole brain (minus cerebellum) from the weaned and non­
weaned 25 day-old rat and the specific binding ratios at Kp.
K d (uM ) Specific Binding Ratios (%)
Weaned Non-weaned Weaned Non-weaned
PH]NTI
Control 0.18 ± 0.01 0.15 ±0.01 71.0 ±3.8 75.5 ±0 .2
50pM GMPPNP- 0.30 ±0.06 0.24 ±0.02 65.0 ±5.8 74.4 ± 1.3
100mMNa+ 022  ±0.04 0.27 ±0.06 75.5 ±2 .0 78.0 ±4 .0
50pM GMPPNP 0.27 ±0.03 0.25 ±0.07 74.5 ±3 .9 78.0 ±2.5
+100mMNa+
PH]DELTI
Control 0.51 ±0.04 0.51 ±0.05 87.1 ±1.1 80.2 ±2 .8
50pM GMPPNP- 0.60 ±0.06 0.54 ±0.07 75.3 ±4.1 68.5 ± 7 .6
100mMNa+ 0.91 ±0.08 0.63 ±0.17 65.3 ±1 .2 52.0 ±8 .9
50pM GMPPNP 2.06 ±0.31** 2.30 ±0.79** 56.5 ±1 .0 43.7 ±5.5
+100mMNa+
pH]DeS,6DELT H
Control 1.79 ±0.40 2.31 ±0.21 43.2 ±4 .0 51.0±4.9
50pM GMPPNP 2.43 ±0.28 1.83 ±0.13 41.3 ± 6.4 39.3 ±3.5
100mMNa+ 3.12 ±0.39* 3.00 ±0.39 21.2 ±3 .0 17.8 ±0 .5
50pM GMPPNP 4.86 ±0.36** 4.90 ±0.66** 14.0 ±1.7 10.8 ±1.3
+100mMNa+
Values represent the mean of 4-6 determinations ± SE. For any one ligand under any 
one binding condition, there was no significant difference in the Kp values between 
the weaned and non weaned groups (Student t -test). Significantly different their 
respective control values * P < 0.05 ** P < 0.01 (1-factor ANOVA and Duncan's post 
hoc test for the comparison of all means)
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Table 23. The effect of 50^M GMPPNP, lOOmM Na+ or both on the Bmax 
relative to wet weight and per brain for the saturation binding of 
pHJNaltrindole, pH]Deltorphin I and [3H]Be^,^Deltorphin H in homogenate of 
whole brain (minus cerebellum) from the weaned and non-weaned 25 day-old 
rat.
Bmax Bmax
(fmol/mg wet weight) (pmol/brain)
Weaned Non-weaned Weaned Non-weaned
pHlNaltrindole
50mM Tris (control) 3.97 ±0.20 3.73 ±0.12 5.36 ±0.23 5.19 ±0.24
50pM GMPPNP 4.26 ±0.43 4.51 ±0.22 5.48 ±0.64 5.50 ±0.33
100mMNa+ 5.47±0.40tt 5.50 ±0 .63# 6.82±0.54t 7.03 ± 1 .1 4 #
50pM GMPPNP 
+ 100mMNa+ 5.75±0.39tt 5.66 ± 0 .6 8 # 7.11±0.49t 7.14 ± 0 .8 8 #
pH]Deltorphin I
50mM Tris (control) 3.64 ±0.18 2.99 ±0.13 4.65 ±0.20 3.75 ±0.17*
50pM GMPPNP 2.33 ± 0 .18# 2.68 ±0.21 3.08 ± 3 .4 0 # 3.40 ±0.26
100mMNa+ 1.34 ±0 .22# 1.17 ± 0 .11# 1.71 ± 0 .2 9 # 1.50 ± 0 .1 8 #
50pM GMPPNP 
+ 10GmMNa+ 1.10±0.14# 1.15 ±0 .09# 1.41 ± 0 .1 8 # 1.47 ± 0 .1 4 #
pH]He^»^Deltorphin II
SOmM Tris (control) 3.58 ±0.30 3.80 ±0.22 4.49 ±0.24 4.90 ±0.21
50pM GMPPNP 4.18±0.28t 4.00 ±0.26 5.27 ±0.43 4.89 ±0.55
10GmMNa+ 2.46±0.29t 2.34 ± 0 .38# 3.12±0.36t 3.00 ± 0 .4 2 #
50pM GMPPNP 
+ lOOmMNa^ 2.32±0.2t 1.69 ± 0 .25# 2.93 ± 0 .2 8 # 2.12 ± 0 .3 2 #
Values are the mean of 4-9 determinations ± SE. Significantly different from all other 
values under control conditions * P < 0.05 (ANOVA and Duncan's post hoc test for 
the comparison of all means). Significantly different from their respective control 
binding condition values t P <  0.05, p < 0.01 (ANOVA and Duncan's post hoc test 
for the comparison of all means).
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Table 24. The effect of SOpM GMPPNP, lOOmM Na+ or both on the Bmax 
relative to total protein for the saturation binding of p  H]Naltrindole, 
pH]Deltorphin I and [^HJBe^j^Deltorphin H in homogenate of whole brain 
(minus cerebellum) from the weaned and non-weaned 25 day-old rat.
Bmax (fmol/mg protein) 
Weaned Non-weaned
pH]Naltrindole
50mM Tris (control) 75.2 ±3.4 76.6 ±2.2
50|iM GMPPNP 82.7 ±6.8 83.4 ±6.0
lOOmM Na+ 89.7 ±3.8 89.1 ±9.4
50|iM GMPPNP + lOOmM Na+ 94.9 ± 9.51 90.9 ±7.5
pHjDeltorphin I
50mM Tris (control) 66.0 ±2.0 57.1 ± 1.5*
50pM GMPPNP 44.4 ± 3.5 tt 54.1 ± 1.8
lOOmM Na+ 23.8 ± 3.4 tt 19.4 ± 1.8 t t
50|iM GMPPNP + lOOmM Na+ 19.8 ± 2.8 tt 19.0 ± 0.9 t t
pH]Be^»^Deltorphin II
50mM Tris (control) 68.8 ±3.0 73.3 ±4.5
50pM GMPPNP 79.8 ±3.5 78.3 ±3.8
lOOmM Na+ 43.2 ± 4.7 tt 50.4±11.6t
50pM GMPPNP + lOOmM Na+ 42.0±3.4tt 35.9 ± 7.4 tt
Values are the mean of 4-9 determinations ± SE. Significantly different from aU other 
values under control conditions * P < 0.05 (ANOVA and Duncan's post hoc test for 
the comparison of all means). Significantly different from their respective control 
values t  p < 0.05, t t  p < 0.01 (ANOVA and Duncan's post hoc test for the 
comparison of aU means).
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Table 25. Brain weights and brain protein ratios in groups of 25 day-old 
weaned and non-weaned rats used in studies on the saturation binding of 
pHJNaltrindole, pHJDELT I and [^H]Be^»^DELT H in homogenates of whole 
brain (minus cerebellum) in the presence of 50p,M GMPPNP, lOOmM Na+or 
both.
Brain Weight (g) Protein/Wet Weight %
Weaned Non-weaned Weaned Non-weaned
PHJNTI
Control 1.36 ±0.03 1.44 ±0.04 5.26 ±0.13 4.89 ±0.17
50p,M GMPPNP- 1.28 ±0.03 1.22 ±0.03 5.17 ±0.34 5.43 ±0.17
lOOmM Na+- 
50pM GMPPNP 
+100mM Na+-
1.25 ±0.02 
1.24 ±0.02
1.26 ±0.00 
1.26 ±0.00
6.14 ±0.54 
6.17 ±0.50
6.20 ±0.42
6.20 ±0.04
PHJDELT I
Control 1.28 ±0.01 1.26 ±0.01 5.50 ±0.20 5.30 ±0.30
50p-M GMPPNP- 1.32 ±0.00 1.27 ±0.02 5.27 ±0.24 4.90 ±0.30
lOOmM Na+- 
50p m  GMPPNP 
+100mM Na+-
1.28 ±0.00 
1.28 ±0.00
1.27 ±0.03
1.27 ±0.03
5.65 ±0.34
5.65 ±0.34
6.08 ±0.22 
6.05 ±0.23
pHjne5,6DELTH
Control 1.37 ±0.03 1.30 ±0.03 5.20 ±0.20 5.20 ±0.20
50pMGMPPNP- 1.27 ±0.03 1.25 ±0.06 5.08 ±0.68 5.09 ±0.40
lOOmM Na+- 
50pM GMPPNP 
+100mM Na+-
1.27 ±0.02
1.27 ±0.02
1.30 ±0.03 
1.27 ±0.02
5.66 ±0.19 
5.50 ±0.10
4.91 ±0.40
4.91 ±0.39
Values represent the mean of 4-6 determinations ± SB. There was no significant 
difference between the means of brain weight or protein ratios of any group. P > 0.05 
(1-factor ANOVA and Duncan's post hoc test for the comparison of all means)
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Figure 44. The effect cf SO^ iM GMPPNP and lOOmM Na+ or both on the Bmax 
for pH]Deltcrphin I, pH]Ilesmeltwphin H and pH]Naltrindole binding in 
homogenate of whde brain (minus cerebellum) from the weaned and non- 
weaned 25 day-old rat expressed as percentage change relative to the control 
values.
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Values are means of 4-6 determinations expressed as the percentage change 
in Bmax, calculated as specific binding of each ligand in fmol/mg protein, 
relative to their respective control mean values. W = weaned: NW = non- 
weaned.
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5.4 DISCUSSION
Saturation binding of [^HJDELT I indicated a significant difference in Ô-receptor 
density in the brain between weaned and non-weaned 25 day-old rats (Table 23). The 
Bmax in the non-weaned rat brain was some 14% less than in the weaned animals 
when expressed relative to total protein, 18% less relative to wet weight and 20% less 
per brain. The affinity of [^HJDELTI was not significantly different in the weaned 
and non-weaned animals and LIGAND analysis of the binding data indicated single­
site binding in both cases. If the increase in the 5-receptor population promoted by 
weaning was the result of the expression of a 5 -receptor subtype then its affinity for 
pH]DELT I is not sufficiently different to allow its detection by analysis of saturation 
binding data. An alternative explanation is that the 5-receptor population prior to 
weaning is not homogeneous with respect to the extent or the nature of G-protein 
coupling and that pH]DELT I is sensitve to the G-protein coupled state. The 
antagonist [^H]NTI does not recognise any difference between the weaned and the 
non-weaned 5-receptor population (Table 23). Guanine nucleotides do not 
substantially affect antagonist binding (Childers and Snyder, 1979; Law et a l ,  1985) 
which suggest that they are insensitive to the G-protein coupled/uncoupled state of the 
receptor and may even hinder receptor - G-protein interaction (Costa et a l,  1990) or 
promote uncoupling (Schütz and Friessmuth, 1992). Therefore, the failure of pH]NTI 
to discriminate between the 5-receptor population in the weaned and non-weaned 
brain is consistent with the possibility that the difference lies in the G-protein coupled 
state of the receptors. However, in vivo studies have suggested that NTI does not 
discriminate between the putative 5i- and 52-opioid receptor subtypes (Crook et al., 
1993) so the possibility of the presence of subtypes is not precluded by the failure of 
pH ]N n to show 2-site binding. The agonist [^HJIle^’^ DELT II might be expected to 
discriminate receptor - G-protein coupled/uncoupled states and if the difference in 
binding affinity were great enough, to evidence 2-site binding if subtypes were 
present. However, [^HJIle^’^ DELT II does not indicate any difference in the 5-
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receptor population of weaned and non-weaned rat brain (Table 23), DELT I and 
He^'^DELT n  are both selective 5-agonists in vivo (Melchiorri et al., 1991; Salvadori 
et al., 1991; Sasaki et al., 1993) but they do differ in three out of seven amino acid 
residues (See Table 4, Chapter 1). Therefore although they are capable of binding to 
the 5-receptor and eliciting a response, the nature of the ligand-receptor interaction at 
the molecular level cannot be exactly the same and there is the possibility that their 
sensitivity to the receptor state differs. Ile^'^DELT II has a selectivity for 5-receptors 
over p-receptors of 3746 (derived from Ki vs. [^HJDAGO/Ki vs. [^HJDADLE) 
compared with 774 for DELT II (Sasaki etal., 1993). However^the in vitro selectivity 
for 5 -receptors over p-receptors expressed as the IC5 0  ratio in GPI/MVD of 
fle5.6DELT n  (2615) is less than that of DELT H (3758) (Sasaki et al., 1993). The 
authors speculate that this may result from subtle differences between central and 
peripheral opioid receptors. Certainly the membrane environment differs greatly 
between the in vitro conditons used for isolated tissues and the buffer system used for 
binding studies. It may also indicate that in spite of its very high affinity for 5- 
receptors, Ile^’^ DELT II may be less than a full agonist It has been demonstrated that 
efficacy can be correlated with degree of sensitivity to GTP, thus a full agonist 
exhibits the greatest GTP shift, an antagonist is insensitive and the partial agonist has 
reduced sensitivity (Kenakin, 1993 and references therein).
The binding of the 5-antagonist pHJNTI is little influenced by the presence of 
GMPPNP or Na+- There is some indication of an increased Bmax in the presence of 
lOOmM Na+ and in the presence of lOOmM Na+ + 50pM GMPPNP but the data 
indicate there is no significant quantitative difference in saturation binding or in 
affinity between weaned and non-weaned groups (Table 24). This is similar to the 
behaviour that has been observed with less selective opioid antagonists, the most 
frequently recorded effect being a increase in antagonist Bmax at p-receptors in the 
presence of Na+ (Nijssen and Childers, 1987; Paterson et al., 1986; Pert and Snyder, 
1974; Wong et al., 1994). The presence of 50pM GMPPNP does not significantly
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influence the Bmax for pHjlle^’^ DELT II in either the weaned or the non-weaned 
animals (Table 24). GMPPNP is thought to favour the accumulation of G-protein 
uncoupled receptors (Wong et al., 1994) and therefore these results suggest that 
pHJIle^’^ DELT II is relatively insensitive to the G-protein coupled state of the 6 - 
receptor. There is no indication of a change in the derived Kd for pHjlle^'^DELT II 
in the presence of GMPPNP (Table 22). The Bmax for pH]DELT I binding in the 
non-weaned animals also shows no change in response to the presence of 50 pM 
GMPPNP. In contrast,in the weaned animals in the presence of GMPPNP, the Bmax 
for pH]DELT I binding shows a 32% decrease compared with the Bmax under control 
conditions (Table 24). Although the 32% decrease does not exactly equate with the 
difference observed between weaned and non-weaned animals under control binding 
conditions (14-20% lower in non-weaned animals depending on the method of 
expression) the results suggest that a proportion of the 6 -receptor population in 
weaned animals is differently G-protein coupled to those in non-weaned animals and 
in the presence of GMPPNP the coupling state of these receptors may be changed 
sufficiently that they are no longer recognised by pH]DELT I. There is no apparent 
change in the affinity of the smaller 5 -receptor population still recognised by 
pHJDELT I in the presence of GMPPNP (Table 22).
In the presence of Na+ alone there is a marked decrease in the binding of both 
agonists in both weaned and non-weaned animals, some 64-70% for pHJDELT I. and 
35-50% for pHJIle^’^ DELT II (Figure 45). This decrease in apparent 0-receptor 
density is not associated with any significant change in affinity (Table 22). This 
response to the presence of Na+ has been observed previously for Ô-binding in guîoeo. 
cortical membranes (Werling et al., 1986). GMPPNP and Na+ result in the same 
decrease in Bmax for both agonists as does Na+ alone but also produce a decrease in 
affinity, Kd increasing by a factor of 4-4.5 for pHJDELT I and by a factor of 2-2.5 for 
pHJIle^’^ DELT II (Table 22) The smaller changes in Bmax and Kd for 
pHJIle^’^ DELT II further indicate that it is less sensitive to the G-protein coupled
206
State of the receptor than is [^HJDELT I. Although there is no apparent difference in 
the effect of Na+ on 0-binding in the weaned and non-weaned animals, cations have 
been reported to have significantly different effects on 6 -binding during development 
Inhibitory effects of Na+ on 6 -binding (pHJDADLE with DAGO |i-displacer) can be 
completely reversed by Mn+ by PN21 whereas prior to this the reversal is incomplete 
(Szucs etal., 1987). The same study also reported inhibition of [^HJDADLE binding 
by GMPPNP with no significant difference in the effect throughout development. 
Again using a different ligand, [^HJDPDPE, in rat brain it has been reported that 
GMPPNP inhibits specific binding by some 35-40% at PN5 and in the adult 
indicating no difference in coupling throughout development (Sziics and Coscia,
1990). However although GMPPNP was linked to inhibition of DPDPE binding, 
DPDPE could not be linked to GTPase activity at PN5 which indicated no receptor - 
G-protein coupling. The highly 6 -selective ligands [^HJDELT I, pHJIle  ^^DELT II 
and pH]NTI have rarely been used in developmental studies and never to study the 
effects of GMPPNP and Na+ on 6 -receptor binding and by comparison, the use of 
pHJDADLE with a |X-displacer may give rise to differences in interpretaion. 
pHJDPDPE exhibits a high degree of non-specific binding (McDoweU and Kitchen, 
1986) which makes it unsuitable to use where 6 -opioid receptor density is low or 
subtle differences are sought.
Differential sensitivity to the presence of GMPPNP has been recorded in sub­
populations of 6 -opioid receptors and it has been suggested a lack of sensitivity to 
GMPPNP may indicate that the receptor is not coupled to G-protein (Roth et al., 
1981; Spain et al., 1988). Such observations are not confined to opioid receptors 
(Lipson et al., 1986). and the hypothesis has been based on evidence from a number 
of rector systems which suggests that GTP destabilises the ligand-receptor-G-protem
complex (Gilman, 1986). Agonist binding to Receptor is hypothesised to be a two
A
step process:
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L + R LR LR*
Where L = agonist, R = receptor, LR = loosely associated complex and LR* = tightly 
associated complex
Subsequently LR* associates with G-protein forming the ternary complex LR*G. LR 
and LR* are more rapidly dissociating complexes than LR*G (Scheibe etal., 1984; 
Spain and Coscia, 1987; Spain et al., 1988). High concentrations of GTP will 
destabilise LR*G and GMPPNP will occupy Ga-subunit effectively making G- 
protein/GDP unavailable for interaction with receptor. Thus GMPPNP will interfere 
with a receptor that is functionally G-protein coupled but will not affect a receptor 
that is uncoupled. The antagonist receptor complex is postulated to be simply
L +R LR
where L = antagonist.
Since the reaction proceeds no further GMPPNP can have no influence on the 
equilibrium. It is also postulated that Na+ stabilises the receptor conformation R by 
preventing the formation of R* thus interfering with agonist binding but not 
antagonist binding (Scheibe et al., 1984). Most of the evidence for a mixed 
coupled/uncoupled 5-receptor population comes from subcellular fractionation (Roth 
et al., 1981; Spain et al., 1988). There has long been evidence that opioid receptors 
are not confined to plasma membranes (Glasel et al., 1980; Klein et a i, 1986; Roth 
et al., 1981). Rigorous homogenization with a Polytron is likely to result in co­
sedimentation at 20,000g of light membranes (LM), comprising endoplasmic 
reticulum and Golgi bodies together with the heavy membranes (HM), principally 
plasma membrane (Bem et al., 1991). Therefor^ the homogenate used in the 
investigations reported here, prepared from membranes collected at 49,000g after
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Polytron homogenization, will certainly contain a mixture of intracellular membrane 
and plasma membrane vesicles. It is hypothesised that in synaptic plasma membranes 
the 6 -opioid receptor is fully G-protein coupled whereas at intracellular sites there is 
only limited coupling (Spain et al., 1988). There is evidence for the different 
sensitivity of |i-receptors to GMPPNP during their development (Bem et al., 1991). 
At PNl |i-receptors are present in both LM and HM fractions of rat brain and the LM 
|i-receptors are less sensitive to GMPPNP than those in the HM fraction i.e. the ji- 
receptors associated with internal membranes are not coupled with G-protein to the 
same degree as those in the plasma membrane. The uncoupled state of the 6 -opioid 
receptor postulated in the unweaned rat is unlikely to be due to inadequate levels of 
G-protein since Gj and Go, both of which have been linked with 6 -opioid receptor 
signal transduction (Prather et al., 1994a) have been shown to exceed levels necessary 
for optimal receptor function in the neonate (Milligan et al., 1987). It has been 
suggested that coupled/uncoupled states have sometimes been ignored and subtypes 
of receptors hypothesised where different G-protein linkages generating different 
affinity states of one receptor would be a better interpretation (Richardson et al., 
1-992). .
It is possible therefore that the differential levels of 6 -receptor seen in the weaned and 
non-weaned 25 day-old rat by [^H]DELT I are due to the presence of a proportion of 
uncoupled receptors in the non-weaned animal. If [^H]DELT I is sensitive to the 
coupled/uncoupled state it may not recognise the possibly intracellular 6 -receptors 
which are subsequently incorporated in the plasma membrane with the potential of 
full G-protein coupling. It is possible that this transfer which might be predicted to be 
a normal developmental process, is stimulated at weaning and results in the higher 
levels of 6 -receptor seen by pH]DELT I after weaning. The antagonist [^HjNTI 
would not be predicted to be sensitive to the difference. The agonist [^Hjlle  ^^DELT 
n  from these experiments seems to be less sensitive than pHjDELT I to the coupling 
state of the receptor and therefore fails to discriminate.
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CHAPTER 6
GENERAL DISCUSSION
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6.1 K-opioid receptor studies.
Until the availability of the benzacetamide ligands such as U-50,488H, U-69,593, 
PD 117,302 and CI-977 (Figure 3b) K-receptors were quantified using less selective 
ligands such as EKC and bremazocine with ji-and 6 -selectve displacers (Figure 3a) 
(Leslie et al., 1982; Spain et a l, 1985). It became clear that not all the K-sites 
recognised by [^H]EKC and [^H]Bremazocine under conditions of p- and 6 - 
suppression were equally sensitive to the benzacetamide ligands as a lower number 
of sites was consistently reported using these ligands (Devlin and Shoemaker, 1990; 
Kinouchi and Pasternak, 1991; Nock etal., 1990; Nock etal., 1988a; Petrillo etal., 
1992; Smith et al., 1989; Zukin et al., 1988). There is general agreement that the 
benzacetamide ligands label the receptors designated K%. (For reviews see Wolleman, 
1993 and Fowler and Fraser, 1994). The -receptor has been demonstrated to be at 
comparatively low levels in rat brain while predominating in the guinea pig brain 
(Zukin et al., 1988). The study presented here has demonstrated that the CI-977 
sensitive K-receptor is present at maximum levels (expressed relative to total protein) 
at PNl and the [^H]U-69,593 measure of K-receptor density is not significantly 
different from the adult at PN5. The measures of Bmax relative to wet weight are 
slightly higher for [^H]CI-977 than for pH]U-69,593 and whereas specific binding of 
pH]CI-977 can be measured down to PNl, pH]U-69,593 specific binding cannot be 
measured before PN5. This may reflect the greater affinity of pH]CI-977. The data 
indicate full development of Ki-receptors at birth and by inference the major 
development of these receptors must have been prenatal. The early development of 
the K-opioid receptor has been documented before using non-selective ligands with |X- 
and 6 -selective displacers (Komblum etal., 1987; Petrillo etal., 1987) and levels in 
the spinal cord at PN9-16 measured with pH]U-69,593 have been shown to be higher 
than in the adult by a factor of 5-6 (AUerton et al., 1989a). pH]EKC with p.- and 6 - 
selective displacers showed K-receptors to plateau in the perinatal period E16-PN1 
(Ruis et al., 1991). The existence of distinct Ki- and i^-opioid receptors suggested by
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pharmacological and ligand binding studies (Section 1.3.1) is not proven and only a 
single K-opioid receptor gene has so far been cloned (Chen et al., 1993a; Li et al., 
1993; Meng û/., 1993; Minami ef a/., 1993; Nishi et al., 1993). Therefore the 
conclusions of this study can be only that the opioid receptor for which [^H]U-69,593 
and [^H]CI-977 are highly selective and have high affinity are at levels equivalent to 
the adult at PNl. These are referred to as K% according to the convention useiby 
Zukin etal., 1988.
This study has also demonstrated K-mediated antinociception in vivo using the Ki- 
selective agonists PD117,302, U-69,593 and CI-977 in the 5 and 10 day-old rat. The 
effects of the agonists have been shown to be naloxone-reversible and to produce 
antinociception against both mechanical and low intensity thermal stimuli. These 
results have been discussed at length in Section 3.4. Briefly^  they confirm that the K -  
receptor quantified in the binding studies is functional with respect to antinociception. 
The ability to produce antinociception against a thermal stimulus shows differences in 
the neonate compared with the adult where K-agonists are reported to be ineffective or 
less potent than against a mechanical stimulus (AUerton et al., 1989a). However, 
increased firing rates in spinal neurones in response to both heat and pressure stimuU 
have been shown to be inhibited by K-agonists (Dong et al., 1991; Parsons and 
Headley, 1989a; Parsons etal., 1989). When heat and pressure stimuli of increased 
intensity were used to produce matched increased firing rates, the K-agonist inhibition 
was shown to be selective, being effective only against the mechanical stimulus 
(Parsons and Headly, 1989b). The results of this study are consistent with the 
proposal that the K-agonists can mediate antinociception to thermal stimuli but their 
effectiveness is dependent on stimulus intensity. The observations may also indicate 
that the Ki-opioid receptors in the neonatal rat play a more significant role than in the 
adult. This would coincide with their relatively high density in the neonate and their 
relatively high levels as a proportion of the total opioid receptor population at this 
time, particularly in the spinal cord (Barr et al., 1986).
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This study has only addressed the properties of the putative Ki-opioid receptor. The 
characterization of the remaining K-receptor population, defined as such by their 
sensitivity to EKC and designated K% because they are not recognised by the 
benzacetamide ligands, remains to be more clearly defined. It has been suggested that 
the benzacetamide labelled receptors are the only 'true’ K-opioid receptors and that the 
remaining sites correspond to e-sites (Nock et a l, 1990; Nock et al., 1993) which had 
been proposed some years earlier (Gillan et a l,  1981; Schulz and Wuster, 1981). 
There is considerable controversy (for a review see Fowler and Fraser, 1994) over the 
existence of a distinct Kg-opioid receptor (Clark et a l, 1989) which shows some of the 
characteristics of the |i-receptor but has also been suggested to correspond to the e- 
binding site (Nock et al., 1993). Identification of a second K-opioid receptor gene is 
the only definitive proof that K-subtypes exist as different gene products. A high 
affinity ligand for the EKC-sensitive sites which can discriminate against the 
benzacetamide sensitive sites i.e. a putative K2 -receptor ligand would provide a tool to 
continue investigations into K-receptor heterogeneity in the absence of proof at the 
molecular level.
6.2 5-opioid receptor studies.
These studies have shown that k- and 5-opioid receptors have a clearly different 
developmental pattern. Most earlier studies relied upon the use of pH]DADLE which 
has only a fourfold selectivity for 5-opioid receptors over p-receptors (Chang and 
Cuatrecasas, 1979b) while being selective for Ô- over K-receptors by a factor of 
>6000 (James and Goldstein, 1984b). However combined with the p-selective 
agonist DAGO (Corbett et al., 1984) to su^ress pH]DADLE binding to p-sites, the 
general picture to emerge has been that Ô-opioid binding appears towards the end of 
the first postnatal week (Spain et al., 1985) and steadily increases to adult levels by 
PN28. This profile was confirmed with pHJDPDPE which is selective for 6 - over p­
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receptors by a factor of some 175 (Mosberg e ta l,  1983). Using pH]DPDPE 5- 
opioid receptor binding was quantified at 34.5ftnol/mg protein at PNIO and shown to 
reach adult levels by PN25 (McDowell and Kitchen, 1986). The high non-specific 
binding of the ligand prevented detection by saturation studies before PNIO but 
clearly there must have been 6 -receptor development before this time. [^HJDADLE 
binding with p-supression has been used to identify 6 -receptors at PN6  (Komblum et 
al., 1987) and homologous displacement studies using [3R]DPDPE has measured 5- 
binding at PN5 at a level of 37fmol/mg protein (Sziics and Coscia, 1990) which is 
considerably in excess of the levels detected in this study at this age. The Bmax at PN 
1 0  of all the ligands used in this study are consistent with the value reported using 
pH]DPDPE (McDowell and Kitchen, 1986). The most sensitive of the ligands was 
the antagonist pH]NTI with which it was possible to quantify binding down to PN3. 
At this age the Kd was significantly higher than at PN5 and upwards which suggests 
that the 6 -receptor population differs in some respect at this age, possibly in terms of 
final processing and G-protein linkage. The influence of GMPPNP on 6 -binding at 
PN5 has been demonstrated in homologous displacement studies which suggests G- 
protein coupling exists at this age (Sziics and Coscia, 1990). It has also been reported 
at PN3 on the basis that 6 -mediated inhibition of adenylate cyclase can be observed 
and is said to predominate over p-mediated control in spite of the fact that p-receptors 
were found to be equivalent to adult levels at this age while the 6 -receptors were only 
just measurable (Milligan et al., 1987). Howeverphese data were obtained using D- 
Ala -^Met^-enkephalinamide which does not discriminate between p- and 6 -receptors 
(Pfeiffer and Herz, 1981) and a 500-fold p- over 6 -selective displacer etonitazene 
(Rice e ta l, 1983).
It may be possible to quantify 6 -receptor binding in brain homogenates before PN3 
using [3H]NTI. Quantitative autoradiography with [^HJNTI may prove a more 
sensitive method in very young animals, a particular advantage being that much less 
tissue is required. The cloning of the 6 -receptor (Evans et al., 1992; Kieffer et al..
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1992) has made available the possibility of identifying cellular mRNA using a 
radiolabelled complementary single stranded mRNA probe sequence. In situ 
hybridization would also be a more appropriate and sensitve method to investigate the 
very early Ô-receptor development in the neonate or foetus.
This study has shown a significant difference between 6 -receptor levels in the weaned 
and non-weaned 25 day-old rat, seen by p H]DELT I both by homologous 
displacement and saturation studies. These results indicate that prior to weaning 20- 
3 5 % of the ô-receptor population differ in some respect from the remainder of the 
population since they are not recognised by pH]DELT I. The comparative levels 
seen by [^HJDELT I, [^Hjlle  ^^ DELT II and pH]NTI in the saturation studies indicate 
that [^Hjlle^’^ DELT II and pH]NTI do not discriminate between the heterologous ô- 
population whereas the comparative levels when [^HjDELT I binding is assessed by 
homologous displacement indicate that pHjlle^'^DELT II and pH]NTI do not 
recognise the additional 6 -receptors which apparently develop in response to weaning. 
The resolution of this anomaly would contribute to the understanding of the reasons 
for the 6 -receptor population heterogeneity. Theoretically this might be resolved by 
heterologous displacement studies. If in the weaned animals [^KQDELTI recognises 
some 30% more 6 -receptors than [3H]NTI (figures from homolgous displacement of 
pH]DELT I ) then NTI should not be able to displace all the pH]DELT I binding in 
the weaned animals but should be able to do so in the non-weaned animals. The same 
argument applies to the heterologous displacement of [^HjDELT I by Ile ’^^ DELT H. 
If the affinity of pH]NTI for the additional 6 -receptors recognised by [^HJDELTI is 
very low, saturation studies over a greater concentration range may detect additional 
pH]NTI labelled sites. If, as indicated by the saturation binding of pH]DELT I, all 
three ligands recognise the same number of sites in weaned animals and only 
pH]DELT I is sensitive to the heterogeneity, failing to recognise some 20% of the 
population in non weaned animals, then DELT I should not be able to displace all 
pH]NTI or all pHjDe '^^DELT II binding in non-weaned animals. The differences
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in pH]DELT I binding between the weaned and non-weaned animals have been 
confirmed by autoradiographic studies (Kitchen et al., 1995) and shown to be 
confined principally to the deep frontal parietal cortex. Displacement studies using 
autoradiographic techniques on brain sections from the appropriate region may prove 
more sensitive than homogenate binding studies in whole brain in which any effect of 
regional differential development will be diluted by the amount of tissue in which the 
difference is not apparent. Homogenate binding in dissected brain regions gives rise 
to the problem of obtaining sufficient tissue.
The two most obvious reasons for a heterogeneous population are either that there are 
distinct 0 -opioid receptor subtypes or that the populations differ in the extent or nature 
of G-protein coupling. Some evidence suggests that the 30% increase seen by 
pH]DELT I in weaned animals is not additional 5-receptor protein but rather that the 
saturation figures give the more accurate picture and all ligands see the same level of 
6 -binding in the weaned animals. In situ hybridization indicates there is no increase 
in receptor message (Kitchen et al., 1995) but additional 6 -opioid receptor protein 
could have arisen as a result of increased efficiency of transcription or translation. If 
there is additional 6 -opioid receptor protein representing a subtype of the 6 -receptor, it 
must be sufficiently different that the mRNA is not recognised by the cDNA probe 
(Kitchen et al., 1995). Also, as discussed in 4.4, homologous displacement can lead 
to overestimates of Bmax with no sign of the possible anomaly in the transformed 
data. However, using heterologous displacement of [3H]DELT I by DPDPE, a Bmax 
for 6 -binding in adult rat brain homogenate of 99fmol/mg protein has been reported 
(Negri et al., 1991). This figure closely matches the levels found in this study with 
pH]DELT I (Figure 36(b)). Significantly  ^some 34% of the pH]DELT I binding was 
displaced by DPDPE with a K% of 2.2nM, the remaining 6 6 % with a K; of 116nM. 
This represents a heterogenous 6 -opioid receptor population of approximately the 
same proportions as identified in this study. A very recent autoradiographic study of 
pH]DELT I displacement in the weaned and non-weaned rat (Kitchen et al., 1996)
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has shown some 25% of pH]DELT I binding in the frontal parietal cortex to be very 
sensitive to displacement by low levels of DPDPE only in the weaned animal. As the 
concentration of DPDPE was increased competitive displacement occurred in both. 
Competition with Ile ’^^ DELT II and DSLET was identical in weaned and non-weaned 
brain and did not show the highly sensitive site. This suggests that the 5-receptor 
expressed or functionally coupled in response to weaning which has been identified 
from the data presented in Chapter 4 is highly sensitive to DPDPE. 5-opioid receptors 
have been classified into putative 5%- and 0 2 -subtypes principally based on 
agonist/antagonist profiles in the mouse (Jiang et al., 1991; Mattia et al., 1991; 
Sofuoglu et al., 1991a; Sofuoglu et al., 1991b). DPDPE sensitive receptors are 
designated 5i although DPDPE does act via putative 5 2 -receptors at higher dose levels 
in the rat (Stewart and Hammond, 1993). In vivo antinociceptive studies in the rat 
have shown antinociceptive effects of DELT I in weaned and non-weaned animals 
(Kitchen et al., 1994) and the binding studies have demonstrated pHjDELT I 
sensitive binding in both. However, DSLET did not produce antinociception in non- 
weaned animals although it was effective in weaned animals indicating that a DSLET 
sensitive 5-receptor was not present or not functional in the non-weaned animal 
(Kitchen et al., 1994). DSLET*sensitive sites have been classified as 5% in the mouse 
(Sofuoglu et al., 1991a). There is therefore some conflicting evidence for the nature 
of the undeveloped 5-receptor in the non-weaned animal, in vivo studies suggest it is 
DSLET-sensitive, Ô2  and autoradiographic competition studies suggest it is most 
sensitive to DPDPE, 5%. However these classifications are based primarily on studies 
in the mouse and differences have been reported for responses to 5-agonists in the rat 
and mouse (Heyman et al., 1987). DPDPE and DSLET are reported to have similar 
sensitivities to antagonism by NTI in antinociceptive tests in the 25 day-old rat and to 
be some ten times more sensitive than DELT I (Crook et al., 1992). This suggests 
that in the rat DPDPE and DSLET may act at a common NTI-sensitive site and this 
would be consistent with the observations that the post-weaning 5 -receptor 
development can be demonstrated to be of a receptor sensitive to both DSLET and to
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DPDPE depending on the methods used. Clearly precise correspondence between in 
vivo studies and ligand receptor binding studies cannot be expected since 
pharmacokinetic considerations apply in vivo and the usual medium for binding 
studies, 50mM Tris-HCl buffer, does not provide receptors in their normal 
physiological state. It would be useful to pursue the weaned/non-weaned difference 
in 0-binding seen with pHjDELT I using a variety of 6 -agonists and antagonists and 
competitve displacement by autoradiographic techniques to establish the profile of the 
two apparently different forms. For example BN1TX is 100-fold more potent in 
competing for [^HjDPDPE labelled sites than for pHjDSLET labelled sites (Sofuoglu 
et a i ,  1993) and the pHjDELT I binding in the weaned rat would be expected to 
show the same high sensitivity displacement as observed for DPDPE (Kitchen et a i, 
1996). It would be useful to confirm the in vivo profiles in the rat so that all the 
information is species specific.
The possibility that the apparent increase in the 8 -receptor population after weaning 
might reflect the G-protein coupled state of the receptors has been investigated 
(Chapter 5). When measured by saturation binding of[^HjDELT I in the weaned rat 
in the presence of 50|iM GMPPNP there was a 30% decrease in the Bmax (Figure 
44). There was no effect of GMPPNP on specific binding of [^HjDELT I in the non- 
weaned rat. The 30% loss is not dissimilar to the difference in pHjDELT I binding 
observed between the weaned and non-weaned rat and suggests that the failure of 
pHjDELT I to detect a proportion of the 5-receptors may be because they are not G- 
protein coupled. Both pHjNTI and [^Hjlle^’^ DELT II binding are unaffected by 
GMPPNP. Antagonist binding is generally observed to be unaffected by the G- 
protein coupled state of the receptor and there are indications that Ile  ^^DELT II may 
be a partial agonist and as such the receptor binding is not as sensitive to G-protein 
coupling as a full agonist would be. These topics have already been discussed more 
fully in Section 5.4. The proportion of the pHjDELT I binding lost in the weaned 
brain homogenate in the presence of GMPPNP also corresponds to the proportion of
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[3H]DELT I binding shown to be very sensitive to displacement by DPDPE (Kitchen 
et al., 1996). It would be useful to provide additional evidence that they were the 
same receptors. If they are, it is predicted that in the presence of GMPPNP the highly 
sensitve displacement by low levels of DPDPE would not be observed. The effects of 
lOOmM Na+ and 50|iM GMPPNP+lOOmM Na+ for any one ligand were no different 
in weaned and non-weaned animals which does not allow any conclusions to be 
drawn as to the nature of the heterogeneous ô-receptor population.
Although it is now four years since the original cloning of the rat Ô-opioid receptor 
(Evans et a l ,  1992; Kieffer et a l, 1992) there is as yet no indication that a 0-subtype 
exists as a separate gene product There are indications that alternative splicing at the 
C-terminal end of the G-protein coupled receptors, which influenes G-protein 
coupling, is quite common (Adam et a l ,  1994; Namba et a l, 1993; Vanetti et a l, 
1992). Such splice variants have been suggested for opioid receptors (Evans et a l ,  
1992; Zimprich e ta l, 1995a; Zimprich e ta l, 1995b). Splice variants can give rise 
to subtypes sufficiently different to account for the differences observed in the 6 - 
receptor population for example, splice variants of the rat p,-opioid receptor have been 
reported to have different second messenger coupling and resistance to desensitization 
(Zimprich et a l, 1995a; Zimprich et a l, 1995b). It is not therefore necesssary to 
argue that the heterogeneity in the 6 -receptor population subsequent to weaning is 
necessarily due to expression of a separate gene.
6.3 Conclusion.
In summary, the studies reported in this thesis have established the differential 
development of the k - and 0-opioid receptors in the neonatal rat. Full development of 
the K-opioid receptor characterised as Ki by the selectivity of the benzacetamide 
ligands used in the binding studies (pH]U-69,593 and pH]CI-977) has been 
demonstrated at PNl and shown to exceed adult levels when expressed relative to
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total protein. Naloxone-reversible K-mediated antinociception to both mechanical and 
low intensity thermal stimuli has been demonstrated at PN5 and PNIO using three Ki- 
selective agonists (PD117,302, U-69,593 and CI-977). 0-opioid receptor development 
has been quantified using three highly selective 5-ligands ([^HJDELT I, 
pH]Ile5,6DELT II and [^HjNTI). First quantified at PN3 with [^HjNTI, a steady 
increase in 5-receptor density to reach levels not significantly different from the adult 
by PN25 was observed with all three ligands in the normally weaned rat. 
Measurement of 5-receptor binding by homologous displacement of [^HjDELT I in 
the weaned and the nonweaned rat brain and spinal cord suggested that weaning 
stimulated the development of further 5-receptor protein recognised only by 
[^HjDELT I. Further investigation under conditions designed to modify the G-protein 
coupled state of the receptors indicated that in the weaned rat, in the presence of 
GMPPNP some 30% of the total 5-receptor population was no longer recognised by 
pHjDELT I and this suggests that the post weaning increase is a result of G-protein 
coupling.
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